



**THE ARTHRITIS RESEARCH CANADA**  
**BOARD MEETING – SEPTEMBER 25, 2025**  
ANNUAL REPORT OF THE SCIENTIFIC DIRECTOR

## TRAINEES

### New Trainees

**Jenyo Banjo** (Supervisor: **Wei Zhang**), started as a Master's student in the Faculty of Pharmaceutical Sciences, University of British Columbia in January 2025. Her thesis project is entitled *Trajectories of work productivity loss: working from home and insights during COVID-19*

**Jordyn Bugar** (Supervisor: **Allyson Jones**) started as a Master's student in the School of Public Health at the University of Alberta, Edmonton in September 2024. Her thesis project is entitled *"Pharmacist-physiotherapist collaborative management for early knee osteoarthritis" (PACE-OA)*.

**Vienna Cheng** (Supervisor: **Mary De Vera**) started in September 2025 as a PhD student in Pharmaceutical Sciences at University of British Columbia. Her thesis project is entitled *"Biologic Disease-Modifying Antirheumatic Drugs in Pregnancy: Patterns of Use and Maternal and Neonatal Outcomes"*.

**Krista Dagsvik** (Supervisor: **Glen Hazlewood**) started as a Master's student in Community Health Sciences, Cumming School of Medicine, University of Calgary in September 2024. Her research investigates "the readability and applicability of health outcome descriptors by partnering with patients, clinicians, and researchers to ensure these descriptors are useful, accurate, and consistently understood".

**Dominique Clarke** (Supervisor: **Jackie Whittaker**) started as a Master's student in Rehabilitation Sciences, University of British Columbia in September 2025. Her Master's research program will involve a mixed-methods study to better understand what factors (including gender) influence knee confidence after a sport-related Anterior Cruciate ligament tear, to inform tailoring of prevention strategies (e.g., the Stop OsteoARthritis or SOAR Program).

**Julia Downey** (Supervisor: **Glen Hazlewood**) started as a Master's student in Community Health Sciences, Cumming School of Medicine, University of Calgary in September 2024. Her research thesis is entitled *"Using patient preferences to inform non-inferiority margins for clinical trials in rheumatology"*.

**Manar Elsayed** (Supervisor: **Carrie Ye**) started as a Master's student at the University of Alberta in April 2025. Her research project is entitled *"Administrative Databases to Explore Rheumatic Toxicities associated with Immune Checkpoint Inhibitors"*.

**Solomon Faro** (Supervisor: **Deborah Marshall**) started as a Post Doctoral Fellow at the University of Calgary.

**Ana Fuhrmann** (Supervisor: **Deborah Marshall**) started as a Post doctoral fellow at University of Calgary.

**Renata Gabuzyan** (Supervisor: **Jackie Whittaker**) started as a Master's student in Rehabilitation Sciences, University of British Columbia in September 2025. Her Master's research program will look at the association between cyclical weight-bearing activities and knee symptoms and degenerative cartilage changes (considering the influence of gender) in people at risk of early-onset post-traumatic osteoarthritis, to inform prevention strategies (e.g., the Stop OsteoARthritis or SOAR Program).

**Daniel Gillespie** (Supervisors: **Claire Barber** and Lauren Beaupre), started as a Postdoctoral Fellow in the Cumming School of Medicine, University of Calgary in December 2024. His research focuses on "telehealth strategies to enhance access to rehabilitation services for individuals with disabilities, particularly those in rural and remote communities" who face barriers to in-person care.

**Nejat Hassen** (Supervisor: **Linda Li**, Co-Supervisor: **Diane Lacaille**) started in September 2025 as a PhD student in Physical Therapy at the University of British Columbia. Her thesis project is entitled *Promoting physical activity in Muslim women and girls living with inflammatory arthritis*.

**Chloe Jessen** (Supervisor: **Sabrina Hoa**) started as a Master's student in Epidemiology at the Faculty of Medicine at L'Université de Montreal in September 2024. Her thesis project is entitled *"Association between immunosuppressive treatments and the risk of developing pulmonary arterial hypertension in systemic sclerosis"*.

**Sydney Joy** (Supervisor: **Ines Colmegna**) started as a PhD student in Experimental Medicine at McGill university in September 2024. Her thesis project is entitled *"Mesenchymal Stromal Cells for the Treatment of Systemic Sclerosis-Associated Lung and Skin Fibrosis"*.

**Derin Karacabeyli** (Supervisor: **Diane Lacaille**) transferred from his Master's to a PhD program in Experimental Medicine at the University of British Columbia. His thesis project is entitled *"Effectiveness and safety of glucagon-like peptide-1 receptor agonists in patients with inflammatory arthritis and type 2 diabetes mellitus"*.

**Emilie McGuire** (Supervisor: **Deborah Da Costa**) started as a Master's student in Counselling Psychology at McGill University in September 2025. Her thesis project is

entitled “*Tailoring an Internet Delivered Cognitive Behavioral Therapy for Insomnia in Persons with Inflammatory Rheumatic Diseases: Acceptability and Feasibility- Phase 2*”.

**Carina Oedingen** (Supervisor: **Deborah Marshall**) started as a Post Doctoral Fellow at the University of Calgary.

**Barath Ramanathan** (Supervisor: **Hugues Allard-Chamard**), started as a Master’s Student in the Department of Immunology and Cell Biology, Université de Sherbrooke in September 2024. His thesis project is entitled *Immuno-characterization of B lymphocytes in a novel histopathologic phenotype of inclusion body myositis*

**Jenna Schulz** (Supervisor: **Jackie Whittaker**) started as a Postdoctoral Fellow in September 2025 in the Department of Physical Therapy, University of British Columbia. Her project is entitled: *Research Priorities for Post-Traumatic Osteoarthritis from Discovery to Health Systems*.

**Abigail Stites** (Supervisor: **Wei Zhang**) started as a Master’s student in the School of Population and Public Health, at UBC, Vancouver in September 2024. Her thesis project title is “*Health care costs associated with high impact pain: Analysis of the Medical Expenditure Panel Survey 2018-2022*”.

**JoAnn Thai** (Supervisor: **Carrie Ye**) started as a new trainee (Medicine Resident) at the University of Alberta in June 2025. Her research project uses AI to triage referral letters in rheumatology, aiming to prioritize patients more efficiently based on the urgency of their condition, while de-identifying information to protect patient privacy.

**Dwayne Tucker** (Supervisor: **Mary De Vera**) started as a new Post-Doctoral Fellow in the Pharmaceutical Sciences, University of British Columbia in May 2025. Dwayne’s postdoctoral research focuses primarily on the pharmacoepidemiology and health outcomes of rheumatoid arthritis medications, particularly during pregnancy.

**Janice Xu** (Supervisor: **Linda Li**), started as a Master’s student in Physical Therapy at the University of British Columbia in September 2025. Her thesis project is entitled *Impact of Brief Action Planning Training on Physiotherapists’ Delivery of Behavior Change Techniques and Patient Adherence in the Otago Exercise Program*.

### **Trainees who completed their degrees**

**Vienna Cheng** (Supervisor: **Mary De Vera**) successfully defended her Masters thesis entitled “*Targeted synthetic disease-modifying antirheumatic drugs among mothers with autoimmune disease: Pharmacoepidemiologic studies*” on June 25, 2025.

**Dani Contreras** (Supervisor: **Cheryl Barnabe**) successfully defended her Master’s thesis on March 05, 2025. Her thesis was entitled “*Avoidable Acute Care Use by Persons with Rheumatoid Arthritis: A Population-Based Study*”. Supervisory Committee included **Claire Barber** and **Antonio Avina-Zubieta**.

**Rashed Hoque** (Supervisor: **Hui Xie**) successfully defended his PhD thesis entitled "*Estimating Causal Effects of Medication Adherence Using Administrative Data*" on May 20, 2025.

**Kamso Mohammed Mujaab** (Supervisor: **Glen Hazlewood**) successfully defended his PhD thesis on May 29, 2024. His thesis was entitled "*A Novel Semi-Automated Approach for Trial Identification and Evaluation of the Certainty of Evidence from Network Meta-Analyses*". Kamso is continuing as a Postdoctoral trainee at the University of Ottawa and the University of Calgary (Co-Supervisors: **Glen Hazlewood** and George Wells, U Ottawa).

**Justin Losciale** (Supervisor: **Jackie Whittaker**) successfully defended his PhD thesis entitled "*Lost but not forgotten: An investigation of muscle performance after sport-related knee injuries*" on October 31, 2024.

**Codie Primeau** (Supervisor **Linda Li**) completed his post-doctoral fellowship at Arthritis Research Canada and started a faculty position at Western University, London, Ontario on January 01, 2025

**John Yan** (Supervisor: **Jackie Whittaker**) successfully defended his Master's thesis on May 26, 2025. His thesis was entitled "*Explosive Neuromuscular Performance of the Quadriceps Muscle following Anterior Cruciate Ligament Reconstruction.*"

**Vivienne Zhou** (Supervisor: **Hui Xie**) successfully defended her PhD thesis on March 10, 2025. Her thesis was entitled "*Evaluating the impacts of biological treatment in inflammatory arthritis patients with quasi-experimental study designs*". She has started a post-doctoral fellowship at the BC Centre for Substance Use (BCCSU)

### **Trainee Salary Awards**

**Jordyn Burgar** (Supervisor: **Allyson Jones**) was awarded a \$30,000 MITACS Accelerate 12-month Internship award for her project. "*Pharmacist-physiotherapist collaborative management for early knee osteoarthritis*" (PACE-OA).

**Jordyn Burgar** (Supervisor: **Allyson Jones**) was also awarded the TD Bank Financial Group Grant for Health Sciences Interdisciplinary Research Fund Award of \$10,000. This award is granted to applicants from the University of Alberta who have active roles with an interdisciplinary (cross- faculty or multiple health/allied health disciplines) research team, relevant to Precision Health and who demonstrate interest and potential to excel in interdisciplinary health research.

**Vienna Cheng**, (Supervisor: **Mary De Vera**) was awarded the Women's Health Research Institute (WHRI) Graduate & Fellowship Research Award in Women's Health – \$40,000 (1 year). This highly competitive award is presented to only one exceptional doctoral student each year whose research is dedicated to advancing women's and/or newborn health.

**Vienna Cheng**, (Supervisor: **Mary De Vera**) was also awarded The Andrew Nord Fellowships in Rheumatology Spring Graduate Award in the amount of \$25,000 for 4 years. Andrew Nord suffered from the effects of arthritis from the age of 15 and the goal for his bequest is "to prevent the disease from its devastating onslaught, to find better ways to live with the disease, and to find the cause, leading to a cure once and for all." This prestigious fellowship is awarded to exceptional doctoral students conducting transformative research in rheumatology.

**Vienna Cheng**, (Supervisor: **Mary De Vera**) was awarded the UBC 4-Year Doctoral Fellowship at \$18,200 per year + full tuition for 4 years. One of UBC's most competitive and distinguished awards, the 4-year Doctoral Fellowship recognizes outstanding academic achievement and exceptional research potential in doctoral students.

**Dominique Clarke** (Supervisor: **Jackie Whittaker**) was awarded a \$6,500 Faculty of Medicine Graduate Award from the University of British Columbia, for September to December 2025.

**Julia Downey** (Supervisor: **Glen Hazlewood**) was awarded a \$17,500 2024-2025 CanTRAIN Clinical Trials Training Program Master's Studentship Award for her project entitled "*Using preferences and best existing evidence to inform the design of future clinical trials in rheumatoid arthritis*".

**Manny Ester** (Supervisor: **Claire Barber**) has received a two-year, \$155,000 Canadian Institutes of Health Research Institute of Musculoskeletal Health and Arthritis (CIHR-IMHA) Alberta Health Systems Impact Fellowship. Manny is one of 20 Post Doctoral Fellows selected to receive this award, for his project "*A proactive approach to health: integrating personalized physical activity behaviour change support into inflammatory arthritis care*". Through this initiative, postdoctoral researchers will collaborate with health organizations across the country to address a variety of critical health system issues.

**Renata Gabuzyan** (Supervisor: **Jackie Whittaker**) was awarded a \$6,500 Faculty of Medicine Graduate Award from the University of British Columbia (September to December 2025).

**Racheal Githumbi** (Supervisor: **Claire Barber**) was awarded a one-year \$20,000 Cumming School of Medicine Graduate Scholarship for her project "*Optimizing Precision in Practice: Standardizing the use of Treat-to-Target Measures for Enhanced Rheumatoid Arthritis Care Delivery*". This scholarship was established to attract the best graduate students to the Cumming School of Medicine and train them to become leading researchers. It is renewable up to four years.

**Nejat Hassen** (Supervisor: **Linda Li**, Co-Supervisor: **Diane Lacaille**) was awarded a UBC 4-Year Doctoral Fellowships, one of only 6 such awards allocated to the Rehabilitation Sciences program for 2025. The award is for \$18,200 per year plus full tuition, for 4 years. One of UBC's most competitive and distinguished awards, the 4-year

Doctoral Fellowship recognizes outstanding academic achievement and exceptional research potential in doctoral students.

**Nejat Hassen** (Supervisor: **Linda Li**, Co-Supervisor: **Diane Lacaille**) received the BPOC graduate student award of \$1,875.00. The BPOC award is to recognize excellence in research and scholarly performance by BPOC (Black and People of Colour) graduate students and to address systemic barriers they experience in their training.

**Nejat Hassen** (Supervisor: **Linda Li**, Co-Supervisor: **Diane Lacaille**) was awarded The Andrew Nord Fellowships in Rheumatology Spring Graduate Award in the amount of \$25,000 for 4 years. Andrew Nord suffered from the effects of arthritis from the age of 15 and the goal for his bequest is "to prevent the disease from its devastating onslaught, to find better ways to live with the disease, and to find the cause, leading to a cure once and for all." This prestigious fellowship is awarded to exceptional doctoral students conducting transformative research in rheumatology.

**Derin Karacabeyli** (Supervisor: **Diane Lacaille**) was awarded a one-year \$27,000 Canadian Institutes of Health Research Canada Graduate Scholarship Master's award for his project "*Effectiveness and safety of glucagon-like peptide-1 receptor agonists in patients with inflammatory arthritis and type 2 diabetes mellitus*".

**Derin Karacabeyli** (Supervisor: **Diane Lacaille**) was also awarded The Andrew Nord Fellowships in Rheumatology Spring Graduate Award for \$25,000 for 3 years. Andrew Nord suffered from the effects of arthritis from the age of 15 and the goal for his bequest is "to prevent the disease from its devastating onslaught, to find better ways to live with the disease, and to find the cause, leading to a cure once and for all." This prestigious fellowship is awarded to exceptional doctoral students conducting transformative research in rheumatology.

**Chloe Jessen** (Supervisor: **Sabrina Hoa**) was awarded €27,188 from her home University, L'Université Paris Saclay for pursuing her Master's degree in Canada for her project "*Association between immunosuppressive treatments and the risk of developing pulmonary arterial hypertension in systemic sclerosis*".

**Sydney Joy** (Supervisor: **Ines Colmegna**) (\$22,000 over 18 months), **Chloe Jessen** (Supervisor: **Sabrina Hoa**) and **Kai Zhao** (Supervisor: **Hui Xie**) (\$7,500 over 6 months) were awarded the inaugural Walter Gulka Scholarship from Arthritis Research Canada, which was awarded in memory of the late Walter Gulka, a highly respected and dedicated teacher. It honours his legacy and longstanding support for arthritis research. Sydney Joy was awarded \$22,000 over 18 months to complete her PhD for her project "*Exploring Mesenchymal Stromal Cells as a Novel Treatment for Systemic Sclerosis-Induced Fibrosis*". Kai Zhao was awarded \$7,500 over 6-months for his project "*Evaluating treatment effect for SLE using novel causal inference methods*". Chloe Jessen declined the award due to also receiving an award from her University (listed above).

**Kasra Moolooghy** (Supervisor: **Diane Lacaille**) has been awarded a two-year \$120,000 MITACS Accelerate award for his Post-Doctoral Project entitled “*Comparing the risk of major cardiovascular events and venous thromboembolisms across different classes of biologics and targeted synthetic agents for inflammatory arthritis: a population-based study*”.

**Tosin Ogunleye** (Supervisor: **Claire Barber**) was awarded a two-year \$12,000 Cumming School of Medicine Graduate Scholarship. The scholarship recognizes academic excellence and research potential. Her research focuses on improving care pathways for patients with Giant Cell Arteritis, a type of vasculitis that can cause blindness.

### **Trainee Other Award and Honours**

**Vienna Cheng**, (Supervisor: **Mary De Vera**) representing the Faculty of Pharmaceutical Sciences/Arthritis Research Canada was awarded runner-up (2nd place) and the People’s Choice Award at the University of British Columbia Three Minute Thesis (3MT) Competition in March. Vienna was one of ten students in the final heat, reduced from 100 students who competed in the open heats and Semi-Final events.

**Derin Karacabeyli** (Supervisor: **Diane Lacaille**) received the American College of Rheumatology (ACR) Distinguished Fellow Award which recognizes clinical and research fellows in a rheumatology fellowship training program who have performed with distinction. It is accompanied by a cash prize of \$1,500 USD.

### **Summer Students**

**Gracie Burns** (Supervisor: **Alex Legge**) was a Canadian Rheumatology Association summer student at Dalhousie University. She conducted a retrospective study to describe the clinical presentation and outcomes of Lyme arthritis among adults presenting to the rheumatology clinic in Halifax, Nova Scotia over the past 15 years.

**Loryann Galvin** (Supervisor: **Laëtitia Michou**), a medical student, did a summer studentship at l’Université Laval working on the Educare project. Educare is a pilot project evaluating the acceptability of a therapeutic patient education program in patients with inflammatory arthritis.

**Brianna Greenwood** (Supervisor: **Carrie Ye**), was a summer student at the University of Alberta. Her project was entitled *Immune Checkpoint Inhibitor Associated Sicca-Like Syndrome: a cohort study from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) Database*.

**Arielle Maccabée** (Supervisor: **Laëtitia Michou**) a medical student, did a summer studentship at l’Université Laval working on a study that will look back at everyone treated for osteoporosis and assess treatment failures.

**Tark Patel** (Supervisor: **Carrie Ye**), was a summer student at the University of Alberta. He worked on an AI project to manually de-identifying medical notes/letters to create a database to train machine learning programs that will perform, in the future, automated de-identifying of information to protect patient privacy.

## **FACULTY**

### **New Appointments**

**Marie Hudson** has been appointed as the McGill Division Director of Rheumatology.

**Deborah Marshall** has been appointed the Scientific Director, Research Evaluation, Partnership and Impact, Alberta Children’s Hospital Research Institute (ACHRI).

**Deborah Marshall** is the Svare Chair in Health Economics, Value and Impact, University of Calgary effective April 01, 2024.

### **Retirement**

**Jolanda Cibere** was appointed Senior Scientist Emeritus upon her retirement from Arthritis Research Canada in July 2025. Dr Cibere joined Arthritis Research Canada at the very beginning as a Research Associate (Trainee) from 2000 to 2004, under the supervision of **Dr. John Esdaile** and **Dr. Jacek Kopec**. In 2004, she was appointed as a Research Scientist until 2012, when she was appointed as a Senior Scientist. She was a PI or Co-I on several osteoarthritis related projects during her time at Arthritis Research Canada, including the IMPAKT-HIP project and the PRECISION project.

She completed her medical and rheumatology training in Saskatoon and her PhD in Health Care and Epidemiology at the University of British Columbia, with her thesis research focusing on osteoarthritis. Dr. Cibere pioneered a study showing that glucosamine sulfate was not effective for osteoarthritis, the results of which have been widely disseminated to consumers across North America.

Dr. Cibere received the Networks of Centres of Excellence Young Innovator Award early in her career. She was awarded a Clinical Scientist Fellowship award, and a Phase II Scholar Award (the highest-level salary award given by the Canadian Institutes of Health Research), and received both the UBC’s Departmental Faculty Scholar Award and the J. W. McConnell Family Foundation Scholar.

### **Scientific Research Grants**

**Claire Barber** is the Principal Investigator on a two-year \$15,000 O’Brien Institute for Public Health, University of Calgary Research Catalyst Grant entitled “*Optimizing Rheumatology Triage – A Learning Health System Approach*”. **Cheryl Barnabe** is a Co-Investigator on this grant.

**Cheryl Barnabe** is a Principal Investigator with Drs Terri-Lynn Fox, Liam O’Neil, Pamela Roach and Stephanie Montesanti on a five-year \$2 million Canadian Institutes of Health Research Team Grant: Embracing Diversity to Achieve Precision & Health Equity entitled “*Indigenous Inflammatory Arthritis Prevention and Treatment Approaches for health Equity (IIA-PATH)*”. This project aims to transform how arthritis care and prevention strategies are delivered in Indigenous communities to address the inequities in health care and outcomes experienced by Indigenous communities. Co-Investigators include **May Choi, Claire Barber, Glen Hazelwood, Diane Lacaille** and other scientists leading Indigenous health research in BC, Alberta, Manitoba, as well as four Indigenous community partners and Indigenous persons living with arthritis.

**Ines Colmegna** is the Principal Investigator on a four-year, \$1,040,400 Canadian Institutes of Health Research Project Grant entitled “*Investigating the anti-fibrotic effects of human multipotent mesenchymal stromal cells*”. Co-Investigators include **Marie Hudson**, Anastasia Nijnik and Qihuang Zhang.)

**Mary De Vera** is the Principal Investigator on a three-year \$105,000 Canadian Institutes of Health Research Project Grant entitled “*Advancing Equity, Diversity, and Inclusion in Arthritis Research: A Mixed-Methods Group Concept Mapping Approach*”. Co-Investigators include **Antonio Avina-Zubieta, Cheryl Barnabe, Hui Xie and Codie Primeau**.

**Sabrina Hoa** is a Co-Principal Investigator with **Susan Bartlett** and **Marie Hudson** as Co-Investigators on a four-year \$684,675 Canadian Institutes of Health Research grant entitled “*Enhancing Patient Engagement in Scleroderma Research: A Series of Cohort-Based RCTs of Tools to Improve Communication of Research Results*”. Other PI’s are Brett Thombs, Amanda Lawrie-Jones, Danielle Rice and Maureen Sauve.

**Allyson Jones** is the Principal Investigator and **Claire Barber** is a Co-Investigator on a two-year \$300,000 grant from the Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta entitled “*Pharmacist-physiotherapist collaborative management for early knee osteoarthritis*”.

**Diane Lacaille** along with Rebecca Grainger are Principal Investigators on a one-year \$33,660 CAD (\$41,331 NZD) Arthritis New Zealand Grant entitled “*Mahi with Arthritis: Exploring Challenges and Implementing an Evidence-Based Program, Making-it-Work, in Aotearoa New Zealand*”.

**Diane Lacaille** is a Co-Principal Investigator along with **Antonio Avina-Zubieta, Hui Xie** and **Jan Dutz** on a one-year, \$100,000 Canadian Institutes of Health Research Project Grant entitled “*Mapping the current landscape, treatment patterns, and access to health services for eczema patients in British Columbia*”. Sunil Kalia is the Principal Investigator.

**Linda Li** is a one of the Principal Investigators on a five-year \$929,476 Canadian Institutes of Health Research Project Grant entitled "*Healthy Heart, Healthy Brain: Aerobic Exercise to Promote Brain Health in Perimenopause*". Teresa Liu-Ambrose is the Nominated Principal Investigator on this grant. Other Principal Investigators include Cindy Barha and Liisa Galea.

**Linda Li** is a Co-Investigator on a three-year \$344,251 Canadian Institutes of Health Research Project Grant entitled "*A mixed methods study of cancer care in Canada*". Kristen Haase is the Principal Investigator on this grant.

**Linda Li** is a Co-Investigator on a three-year \$355,000 Canadian Institutes of Health Research Project Grant entitled "*Improving integrated knowledge translation for evidence-informed health care by attending to power*". Anita Kothari AR and Heather Gainforth are the Principal Investigators on this grant.

**Linda Li, Diane Lacaille, and Jasmin Ma** are Co-Principal Investigators on a one-year \$20,000 Canadian Institutes of Health Research Grant entitled "*Facilitating Adoption of Strength Training in people with Rheumatoid Arthritis (FAST-RA)*". Co-investigators include Linda Wilhelm, **Antonio Avina-Zubieta**, Dianne Gromala, **Eileen Davidson, Alison Hoens, Allyson Jones, Chris Shaw, Codie Primeau, Ellen Wang, Heather Worthington, Kelly English** and Laurie Proulx.

**Jasmin Ma** is the Principal Investigator on a two-year \$49,869 UBC Small Teaching and Learning Enhancement Fund Grant entitled "*UBC School of Kinesiology: Implementation of a Clinical Exercise Physiologist Curriculum Pathway.*"

**Jasmin Ma** is the Principal Investigator on a one-year \$3,000 UBC Advancing Community Engaged Learning Fund Grant entitled "*Research to Impact 2.0 KxM Fellowship.*"

**Deborah Marshall** is the Principal Investigator for a four-year \$1,598,238 Canadian Institutes of Health Research Team Grant – Improving Health and Administrative Data and Monitoring for Rare Diseases. The project is entitled "***RAre Disease Administrative Data Research (RADAR) Team: putting the health system impact of rare diseases on the radar***".

**Laëtitia Michou** was awarded a one-year \$20,000 Clinical Research grant from the CHU de Québec clinical research platform entitled: "*Therapeutic patient education, a new educational care program for adults living with inflammatory arthritis, the Educare project*".

**Codie Primeau** is the Principal Investigator on a one-year \$20,000 Canadian Institutes of Health Research grant titled "*Co-Developing Research Questions About Chronic Pain with 2SLGBTQIA+ Communities through Citizen Science*". AR Verma, A Samson, G Schultz, J Stevenot, E Abreu, T Salway, M Kwag, **Alison Hoens, and Linda Li** are Co-investigators.

**Jackie Whittaker** is a Co-Investigator on a four-year National Health and Medical Research Council of Australia grant for a total of \$2,500,000, AUS entitled *“HERKnee Centre of Research Excellence: Preventing Knee Injury and Osteoarthritis Burden of Women and Girls”*. The Principal Investigator is Kay Crossley and other co-investigators are R Hinman, M Dowsey, J Kemp, K Henne, C Emery, C Barton, A Culvenor, A Smith, B Patterson, A Bruder, I Ackerman, P Choong and M Moller.

**Jackie Whittaker** is a Co-Investigator on a one-year \$226,530 WorkSafe BC grant entitled *“High load exercise with biofeedback and dose monitoring for Achilles tendinopathy: an exploratory cohort study”*. The Principal Investigator is Alex Scott and the other co-investigators are Michael Hunt, L Hung and **Khole Merry**.

**Jackie Whittaker** is the Principal Investigator on a four-year \$670,000 Canadian Institutes of Health Research Project Grant entitled *“Preventing symptomatic post-traumatic osteoarthritis in young people at high risk: The Stop OsteoARThritis (SOAR) Randomized Controlled Trial.”* **Linda Li, Hui Xie, Alison Hoens** and Michael Hunt are Co-Investigators. **Trish Silvester-Lee** is the Patient Collaborator on the project.

**Jackie Whittaker** is a Co-Investigator on a one-year \$100,000 Canadian Institutes of Health Research Catalyst Grant entitled *“Biomechanical and Imaging Assessments of Hip Micro-instability”*. David Wilson is the Principal Investigator.

**Jackie Whittaker** is a Co-Investigator on a one-year \$100,000 Canadian Institutes of Health Research Project Grant entitled *“Tracking the Exposure to and Biomechanical Features of 'Risky' Movements in Soccer”*. Calvin Kuo is the Principal Investigator.

**Jackie Whittaker** is a Co-Investigator on a one-year \$20,000 Canadian Institutes of Health Research Planning and Dissemination Grant entitled *“Alleviating waitlist woes: Adapting a health-promotion program for people awaiting hip and knee replacement for osteoarthritis”*. J Sims-Gould is the Principal Investigator.

**Jackie Whittaker** is a Co-Investigator on a one-year £41,709 Physiotherapy Research Foundation (UK) Research Investigator Grant entitled *“Development of digital health intervention to support post-traumatic knee osteoarthritis prevention: a mixed methods study”*. Josh Cosgrove is the Principal Investigator.

**Carrie Ye** is the Principal Investigator and **Marie Hudson, Janet Roberts and Shahin Jamal** are Co-Investigators on a four-year \$778,000 Canadian Institutes of Health Research Project Grant entitled *“Gaining Insight Into Immune Checkpoint Inhibitor Associated Inflammatory Arthritis Using Administrative Health Data.”*

**Carrie Ye** is the Principal Investigator on a one-year \$25,000 Canadian Institutes of Health Research Project Grant entitled *“ChatRheum: Developing and evaluating a*

source-verified large language model to answer rheumatology patient questions”. Co-investigators include Mohamed Abdalla, Steven Katz amongst others.

### **Salary Awards**

**Meghan Barber** was awarded a two-year LuCIN Clinical Trial Investigator Award (\$100,000 USD) from Lupus Therapeutics to support her salary.

### **Honours and Merit Awards**

**Antonio Avina-Zubieta** has achieved promotion to Professor, Division of Rheumatology, Department of Medicine, UBC. This is the highest rank in academia and requires a senior scientist to have made substantial research contributions for which they have international recognition, to have excelled in their research productivity in terms of publications and grants awarded, and have successfully trained graduate students. These are no easy milestones, and Dr Avina clearly met all criteria!

**Claire Barber** was awarded the 2025 Canadian Rheumatology Association Silver Practice Reflection Award at the Canadian Rheumatology Association Annual Scientific Meeting in Calgary, Alberta in February. The CRA Practice Reflection Award recognizes the importance of reflection and practice change to ultimately improve patient care. This award encourages CRA members to develop, innovative and practical self-assessment programs and quality improvement initiatives. She received this award for her work on developing a Learning Health System for rheumatology care in Alberta that allows the real-time collection of data alongside the provision of clinical care to provide feedback to improve the quality of care delivered.

**Cheryl Barnabe** was awarded the Top 10 Articles of 2024, CIHR Institute for Health Services and Policy Research: *“Prevalence and characteristics of anti-Indigenous bias among Albertan physicians: a cross-sectional survey and framework analysis”*.

**Cheryl Barnabe** is the recipient of the 2025 Killam Annual Professorship. The prestigious Killam Professorship recognizes her for research and teaching excellence, service to the University of Calgary and the wider academic community. This \$10,000 cash prize is awarded to individuals who have demonstrated a sustained record, typically spanning over a decade of nationally and internationally recognized scholarship and educational leadership in their field.

**Susan Bartlett** was awarded the American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP) Master Designation. The ARP Master Award is one of the highest honors the College bestows. This award is presented to ARP members who have made outstanding contributions to the field of rheumatology through service to the ACR/ARP and advancements in research, practice, education, and/or advocacy.

**Susan Bartlett** was awarded the 2025 Arthritis Health Professions Association Lifetime Achievement Award at the Canadian Rheumatology Association Annual Scientific Meeting in Calgary, Alberta in February. This award is given to a candidate who has brought honour to the profession throughout their career lifetime by modeling mentorship, innovation, enthusiasm, and ongoing commitment in Arthritis care. Dr Bartlett received this award in recognition of her tremendous contribution to patient-centred arthritis research, her advocacy for the crucial role of allied health professionals in arthritis care, and her commitment to patient engagement in research.

**Susan Bartlett** is also the recipient of the Arthritis Health Professions Association's Carolyn Thomas Award for the highest ranked scientific abstract for her study entitled: *"Distinct Symptom Clusters Predict Initial Response to Methotrexate in Adults with New Rheumatoid Arthritis: a Longitudinal Analysis of the Canadian Early Arthritis Cohort"*. This work was selected for a plenary podium presentation at the 2025 Canadian Rheumatology Association Annual Scientific Meeting in Calgary in February.

**May Choi** was awarded the 2025 Emerging Investigator Award at the Canadian Rheumatology Association Annual Scientific Meeting in Calgary, Alberta in February. This award is given to an early career Canadian investigator who has contributed significant, original research in rheumatology.

**Raheem Kherani** is the recipient for the 2024 Larry Collins for Committee Service Award from Vancouver Coastal Health. This award recognizes individuals who exemplify the spirit of collaboration, empathy, and unwavering dedication to improving healthcare and supporting colleagues.

**Diane Lacaille** was awarded the Excellence in Investigative Mentoring Award from the American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP). The Excellence in Investigative Mentoring Award recognizes the importance of the mentor/mentee relationship. This award honors an active ACR or ARP member for their contributions to the rheumatology profession through outstanding and ongoing mentoring.

**Deborah Marshall** was amongst five University of Calgary faculty members to be elected as a new Fellow at Royal Society of Canada (RSC). She was formally inducted into the Royal Society of Canada (RSC) at a ceremony in November 2024. The RSC recognizes outstanding scholarly, scientific, and artistic achievement; elected by their peers. It is the highest honour an individual can achieve in the arts, social sciences and sciences.

**Laëtitia Michou** has been recognised by The Fonds de Recherche du Quebec with a renewal of her "chercheur clinicien chevronné" from 2025 to 2029 which is awarded in recognition of the scientific excellence of experienced clinical scientists.

**Janet Roberts** was awarded the 2024-2025 Dalhousie University Department of Medicine Research Excellence Award. This is awarded to members within the Department who have demonstrated excellence in research in the previous three years and to honour and publicly recognize the members' research achievements.

Signed:



---

Diane Lacaille, MD, MHSc, FRCPC  
Mary Pack Chair in Rheumatology Research,  
Scientific Director, Arthritis Research Canada/Arthrite-recherche Canada  
Professor of Medicine, University of British Columbia

**Appendix I**

**FUNDING FROM JULY 1, 2024 TO JUNE 30, 2025**

AIHS - Alberta Innovates Health Solutions; CIORA – Canadian Initiative for Outcomes in Rheumatoid Arthritis; CIHR – Canadian Institutes of Health Research; CRA - Canadian Rheumatology Association; EULAR – European League Against Rheumatism; MSFHR – Michael Smith Foundation for Health Research; NIH – National Institutes of Health; NCE – Networks of Centres of Excellence; TAS - The Arthritis Society; UBC – University of British Columbia; Spondyloarthritis Research Consortium of Canada

| <b>SCIENTIST FUNDING - Operating Grants for Research</b> |   |  |   |                              |                      |                   |                 |
|--|---|--|---|------------------------------|----------------------|-------------------|-----------------|
| <b>PI(s)</b>   | <b>Co-I(s)</b>  | <b>Title</b>   | <b>Funding Agency</b>                             | <b>Annual Amount 2024-25</b> | <b>Total Awarded</b> | <b>Start Date</b> | <b>End Date</b> |
| <b>Abrahamowicz M</b>                                    | <b>JA Aviña-Zubieta</b> , S Bernatsky, A Bérard, W Dixon, M. Durand, L Eder, S Ferreira Guerra, <b>D Lacaille</b> , S Perreault, L Pilote, R Sapir-Pichhadze, R Tamblyn, J Widdifield, G Yi | New statistical methods for population-based studies of time-varying drug exposures: Development, validation, and real-world analyses of drug safety and effectiveness | CIHR  | \$160,650                    | \$481,950            | Apr-22            | Mar-25          |
| Tamblyn R, Totino L                                      | <b>Abrahamowicz A, Bartlett S</b> , Buckeridge D, Lee T, McDonald E, Motusky A, Pupo R, Thavon K, Weir D  | Evaluating the effectiveness of Smart About Meds (SAM), a mobile app to improve medication management following hospital discharge                                     | CIHR  | \$46,139                     | \$184,556            | Apr-22            | Mar-26          |
| Bernatsky S, Smargiassi A                                | <b>M Abrahamowicz, J Aviña-Zubieta</b> , P Awadalla, H Chen, T Dummer, M Goldberg, S Jean, M Johnson, D Levy, J Spinelli, S Weichenthal, J Widdifield                                       | Air pollution and systemic autoimmune rheumatic diseases   | CIHR  | \$128,775                    | \$772,650            | Oct-18            | Sep-24          |
| Kalia, S   | <b>Avina-Zubieta JA, Dutz JP, Lacaille D</b> , Lui H  | Mapping the current landscape, treatment patterns, and access to health services for eczema patients in British Columbia   | CIHR, Project Grant - Priority Announcement: IMHA | \$100,000                    | \$100,000            | Feb-25            | Jan-26          |

|   |  |  |  |              |             |        |        |
|---|--|--|--|--------------|-------------|--------|--------|
| MacDermid J,<br><b>Backman C</b> ,<br>Birmingham T,<br>Bouer L,<br><b>Marshall D</b> ,<br>Moyer R, Ronsky<br>J, Roy JS,<br>Thomas A | <b>Knowledge User:</b> K Hofstetter, M<br>Hunt, J Whittaker  | Canadian Musculoskeletal<br>(MSK) Rehab Research<br>Network  | CIHR   | \$299,549    | \$1,996,990 | Jan-20 | Dec-24 |
| van der Veer S,<br>Dixon W  | <b>N Bansback</b>  | Transforming outpatient<br>consultations by integrating<br>regular symptom tracking into<br>clinical care: the Remote<br>Monitoring of Rheumatoid<br>Arthritis (REMORA2) study | VERSUS Arthritis<br>UK & NIHR  | \$925,000    | \$3,700,000 | Oct-21 | Nov-25 |
| <b>Barber C</b>   | <b>Jones CA, Barnabe C, Lacaille<br/>D, Hazlewood G</b> , Widdifield J,<br>Wallace Y (pt)  | Implementation of the Alberta<br>Rheumatology Provincial<br>Learning Health System   | CIHR   | \$104,549.67 | \$313,649   | Apr-23 | Mar-26 |
| <b>Barber C</b> , Crump<br>T  | <b>C Barnabe</b> , E Dempsey, G<br><b>Hazlewood, A Hoens</b> , S. Katz, <b>J<br/>Kopec, D Lacaille</b> , P MacMullan,<br>D Mosher, J Rankin, J Sutherland,<br>K Then | Psychometric evaluation of a<br>measure of care complexity in<br>rheumatoid arthritis  | CIHR   | \$99,195     | \$297,584   | Sep-22 | Aug-25 |
| <b>Barber C</b>   | <b>Jones CA, Barnabe C, Lacaille<br/>D, Hazlewood G</b> , Widdifield J,<br>Wallace Y (pt)  | Implementation of the Alberta<br>Rheumatology Provincial<br>Learning Health System   | CIHR   | \$104,550    | \$313,649   | Apr-23 | Mar-26 |
| <b>Barber C</b>   | <b>Barnabe C</b>   | Optimizing Rheumatology<br>Triage – A Learning Health<br>System Approach   | O'Brien Institute for<br>Public Health,<br>University of<br>Calgary Research<br>Catalyst Grant | \$15,000     | \$15,000    | Apr-25 | Mar-26 |

|  |  |  |      |              |             |        |        |
|--|--|--|------|--------------|-------------|--------|--------|
| Ahluwalia V,<br>Apple T, Eder L,<br>Laur C, Thorne<br>C, Widdifield J  | <b>C Barber</b> , S Bernatsky, G<br>Hawker, C Hofstetter, N Ivers, B<br>Kuriya, L Passalent, P Rochon, L<br>Soever, A Steiman  | The Ontario Rheumatology<br>Learning Health System for<br>Transforming Integrated Care<br>for Patients with Rheumatic and<br>Musculoskeletal Disorders         | CIHR | \$391,303    | \$1,956,515 | Apr-23 | Mar-28 |
| Beaupre L,<br>Finseth E,<br>Eubank B,<br>Ferguson-Pell M,<br>Sheps D   | E Armstrong, <b>C Barber</b> , A<br>Charlton, A Kania-Richmond, J<br>Martyn, P Paul, A Ramadi, J<br>Robert, J Round, C Smith   | Using Digital Health to Better<br>Serve Rural Albertans living<br>with Shoulder Pathology:<br>Alberta's Remote Management<br>of ShoUlders Program (ARMS<br>UP) | CIHR | \$264,643.80 | \$1,323,219 | Apr-23 | Mar-28 |
| Tugwell PS,<br>Welch V   | S Ali, <b>C Barber</b> , <b>C Barnabe</b> , A<br>Darzi, O Dewidar, <b>G Hazlewood</b> ,<br>A Lee, LC Li, O Magwood, L<br>Maxwell, J Petkovic, B Shea, E<br>Tomlinson, K Toupin-April | Reducing inequitable<br>differences in health outcomes<br>in the treatment of Arthritis  | CIHR | \$138,974.67 | \$416,924   | Oct-23 | Sep-26 |
| <b>Barnabe C</b> ,<br>Healy B,<br>Tailfeathers E,<br>Crowshoe L,<br>Currie C, Fellner<br>K, Henry R,<br>Voyageur C | R Weasel Fat, J Baker, B Bastien,<br>S Chisan, A Greenshaw, R<br>Henderson, A Kennedy, S Kutz, A<br>Loyola-Sanchez, L ManyGuns, T<br>Oosterbroek, M Rock, W Shotyk                   | Alberta Indigenous Mentorship<br>in Health Innovation Network<br>(AIM-HI Network)  | CIHR | \$200,000    | \$1,000,000 | Oct-19 | Sep-24 |

|   |  |   |   |           |             |        |        |
|---|--|---|---|-----------|-------------|--------|--------|
| <b>Barnabe C</b> , Crowshoe L, Bablitz C, Green M, Henderson R, Kennedy A, Montesanti S, Murry A, Roach P, Tailfeathers E | Auger C, Auger J, Baker J, Chowdhury C, Crowshoe T et al   | Indigenous Primary Health Care and Policy Research (IPH CPR) Network in Alberta   | CIHR  | \$700,000 | \$3,500,000 | Oct-19 | Sep-24 |
| <b>Barnabe C</b>  |  | Implementation and Evaluation of Shared Decision-Making Strategies with Indigenous Peoples for Rheumatoid Arthritis Treatment | University of Calgary Cumming School of Medicine Clinical Research Fund (CRF) | \$12,500  | \$25,000    | Apr-24 | Mar-26 |
| <b>Barnabe C</b>  |  | Indigenous Inflammatory Arthritis Prevention And Treatment approaches for Health equity (IIA-PATH)                            | CIHR - team planning grant  | \$20,000  | \$20,000    | Nov-24 | Oct-25 |
| <b>Barnabe C</b> (NPA), Fox TL, Montesanti SR, O'Neil LJ, Roach PM  | Aminghafari DM, <b>Barber CEH</b> , <b>Choi M</b> , Dufour A, El-Gabalawy H, <b>Hazlewood, G</b> , <b>Lacaille D</b> , Oster, R, Pardo Pardo J, Toupin April K, Turcotte C, Twilt M, Wasylak T | Indigenous Inflammatory Arthritis Prevention And Treatment approaches for Health equity (IIA-PATH)                            | CIHR team grant   | \$400,000 | \$2,000,000 | Apr-25 | Mar-30 |
| McLane P, Bartel R, James A   | Le Chaifoux N, Kima J, Boubake A, Holrod B, Rosychuk R, Tate K, Curtin K, Neri D, Roach P, <b>Barnabe C</b> , Oster R  | Quality of Care for Metis in Alberta Emergency Departments: Co-Creating Understandings and Definitions                        | U of A Otipemisiwak Métis Government's Department of Health                   | \$104,437 | \$313,310   | Apr-23 | Mar-26 |

|  |   |  |                       |           |             |        |        |
|--|---|--|-----------------------|-----------|-------------|--------|--------|
| Austen Wiebe VJ, Bill, Kashuba S, McLane P, Tailfeathers E | <b>C Barnabe</b> , R Bartel, R Henderson, B Holroyd, A James, K Janvier, J Khangura, M Landry, E Lang, E Louis, R Oster, K Rittenbach, P Roach, T Big Plume, K Foudy                                    | Advancing Anti-Racist and Equity-Oriented Care in the Emergency Department with First Nations Partners     | CIHR                  | \$437,963 | \$1,751,852 | Apr-23 | Mar-27 |
| Boyd S, Cheung A, Morin S                                  | Alexander T, Alos N, Andronowski J, <b>Barnabe C</b> et al (+50)  | OsNET: The Canadian Bone Health Research Network   | CIHR                  | \$400,000 | \$1,200,000 | Jul-23 | Jun-26 |
| Emery C  | <b>C Barnabe</b> , K Belton, L Benson, A Black, P Elson, R Ferber, P Fuselli, C Goulet, E Brent, M Jordon, S Kenny G Kuntze, C Lebrun, K MacDonald, A Macpherson, <b>DA Marshall, J Whittaker</b> et al | SHRed Injuries: Preventing Injuries and their consequences in youth sport and recreation                   | CIHR                  | \$148,493 | \$1,039,450 | Jul-18 | Jun-25 |
| <b>Benseler S, Marshall DA,</b> Wilson J                   | Celluci T, Currie G, Page S, Stringer E, Swart J, Wulfraat N, Yeung R   | Producing an Arthritis Value-framework with economic Evidence - Paving the Way for Rare Childhood Diseases | CIHR                  | \$150,000 | \$300,000   | Jan-22 | Dec-24 |
| Bernatsky S, Smargiassi A                                  | <b>M Abrahamowicz, J Avina-Zubieta</b> , P Awadalla, H Chen, T Dummer, M Goldberg, S Jean, M Johnson, D Levy, J Spinelli, S Weichenthal, J Widdifield   | Air pollution and systemic autoimmune rheumatic diseases   | CIHR                  | \$154,530 | \$772,650   | Oct-18 | Sep-24 |
| <b>Choi M</b>  |   | CLIMB: Complement activation Levels and Interferon activity as novel Myositis Biomarkers                   | The Arthritis Society | 119,000   | 357,000     | Apr-24 | Mar-27 |

|   |  |   |      |              |             |        |        |
|---|--|---|------|--------------|-------------|--------|--------|
| <b>Cibere J</b>                           | <b>J Esdaile</b> , B Forster, <b>J Kopec</b> , <b>L Li</b> , D Wilson, H Wong, | Population-based longitudinal cohort study of femoroacetabular impingement of the hip using magnetic resonance imaging outcomes   | CIHR | \$177,225    | \$531,674   | Oct-20 | Sep-25 |
| Vinet E                                   | S Bernatsky, <b>AE Clark</b> , <b>PR Fortin</b> , J Hanly, C Peschken, Z Touma | Risk stratification and personalized therapy in lupus pregnancies   | CIHR | \$151,470    | \$757,350   | Oct-22 | Sep-27 |
| <b>Colmegna I</b> , Nijnik A, Langlais D  |  | Hematopoietic stem and progenitor cells as mediators of trained immunity in rheumatoid arthritis  | CIHR | \$199,800    | \$999,000   | Oct-20 | Sep-25 |
| <b>Colmegna I</b> , Langlais D, Martin JG | <b>Hudson M</b> , Nijnik A, Zhang Q  | Investigating the anti-fibrotic effects of human multipotent mesenchymal stromal cells.   | CIHR | \$260,100    | \$1,040,400 | Feb-25 | Oct-29 |
| Greenwood C                               | <b>I Colmegna</b> , <b>M Hudson</b>  | X-inactivation in rheumatoid arthritis and impact on sex-specific disease risks   | TAS  | \$125,536.67 | \$376,610   | Apr-24 | Mar-27 |
| <b>Da Costa D</b>                         | <b>M De Vera</b> , <b>PR Fortin</b> , E Rahme, E Vinet, F de Montigny          | Mental Health in Individuals with Autoimmune Rheumatic Diseases During the Transition to Parenthood: A Mixed Methods Study to Identify Associated Factors and Support Needs | CIHR | \$79,560     | \$198,900   | Apr-23 | Sep-25 |
| Giangregorio L, Morin S                   | Adachi J, Billington E, Boyd S, Cheung A, <b>Da Costa D</b> et al              | Multifaceted Intervention using Telehealth to Reduce the risk of Falls and Fractures in Older Men (MisterFit study): a Pilot Study  | CIHR | \$55,076     | \$220,304   | Oct-21 | Sep-25 |

|   |   |  |                       |           |           |        |        |
|---|---|--|-----------------------|-----------|-----------|--------|--------|
| <b>De Vera M</b>                        | <b>N Amiri</b> , E Sayre, S Ensworth, C Baldwin, <b>N Rebic</b>   | Following maternal, neonatal, and childhood outcomes associated with use of arthritis medications perinatally (FAMILY) | The Arthritis Society | \$140,000 | \$420,000 | Apr-23 | Mar-26 |
| <b>De Vera M</b>                        | <b>C Barnabe</b> , <b>A Avina-Zubieta</b> , <b>N Gheshlaghi</b> , <b>M Harrison</b> , P Kang, <b>M Thomas</b> | Applying an equity and intersectionality lens to understanding the burden of arthritis on aging Canadians (APPROACH)   | CIHR                  | \$69,094  | \$69,094  | Jul-24 | Jun-25 |
| Boilard, E                              | Droit A, <b>Fortin PR</b>   | Role of megakaryocytes in Systemic Lupus Erythematosus   | CIHR                  | \$146,880 | \$734,400 | Apr-23 | Mar-28 |
| Boilard, E                              | <b>P Fortin</b> , C Belleannee, S Lacroix   | Platelets and neutrophils: The two culprits mediating pain in inflammatory arthritis                                   | CIHR                  | \$96,390  | \$910,350 | Apr-20 | Mar-25 |
| Bourgoin S                              | <b>Fortin P</b>   | Role of phosphatidylserine-specific phospholipase A1 (PLA1A) in the pathogenesis of rheumatic diseases                 | The Arthritis Society | \$150,000 | \$450,000 | Apr-23 | Mar-26 |
| Dieudé M                                | <b>P Fortin</b> , E Boillard, H Cardinal,   | Impact of Vascular Injury Derived Exosomes on Lupus Nephritis  | CIHR                  | \$115,515 | \$577,575 | Apr-22 | Mar-27 |
| <b>Hazlewood G</b> , Tugwell P, Wells G | <b>Bansback N</b> , <b>Barber CE</b> , Elliott J, <b>Kamso M</b> , Kelly S, Maxwell M                         | Living systematic reviews of pharmacological treatments for Rheumatoid Arthritis                                       | CIHR                  | \$46,279  | \$185,114 | Oct-21 | Sep-25 |

|   |  |  |      |              |           |        |        |
|---|--|--|------|--------------|-----------|--------|--------|
| <b>Hazlewood G,</b><br>Wells G                            | <b>N Bansback, C Barber, C Barnabe,</b> C Bombardier, V Bykerk, P Charlton, A Scott, D Choquette, R Deardon, J Elliott, <b>MM Kamso,</b> S Kelly, L Proulx, L Richards, O Schieir, <b>J Thomas</b> | Personalizing the choice of therapy in rheumatoid arthritis  | CIHR | \$420,752    | \$420,752 | Apr-22 | Mar-26 |
| Graham MM,<br>James MT,<br>Sajobi T, Wilton<br>SB         | O Awosoga, B Har, <b>G Hazlewood,</b> L Lix, A McRae, C Norris, MJ Parilla Lopez, H Quan, RD Turgeon, T Wilson, M Wang   | Characterizing patient preferences and personalizing risk information for optimal patient-centered management of coronary artery disease   | CIHR | \$127,181    | \$508,724 | Apr-23 | Mar-27 |
| Tugwell PS,<br>Welch V                                    | S Ali, <b>C Barber, C Barnabe,</b> A Darzi, O Dewidar, G Hazlewood, A Lee, LC Li, O Magwood, L Maxwell, J Petkovic, B Shea, E Tomlinson, K Toupin-April  | Reducing inequitable differences in health outcomes in the treatment of Arthritis  | CIHR | \$138,974.67 | \$416,924 | Oct-23 | Sep-26 |
| Hutton B, Moher<br>D, Straus SE,<br>Tricco AC, Wells<br>G | AM Abou-Setta, <b>G Hazlewood,</b> B Hemmelgarn, A Hossain, Z Jordan, S Kelly, E Langlois, J Presseau, A Proctor, B Reeves, A Stevens, K Thavorn, M Tunis, J Watt                                  | Drug Safety and Effectiveness Network Methods and Applications Group in Indirect Comparisons (DSEN MAGIC) Team   | CIHR | \$272,174    | \$816,522 | Apr-20 | Mar-25 |
| <b>Hoa S</b>  | D Assayag, M Baron, S Golch, M Hambly, <b>M Hudson, M Larche,</b> JL Senecal   | Randomized Double-Blind Placebo-Controlled Clinical Trial to Assess the Efficacy of Mycophenolate Mofetil in Subclinical Interstitial Lung Disease Associated with Systemic Sclerosis: a Feasibility Study | CIHR | \$92,437     | \$346,640 | Oct-22 | Jun-26 |

|   |   |   |       |             |              |        |        |
|---|---|---|-------|-------------|--------------|--------|--------|
| <b>Hoa S, Bartlett S, Hudson M</b>                            | Thombs B, Lawrie-Jones A, Rice D, Sauve M                                   | Enhancing Patient Engagement in Scleroderma Research: A Series of Cohort-Based RCTs of Tools to Improve Communication of Research Results                   | CIHR  | \$171,169   | \$684,675    | Nov-24 | Oct-28 |
| Archambault P, Awadalla P et al                               | Allin S, Arino J, <b>Hoens A</b> et al +50                                  | Long COVID Web: Pan-Canadian Post-COVID Condition Research Network  | CIHR  | \$3,999,923 | \$19,999,614 | Nov-22 | Oct-27 |
| Bostick G, Bussieres A, Cooper L, McNiven N, Wideman T, et al | Bement M, Bhanji F, Fishman S, Hudon A, <b>Hoens A</b> (Collaborator) et al | Improving pain education across entry-level physiotherapy programs in Canada: An integrated knowledge translation study                                     | CIHR  | \$120,870   | \$604,350    | Apr-21 | Mar-26 |
| <b>Hudson M</b>   | <b>Hoa S</b> , Miller W, Lapointe R, Del Rincon S, Esfahani K               | Identification of immune signatures of rheumatic immune-related adverse events secondary to immune checkpoint inhibitors                                    | TAS   | \$150,000   | \$450,000    | Apr-24 | Mar-27 |
| Leask A, Philip A   | <b>M Hudson</b>   | Characterization of a novel anti-fibrotic peptide for the treatment of scleroderma  | CIHR  | \$97,308    | \$486,540    | Apr-21 | Mar-26 |
| <b>Jamal S</b> , Appleton T                                   | <b>C Ye</b> , J Pope, <b>M Hudson</b>                                       | Early Adalimumab Induction for Treatment of Steroid-Dependent Checkpoint Inhibitor Associated Inflammatory Arthritis: A Pragmatic Randomized Clinical Trial | CIORA | \$58,200    | \$116,400    | Oct-23 | Sep-25 |

|                                      |  |   |   |           |           |        |        |
|--------------------------------------|--|---|---|-----------|-----------|--------|--------|
| <b>Jones CA</b>                      | <b>Barber CEB</b>  | Pharmacist-physiotherapist collaborative management for early knee osteoarthritis                               | Faculty of Pharmacy & Pharmaceutical Sciences, UofA | \$150,000 | \$300,000 | Nov-24 | Oct-26 |
| <b>Lacaille D</b>                    | <b>Bansback N, Barber C, Barnabe C, Bartlett S, Colmegna I, Da Costa D, Fortin P, Hazlewood G, Hoens A, Koehn C, Li L, Michou L, Oelke N</b>                   | FlexCAre: Co-developing a Flexible Care Delivery Model for Inflammatory Arthritis                               | The Arthritis Society                               | \$112,500 | \$450,000 | Dec-22 | Mar-26 |
| <b>Li LC, Liu Ambrose T</b>          | C Bartha, J Brubacher, J Davis, T Dignum, R Falck, C Hsu, M Kho, T Manyango, L Nagamatsu, N Parmar, D Skelton, O Theou, H Wong                                 | ACTIVE: Adding Life to Years in Cognitive Frailty by Preventing Falls   | CIHR  | \$163,710 | \$818,550 | Apr-23 | Mar-28 |
| <b>Li LC, Liu-Ambrose T, Davis J</b> | R Falk, K Madden, R Rhodes, M Sadatsafavi, HC Wong   | SuPA Mobility: Supporting Physical Activity to Promote Mobility in Mobility-Limited Older Adults                | CIHR  | \$105,188 | \$631,128 | Apr-21 | Mar-27 |
| <b>Li LC, Liu-Ambrose T</b>          | Bartha C, Davis J, Falck R, Feehan L, <b>Hoens A</b> , Holmes B, Kho M, <b>Leese J, Ma J</b> , Mackay-Lyons M, Madden K, Mayo N, Theou O, Wong H, <b>Xie H</b> | Moving More: Supporting uptake of evidence for physical activity in older adults with complex health care needs | CIHR  | \$129,094 | \$516,376 | Apr-22 | Sep-25 |

|  |  |  |      |              |             |        |        |
|--|--|--|------|--------------|-------------|--------|--------|
| Jung ME, Alexander A, Casmey S, Coes C, Compton S, Cullen L, Hartley-Folz S, Hughes CL, Kyle JL, Logan SM, Paterson K, Squires S, Bean C, Fuller DL, <b>Li LC</b> , Martin Ginis KA, Sherifali DT, Witteman HM | Davis JC, McGavock JM, Ndjaboue R, Singer J, Strachan SM   | Small steps for big changes: Implementing an evidence-based diabetes prevention program into diverse urban communities | CIHR | \$493,117.17 | \$2,958,703 | Oct-22 | Sep-28 |
| <b>Li LC, Lacaille D, Ma J</b>   | Woof A, Wilhelm L, <b>Avina-Zubieta A</b> , Gromala D, <b>Davidson E, Hoens A, Jones CA</b> , Shaw C, <b>Primeau C, Wang, E, Worthington H, English K</b> , Proulx L | Facilitating Adoption of Strength Training in people with Rheumatoid Arthritis (FAST-RA)                               | CIHR | \$20,000.00  | \$20,000    | Nov-24 | Oct-25 |
| Liu-Ambrose T, <b>Li LC</b> , Bartha C, Galea L  | J Davis, L Bherer, N D Boa Sorte Silva, E Dao, R Falk, CL Hsu, C Jacova, S Kolind, J Singer  | EPIC Health: Exercise in Perimenopause to Improve Cognitive Health   | CIHR | \$100,000.00 | \$100,000   | Apr-24 | Mar-25 |

|  |   |   |      |             |              |        |        |
|--|---|---|------|-------------|--------------|--------|--------|
| Black A, Bosma R, Fernandez N, Goldwitz D, Kent A, King M, Leblanc A, McCormick R, Poitras ME, Robinson-Settee H, Smithman MA, Turcotte S, Witteman H  | Abou-Setta A, Atherton P, Aubin D, Bacon S, <b>Li LC</b> , Tricco A et al | Innovative National Strategies for Patient-Oriented Research Education / Stratégies Nationales Innovantes pour l'Éducation en Recherche axée sur le Patient (INSPIRE) | CIHR | \$875,000   | \$5,250,000  | Mar-21 | Feb-27 |
| Bourbeau J, Anderson DR, Batist G, Bell EC, Benoit BL, Collister D, Dasgupta K, Fahim C, Fergusson DA, Fillion KB, Gahagan JC, Goos L, Khan NA, King M, <b>Li LC</b> , Mitra S, Morin SN, Pilote L, Reiman T, Richer LP, Saleh RR, Sapp JL, Tomblin Murphy GG, Yeh, AE | <b>Lacaille D, Bansback N</b> and 58 co-investigators                     | Canadian Consortium of Clinical Trial Training (CANTRAIN) platform: enhancing career preparedness in RCT research targeting different audiences across the continuum  | CIHR | \$3,772,441 | \$11,317,324 | Sep-22 | Aug-25 |

|  |   |   |  |             |             |        |        |
|--|---|---|--|-------------|-------------|--------|--------|
| Guzman, J  | Cabral D, Feldman B, <b>Li LC</b> , Loughin T, Stringer E, Toupin-April K, Tucker L   | Treating children with arthritis according to their individual probability of outcomes and response to treatments - The PERSON-JIA Trial                    | CIHR   | \$91,035    | \$455,175   | Apr-21 | Mar-26 |
| Tricco A, Straus SE, Clement F, Curran J, Colquhoun H, Gall C, Godfrey CM, Gunderson JR, Isaranuwachai W, LeBlanc A, Moher D, Proctor A, Smith LP, Smith MM, Wilhelm L, <b>Li LC</b> | <b>C Barnabe</b> , I Graham, N Ivers, T Klassen, F Legare, C Mitton, S Morin, S Scott, K Sibely, E Snelgrove-Clarke, J Squires, GF Teare plus > 100 investigators | Strategy for Patient-Oriented Research Evidence Alliance, Canadian Institutes of Health Research, Operating Grant: SPOR – Guidelines and Systematic Reviews | CIHR   | \$1,380,000 | \$1,380,000 | Apr-24 | Mar-25 |
| Tucker L   | Guzman J, Cabral D, Feldman B, <b>Li LC</b> , Loughin T, Stringer E, Toupin-April K, Tucker L   | PERSON-JIA: the Personalized Estimates of Response and Severity Outcomes in Newly-diagnosed Juvenile Idiopathic Arthritis trial                             | The Arthritis Society                                  | \$98,027    | \$294,080   | Apr-21 | Mar-26 |
| <b>Ma J</b>  |   | UBC School of Kinesiology: Implementation of a Clinical Exercise Physiologist Curriculum Pathway  | UBC Small Teaching and Learning Enhancement Fund Grant | \$24,935    | \$49,869    | Apr-25 | Mar-27 |

|   |   |   |   |           |             |        |        |
|---|---|---|---|-----------|-------------|--------|--------|
| <b>Ma J</b>   |   | Research to Impact 2.0 KxM Fellowship   | UBC Advancing Community Engaged Learning Fund Grant | \$3,000   | \$3,000     | Apr-25 | Mar-27 |
| <b>Marshall DA, Johnson J</b>   | Wozniak L, Ademola I, Smith C   | Effectiveness of an individualized decision aid for total knee arthroplasty implemented in routine clinical practice  | EUROQOL   | \$134,946 | \$269,891   | Apr-23 | Mar-25 |
| Baumgart D, Bercik P, Bernstein C, Calliou S, D'Silva A, Daley K, De Nino A, De Souza R, <b>Marshall DA</b> , Nguyen G, Otley A et al |   | IMAGINE (Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects) SPOR Chronic Disease Network - Knowledge Mobilization & Implementation Science Phase 2 | CIHR  | \$183,438 | \$733,750   | Apr-22 | Mar-26 |
| <b>Marshall DA, Baribeau DA, Bernier F, Stedman I</b>   | Langlois L, Anagnostou E, Boycott KM, Currie MG, Derfalvi B, Dragojlovic N, Fehlings DL, Friedman JM, Hartley TS, Hayeems RZ, Lehman AM, Lynd LD, Martens RE, Potter EK, Quan H, Salami BO, Saunders NR, Scherer SW, Wong-Rieger D, Wright NA | RAre Disease Administrative Data Research (RADAR) Team: putting the health system impact of rare diseases on the radar  | CIHR Team Grant                                     | \$399,560 | \$1,598,238 | Apr-24 | Mar-28 |

|  |  |   |  |           |           |        |        |
|--|--|---|--|-----------|-----------|--------|--------|
| Bryan S, Doupe M, Gallant N, <b>Lopatina E</b> , Manhas K, Jot P, McGrail K, Noseworthy T, Singal D, Wasylak T, Zelinsky S, <b>Marshall DA</b> | Bielska I, Bruce M, Hamilton C et al   | Enhancing a Community of Practice for the Health System Impact Fellowship Program: Advancing Capacity for Sustainable & Patient-Centred Learning Health Systems across Canada | CIHR                                     | \$140,000 | \$350,000 | Jul-22 | Dec-24 |
| <b>C Primeau</b>   | AR Verma, A Samson, G Schultz, J Stevenot, E Abreu, T Salway, M Kwag, <b>A Hoens, L Li</b>   | Co-Developing Research Questions About Chronic Pain with 2SLGBTQIA+ Communities through Citizen Science   | CIHR                                     | \$20,000  | \$20,000  | Sep-24 | Aug-25 |
| <b>C Primeau</b>   | Verma AR, Kwag M, Samson A, Schultz G, Salway T, Abreu E, Stevenot J, <b>Hoens A, Li L</b>   | Citizen Science: An approach to engage the 2SLGBTQIA+ public with arthritis and co-develop research questions for pain  | Arthritis Health Professions Association | \$10,000  | \$10,000  | Jan-25 | Dec-25 |
| <b>J Whittaker</b>   | <b>A Hoens, H Xie, LC Li</b> , J Davis, A Mosewich, M Miciak, E Roos, Patient Collaborators: <b>T Silvester-Lee</b> , A Ko   | Self-managing knee health in young people at high-risk of early-onset osteoarthritis: The MyKnee randomized controlled trial  | TAS                                      | \$150,000 | \$450,000 | Apr-24 | Mar-27 |
| <b>J Whittaker</b>   | J Davis, <b>A Hoens</b> , M Hunt, <b>L Li, J Losciale</b> , M Miciak, A Mosewich, E Roos, A Sheikh, L Truon, D Wilson, <b>H Xie, Collaborator: T Silvester-Lee</b> | The Stop Osteoarthritis (SOAR) Hybrid Effectiveness-Implementation Type 1 Randomized Controlled Trial for Young People at-High-Risk of Early Onset Knee Osteoarthritis        | CIHR                                     | \$100,000 | \$100,000 | Apr-24 | Mar-25 |

|                     |  |  |   |           |           |        |        |
|---------------------|--|--|---|-----------|-----------|--------|--------|
| J Whittaker, L Boyd |  | How does knee osteoarthritis alter the sensorimotor cortex   | UBC Faculty of Medicine, Department of Physical Therapy Research Seed Grant | \$20,000  | \$20,000  | Jun-24 | May-25 |
| Whittaker J         | J Davis, <b>A Hoens</b> , M Hunt, <b>L Li</b> , J Losciale, M Miciak, A Mosewich, E Roos, A Sheikh, <b>L Truong</b> , D Wilson, <b>H Xie</b><br>Collaborators: M Aljarie, C Archibald, A Brooks-Hill, P Chin, S Clark, K Kausky, A Ko, L Leveille, P Lodhia, <b>T Silvester-Lee</b> , D Wade | Preventing symptomatic post-traumatic osteoarthritis in young people at high risk: The Stop OsteoARThritis (SOAR) Randomized Controlled Trial. | CIHR Project Grant  | \$167,344 | \$669,376 | Apr-25 | Mar-29 |
| Ellis R             | <b>J Whittaker</b>   | Community of practice co-creation of a life-span approach to managing ACL injury   | Health Research Council of New Zealand                                      | \$24,118  | \$24,118  | Apr-24 | Mar-25 |
| D O'Brien           | <b>J Whittaker</b> , Reid, R Ellis, T Wilson-Uluinayau   | Exploring the medium to long term well-being of people with post-traumatic knee osteoarthritis following ACL tear in Aotearoa (New Zealand)    | Arthritis New Zealand   | \$45,630  | \$45,630  | Jul-22 | Jun-25 |

|                                   |   |   |   |                     |             |        |        |
|-----------------------------------|---|---|---|---------------------|-------------|--------|--------|
| Abbott J                          | R Wilson, K Coppel, J Kidd, R Bell, S Skou, K Smiler, T Stokes, Y Pryymachenko, P Nicolson, D Gwynne-Jones, A Tangiora, P Choong, K Bennell, R Buchbinder, <b>D Marshall</b> , M Dowsey, <b>J Whittaker</b> | Reducing the burden of osteoarthritis in Aotearoa (New Zealand).  | Health Research Council of New Zealand                    | \$809,700           | \$4,048,500 | Jul-23 | Jun-27 |
| Crossley K                        | R Hinman, M Dowsey, J Kemp, K Henne, C Emery, C Barton, A Culvenor, A Smith, B Patterson, A Bruder, I Ackerman, P Choong, M Moller, <b>J Whittaker</b>  | HERKnee Centre of Research Excellence: Preventing Knee Injury and Osteoarthritis Burden of Women and Girls<br>\$2.5 million AUD | National Health and Medical Research Council of Australia | \$625,000           | \$2,500,000 | Sep-24 | Aug-28 |
| Wilson D                          | <b>Whittaker J</b>  | Biomechanical and Imaging Assessments of Hip Micro-instability  | CIHR  | \$100,000           | \$100,000   | Jan-25 | Dec-25 |
| <b>Xie, H</b>                     |   | Knowledge Discovery Using Non-random Data Samples   | Natural Sciences & Engineering Research Council (NSERC)   | \$21,000            | \$105,000   | Apr-24 | Mar-29 |
| <b>W Zhang</b>                    | M Gignac, G Johnd, <b>D Lacaille</b> , C McLeod   | Trajectories of work productivity loss: Working from home and insights during COVID-19  | CIHR  | \$70,000            | \$70,000    | Apr-24 | Mar-25 |
| <b>Annual Total<br/>2024-2025</b> |   |   |   | <b>\$23,625,945</b> |             |        |        |

| <b>SCIENTIST FUNDING - Salary Grants</b> |              |                |                       |                      |                      |
|--|--------------|----------------|-----------------------|----------------------|----------------------|
| <b>Peer Review</b>                       |              |                |                       |                      |                      |
| <b>Funding Agency</b>                    | <b>Title</b> | <b>Faculty</b> | <b>Start/End Date</b> | <b>Annual Amount</b> | <b>Total Awarded</b> |

|                               |  |                        |                 |           |             |
|-------------------------------|--|------------------------|-----------------|-----------|-------------|
| BC Lupus                      | Lupus Scholar Award  | <b>Aviña-Zubieta A</b> | 2010 -          | \$50,000  | \$700,000   |
| CIHR                          | Canada Research Chair in Rheumatoid Arthritis and Autoimmune Diseases (Tier 2)       | <b>Barnabe C</b>       | Oct 19 - Sep 24 | \$100,000 | \$500,000   |
| CIHR                          | Canada Research Chair in Health Outcomes & Treatment Adherence (Tier 2)              | <b>De Vera M</b>       | Apr 22 - Mar 27 | \$100,000 | \$500,000   |
| CIHR                          | Canada Research Chair in Systematic Autoimmune Rheumatic Diseases (Tier I) - Renewal | <b>Fortin PR</b>       | Jul 12 - Mar 26 | \$200,000 | \$1,950,000 |
| Canada Research Chair Program | Canada Research Chair in Patient-Oriented Knowledge Translation                      | <b>Li L</b>            | Apr-19 - Mar 24 | \$100,000 | \$500,000   |
| UBC                           | Knowledge Exchange and Mobilization (KxM) Scholar Award                              | <b>Ma J</b>            | Apr 23 - Mar 25 | \$10,000  | \$20,000    |
| MSFHR                         | MSFHR Salary Award   | <b>Whittaker J</b>     | Jul 20 - Jun 25 | \$90,000  | \$450,000   |

**Annual Total**      **\$650,000**  
**2024-2025**

| <b>Endowed Chairs</b> |  |                   |           |  |  |
|-----------------------|--|-------------------|-----------|--|--|
| UBC                   | Mary Pack Chair in Rheumatology Research                           | <b>Lacaille D</b> | Sep 11 -  |  |  |
| UofC                  | Arthur J.E. Child Chair in Rheumatology Outcomes Research          | <b>Barnabe C</b>  | July 22 - |  |  |
| UBC                   | Harold Robinson-Arthritis Society Chair in Rehabilitation Sciences | <b>Li L</b>       | Jul 16 -  |  |  |

|  |   |                         |                 |           |           |
|--|---|-------------------------|-----------------|-----------|-----------|
| SFU  | Maureen and Milan Illich Chair in Statistics and Information Sciences for Arthritis and Musculoskeletal Disease | <b>Xie H</b>            | Sep15 -         |           |           |
| Dalhousie University / Nova Scotia Health. | Quigley Family Endowed Chair in Rheumatology Research   | <b>Legge A</b>          | Apr 25 - Jun 30 | \$180,000 | \$900,000 |
| Universite de Sherbrooke                   | André Lussier Chaire de Rhumatologie  | <b>Allard-Chamard H</b> | TBA             |           |           |
| Université de Montréal                     | Université de Montréal Chair in Scleroderma Research  | <b>Sabrina Hoa</b>      | TBA             |           |           |
| University of Calgary                      | Svare Chair in Health Economics, Value and Impact   | <b>Deborah Marshall</b> | Oct 24 - Sep 29 |           |           |

| <b>TRAINEE SALARY AWARDS</b> |  |                 |                   |                       |                      |                      |
|------------------------------|--|-----------------|-------------------|-----------------------|----------------------|----------------------|
| <b>Funding Agency</b>        | <b>Award Type and/or Research Title</b>  | <b>Trainee</b>  | <b>Supervisor</b> | <b>Start/End Date</b> | <b>Annual Amount</b> | <b>Total Awarded</b> |
| MITACS                       | Pharmacist-physiotherapist collaborative management for early knee osteoarthritis" (PACE-OA)   | <b>Burgar J</b> | <b>Jones A</b>    | Nov 24 - Oct 25       | \$30,000             | \$30,000             |
| TD Bank                      | TD Bank Financial Group Grant for Health Sciences Interdisciplinary Research Fund Award  | <b>Burgar J</b> | <b>Jones A</b>    | Nov 24 - Oct 25       | \$10,000             | \$10,000             |
| MITACS                       | Targeted synthetic and biosimilar disease modifying antirheumatic drugs in pregnancy: Patterns of use among females with rheumatic diseases and outcomes | <b>Cheng V</b>  | <b>De Vera M</b>  | Jan 24 - Feb 25       | \$45,000             | \$45,000             |

|  |   |                      |                         |                   |          |           |
|--|---|----------------------|-------------------------|-------------------|----------|-----------|
| University of British Columbia   | Andrew Nord Fellowship in Rheumatology  | <b>Daftarian N</b>   | <b>Aviña-Zubieta JA</b> | Jul 22 - Jun 26   | \$22,000 | \$88,000  |
| CIHR   | Doctoral Research Award - RetINal Toxicity And hydroxyChloroquine Therapy (INTACT)  | <b>N Daftarian</b>   | <b>Aviña-Zubieta JA</b> | Jun 23 - May 26   | \$35,000 | \$105,000 |
| (CIHR-IMHA) Alberta Health Systems Impact Fellowship                         | (CIHR-IMHA) Alberta Health Systems Impact Fellowship - A proactive approach to health: integrating personalized physical activity behaviour change support into inflammatory arthritis care | <b>M Ester</b>       | <b>Barber CEH</b>       | Sep 24 - Aug 26   | \$77,500 | \$155,000 |
| University of Calgary, Cumming School of Medicine Graduate Scholarship Award | Optimizing Precision in Practice: Standardizing the use of Treat-to-Target Measures for Enhanced Rheumatoid Arthritis Care Delivery   | <b>R Githumbi</b>    | <b>Barber CEH</b>       | April 25 - Mar 26 | \$20,000 | \$20,000  |
| Walter Gulka Scholarship   | Exploring Mesenchymal Stromal Cells as a Novel Treatment for Systemic Sclerosis-Induced Fibrosis  | <b>S Joy</b>         | <b>Colmegna I</b>       | Jan 25 - Jun 26   | \$14,666 | \$22,000  |
| UBC  | Experimental Medicine Entrance Award  | <b>D Karacabeyli</b> | <b>Lacaille D</b>       | April 25 - Mar 26 | \$5,000  | \$5,000   |
| CIHR Canada Graduate Scholarship Master's award                              | Effectiveness and safety of glucagon-like peptide-1 receptor agonists in patients with inflammatory arthritis and type 2 diabetes mellitus  | <b>D Karacabeyli</b> | <b>Lacaille D</b>       | April 25 - Mar 26 | \$27,000 | \$27,000  |

|   |   |                      |                    |                 |          |           |
|---|---|----------------------|--------------------|-----------------|----------|-----------|
| UBC   | Andrew Nord Fellowships in Rheumatology Spring Graduate Award   | <b>D Karacabeyli</b> | <b>Lacaille D</b>  | Apr 25 - Mar 27 | \$8,333  | \$25,000  |
| UBC   | University of British Columbia 4-year Fellowship  | <b>Losciale, J</b>   | <b>Whittaker J</b> | Jul 22 - Jun 26 | \$18,200 | \$72,800  |
| The Arthritis Society   | PhD Salary Award for The Stop OsteoARthritis (SOAR) Proof-of-Concept Delayed Control Randomized Trial: Can We Mitigate A Key Risk Factor for Osteoarthritis following Sport-related Knee Trauma?" | <b>Losciale, J</b>   | <b>Whittaker J</b> | Sep 21 - Aug 25 | \$10,500 | \$31,500  |
| MITACS  | Comparing the risk of adverse events across different classes of biologics prescribed for inflammatory arthritis  | <b>Moolooghy K</b>   | <b>Lacaille D</b>  | Jan 24 - Feb 25 | \$45,000 | \$45,000  |
| University of Calgary Cumming School of Medicine Graduate Scholarship | Improving care pathways for patients with Giant Cell Arteritis  | <b>Ogunleye T</b>    | <b>Barber CEH</b>  | Apr 24 - Mar 26 | \$6,000  | \$12,000  |
| Michael Smith Health Research BC Research                             | Trainee Award - Exploring the Lived Experiences of Sexual and Gender Minority Populations Living with Arthritis: A Patient Engagement Centered Approach   | <b>Primeau C</b>     | <b>Li L</b>        | Apr 23 - Mar 26 | \$49,500 | \$148,500 |

|                                       |  |                  |                   |                 |          |           |
|---------------------------------------|--|------------------|-------------------|-----------------|----------|-----------|
| The Arthritis Society                 | Postdoctoral Research Fellowship award - Exploring the Lived Experiences of Sexual and Gender Minority Populations Living with Arthritis: A Patient Engagement Centered Approach | <b>Primeau C</b> | <b>Li L</b>       | Oct 23 - Sep 26 | \$50,000 | \$150,000 |
| CIHR Banting Post-doctoral Fellowship | Leveraging Citizen Science for Inclusive Pain Research: Maximizing Public Engagement for Co-Developing Research Questions with Sexual and Gender Minority Communities            | <b>Primeau C</b> | <b>Li L</b>       | May 24 - Apr 26 | \$70,000 | \$140,000 |
| CIHR                                  | Postdoctoral Research fellowship - Prouricemic diets, microbial composition and functional potential, and plasma uric acid   | <b>Rai S</b>     | <b>Choi H</b>     | Oct 22 - Sep 25 | \$50,000 | \$150,000 |
| CIHR                                  | Doctoral Research Award - Optimizing medication and vaccination adherence in rheumatoid arthritis in the COVID-19 era: Development of a patient-centred intervention             | <b>Ta V</b>      | <b>Bartlett S</b> | Jun 23 - May 26 | \$35,000 | \$105,000 |
| CIHR                                  | Doctoral Research Award - Assessing equity considerations in the research and care of patients with inflammatory arthritis (ACCESS)".  | <b>Thomas M</b>  | <b>De Vera M</b>  | Jun 23 - May 26 | \$35,000 | \$105,000 |

|                               |   |                        |                    |                 |                  |           |
|-------------------------------|---|------------------------|--------------------|-----------------|------------------|-----------|
| The Arthritis Society         | PhD Salary Award - Differences in health for patients with inflammatory arthritis: Are they preventable?  | <b>Thomas M</b>        | <b>De Vera M</b>   | Oct 21 - Sep 24 | \$10,500         | \$31,500  |
| The Arthritis Society         | PhD Salary award - Moving towards the personalization of treatment choices in rheumatoid arthritis: Combining clinical modelling strategies to personalize risk estimates | <b>Thomas-Purdue J</b> | <b>Hazlewood G</b> | Oct 23 - Sep 26 | \$17,500         | \$52,500  |
| CIHR                          | Doctoral Research Award - Access to outpatient physiotherapy in British Columbia following anterior cruciate ligament injury  | <b>Worthington H</b>   | <b>Li L</b>        | Apr 23 - Mar 25 | \$35,000         | \$105,000 |
| MITACS                        | Addressing Endogeneity in count data using a two-stage copula generated regressor approach  | <b>Zhao K</b>          | <b>Xie H</b>       | Nov 24 - Oct 25 | \$30,000         | \$30,000  |
| Walter Gulka Scholarship      | Evaluating treatment effect for SLE using novel causal inference methods  | <b>Zhao K</b>          | <b>Xie H</b>       | Jan 25 - Jun 25 | \$7,500          | \$7,500   |
| <b>Annual Total 2024-2025</b> |   |                        |                    |                 | <b>\$764,199</b> |           |

## Appendix II – Publications & Abstracts, July 1, 2024 – June 30, 2025

Names in bold indicate Arthritis Research Canada/Arthrite-recherche Canada Scientists, Trainees and Patient Advisory Board Members

### PUBLICATIONS

1. Abbaticchio A, Theodorlis M, **Marshall DA**, MacKay C, Borkhoff CM, Hazlewood GS, Battistella M, Lofters A, Ahluwalia V, Gagliardi AR. Policies in Canada fail to address disparities in access to person-centred osteoarthritis care: A content analysis. *BMC Health Res*, Apr 2024;24(1):522.
2. **Abrahamowicz M**, Beauchamp ME, Boulesteix AL, Morris TP, Sauerbrei W, Kaufman JS, Stratos Simulation Panel OBOT. Data-Driven Simulations to Assess the Impact of Study Imperfections in Time-to-Event Analyses. *Am J Epidemiol*. 2024 May 6:kwae058. doi: 10.1093/aje/kwae058. Online ahead of print.
3. Adams C, Nassar EL, Carrier ME, Kwakkenbos L, Henry RS, Virgili-Gervais G, Hu S, **Bartlett SJ**, Fortuné C, Gietzen A, Gottesman K, Guillot G, **Hudson M**, Lawrie-Jones A, Lewis N, Malcarne V, Mayes MD, Patten SB, Richard M, Sauvé M, Varga J, Welling J, Wojcek R, Mouthon L, Benedetti A, Thombs BD; SPIN Investigators. Changes in work and adequacy of financial resources during COVID-19 among people with systemic sclerosis: A Scleroderma Patient-centered Intervention Network study. *J Scleroderma Relat Disord*. 2024 Oct;9(3):242-247. doi: 10.1177/23971983241262655. Epub 2024 Aug 5.
4. Alkan A, Carrier ME, Henry RS, Kwakkenbos L, **Bartlett SJ**, Gietzen A, Gottesman K, Guillot G, Lawrie-Jones A, **Hudson M**, Hummers LK, Malcarne VL, Mayes MD, Mouthon L, Richard M, Wojcek RK, Worrone-Sauvé M, Benedetti A, Thombs BD, **Fortin PR**; Scleroderma Patient-Centered Intervention Network Investigators. Minimal Detectable Changes of the Health Assessment Questionnaire-Disability Index, Patient-Reported Outcomes Measurement Information System-29 Profile Version 2.0 Domains, and Patient Health Questionnaire-8 in People with Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Cross-Sectional Study. *Arthritis Care Res (Hoboken)*. 2024 Nov;76(11):1549-1557. doi: 10.1002/acr.25397. Epub 2024 Aug 27.
5. **Allard-Chamard H**, Hillier K, Ramseier ML, Bertocchi A, Kaneko N, Premo K, Yuen G, Karpel M, Mahajan VS, Tsekeri C, Hong JS, Vencic J, Sharda AV, Barmettler S, Westermann-Clark E, Walter JE, Ghebremichael M, Shalek AK, Farmer JR, Pillai S. Congenital T cell activation impairs transitional to follicular B cell maturation in humans. *Blood Adv*. 2025 Feb 11;9(3):520-532. doi: 10.1182/bloodadvances.2024013267.
6. AlShehri Y, Megaloikonomos PD, Neufeld ME, Howard LC, **Greidanus NV**, **Garbuz DS**, Masri BA. Cementless Total Knee Arthroplasty: A State-of-the-Art Review. *JBJS Rev*. 2024 Jul 5;12(7). doi: 10.2106/JBJS.RVW.24.00064. eCollection 2024 Jul 1.
7. Andrade LEC, Klotz W, Herold M, Musset L, Damoiseaux J, Infantino M, Carballo OG, **Choi M**, von Mühlen CA, Garcia-De La Torre I, Satoh M, Francescantonio PLC,

- Mimori T, Conrad K, de Melo Cruvinel W, Chan EKL, Fritzler MJ. Reflecting on a decade of the international consensus on ANA patterns (ICAP): Accomplishments and challenges from the perspective of the 7th ICAP workshop. *Autoimmun Rev*. 2024 Sep;23(9):103608. doi: 10.1016/j.autrev.2024.103608. Epub 2024 Aug 24.
8. Arnaud L, Ruiz-Irastorza G, Aranow C, Bernatsky S, Dall'Er M, et al. (including **Legge A & Clarke AE**) European Reference Network on Rare and Complex Connective tissue and Musculoskeletal Disease; Systemic Lupus Erythematosus Collaborating Clinics group; European Lupus Society rare systemic lupus erythematosus taskforce member panel. ERN ReCONNET – SLICC – SLEuro consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. *The Lancet Rheumatology*. 2025:S2665-9913(25)00063-3.
  9. Aubert A, Liu A, Kao M, Goeres J, Richardson KC, Nierves L, Jung K, Nabai L, Zhao H, Orend G, Krawetz R, Lange PF, Younger A, **Chan J**, Granville DJ. Granzyme B cleaves tenascin-C to release its C-terminal domain in rheumatoid arthritis. *JCI Insight*. 2024 Oct 30;9(23):e181935. doi: 10.1172/jci.insight.181935.
  10. Aydemir B, Schieir O, Valois MF, Muhammad LN, Song J, Dunlop D, Chang RW, **Bartlett SJ**, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Pope J, Thorne C, Tin D, Bykerk VP, Lee YC. Association Between Sleep Disturbance and Subsequent Pain Interference in Patients with Early Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2025 May 12. doi: 10.1002/acr.25568. Online ahead of print.
  11. Bacher S, **Whittaker JL**. Prevention is better than a cure: Prevention strategies for osteoarthritis. *Muskuloskelettale Physiotherapie*. 2025 29(1):17-26 doi: 10.1055/a-2452-1533.
  12. Bakunda L, Crooks R, Johnson N, Osei-Tutu K, Bharwani A, Gye E, Okoro D, Hinz H, Nearing S, Peer L, Kassam A, Smyth P, Chu P, Ruzycki S, Joneja M, Rabi D, **Barnabe C**, Roach P. Redefining professionalism to improve health equity in competency based medical education (CBME): A qualitative study. *MedEdPublish (2016)*. 2024 Oct 18;14:237. doi: 10.12688/mep.20489.1. eCollection 2024.
  13. Barbhैया M, Zuily S, Amigo MC, Andrade D, Avcin T, Bertolaccini ML, Branch DW, Costedoat-Chalumeau N, Crowther M, Ramires de Jesus G, Devreese KMJ, Frances C, Garcia D, Gómez-Puerta JA, Guillemain F, Levine SR, Levy RA, Lockshin MD, Ortel TL, Petri M, Sanna G, Sciascia S, Seshan SV, Tektonidou MG, Wahl D, Willis R, Yelnik C, Hendry A, Naden R, Costenbader K, Erkan D; **Fortin PR**, ACR/EULAR APS Classification Criteria Collaborators. Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-D Report: Multicriteria Decision Analysis. *Arthritis Care Res (Hoboken)*. 2024 Dec;76(12):1617-1625. doi: 10.1002/acr.25415. Epub 2024 Sep 30.
  14. Baron M, Nikpour M, Hansen D, Proudman S, Stevens W; Australian Scleroderma Interest Group (ASIG) and the Canadian Scleroderma Research Group (CSRG); Wang M, **Fortin PR**. Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage Accrual. *Arthritis Care Res (Hoboken)*. 2025 May;77(5):640-648. doi: 10.1002/acr.25467. Epub 2025 Feb 2.

15. Beckett M, Spaner C, Goubran M, Wade J, **Aviña-Zubieta JA**, Setiadi A, Tucker L, **Shojania K**, Au S, Mattman A, Lee AYY, Fajgenbaum DC, Chen LYC. CRP and sCD25 help distinguish between adult-onset Still's disease and HLH. *Eur J Haematol*. 2024 Nov;113(5):576-583. doi: 10.1111/ejh.14267. Epub 2024 Jul 10.
16. Bernstein C, Panaccione R, Nugent Z, **Marshall DA**, Kaplan G, Vanner S, Dieleman L, Graff L, Otley A, Jones J, Buresi M, Murthy S, Borgaonkar M, Bressler B, Bitton A, Croitoru K, Sidani S, Fernandes A, Moayyedi P. Crohn's disease phenotypes and associates with comorbidities, surgery risk, medications and nonmedication approaches: The MAGIC in IMAGINE study. *Inflamm Bowel Dis*. 2025 Jan 6;31(1):113-122. doi: 10.1093/ibd/izae055.
17. Berthelot W, Sirois C, Julien AS, Amiable N, Bessette L, Desaulniers P, Audet MC, Lagacé S, **Fortin PR**. The association between polypharmacy and disease control in rheumatoid arthritis and systemic lupus erythematosus: a cohort study. *Rheumatol Int*. 2025 Feb 8;45(3):44. doi: 10.1007/s00296-025-05804-8.
18. Benoit JM, Breznik JA, Wu Y, Kennedy A, Liu LM, Cowbrough B, Baker B, Hagerman M, Andary CM, Mushtaha M, Abdalla N, McNicol JD, Gauvreau G, Kim PY, Denburg JA, Costa AP, Leong DP, Nazy I, Duong M, Bramson JL, **Larché MJ**, Verschoor CP, Bowdish DME. No evidence of immune exhaustion after repeated SARS-CoV-2 vaccination in vulnerable and healthy populations. *Nat Commun*. 2025 Jun 5;16(1):5219. doi: 10.1038/s41467-025-60216-3.
19. Biln NK, **Bansback N**, **Shojania K**, Puil L, **Harrison M**. A scoping review of triage approaches for the referral of patients with suspected inflammatory arthritis, from primary to rheumatology care. *Rheumatol Int*. 2024 Nov;44(11):2279-2292. doi: 10.1007/s00296-024-05575-8. Epub 2024 Mar 26.
20. Bingham CO, **Bartlett SJ**. Using patient reported outcomes measurement information system (PROMIS®) measures in rheumatoid arthritis clinical care, research, and trials. *Semin Arthritis Rheum*. 2025 Feb;70S:152576. doi: 10.1016/j.semarthrit.2024.152576. Epub 2024 Nov 8.
21. Bishnoi A, Tang IYK, Yoshida A, Pais FM, Usman SY, Dominguez SA, Kavadiachanda CG, Rivero-Gallegos D, Dourado E, Conticini E, Bozán F, Tulluru G, Lilleker JB, Sreerama Reddy K, Landon-Cardinal O, Smaili R, Keret S, Khoo T, Lan TY, **Leclair V**, Oddis CV, Vencovský J, Kuwana M, Gandiga PC, Aggarwal R. The Myositis Clinical Trials Consortium: an international collaborative initiative to promote clinical trials in adult and juvenile myositis. *Clin Exp Rheumatol*. 2025 Feb;43(2):202-210. doi: 10.55563/clinexprheumatol/k7665a. Epub 2025 Feb 20.
22. Blazey P, Scott A, Ardern CL, Davis JC, **Whittaker JL**, **Losciale JM**, Khan KM. (2024). Consensus methods in patellofemoral pain. How rigorous are they? A scoping review. *Br J Sports Med*. 2024 Jun 20;58(13):733-744. doi: 10.1136/bjsports-2023-107552.
23. Brizio M, Mancini M, Lora M, **Joy S**, Zhu S, Brilland B, Reinhardt DP, Farge D, Langlais D, **Colmegna I**. Cytokine priming enhances the antifibrotic effects of human adipose derived mesenchymal stromal cells conditioned medium. *Stem Cell Res Ther*. 2024 Sep 27;15(1):329. doi: 10.1186/s13287-024-03916-9.

24. Bruce M, Yogaratnam K, Suryaprasash N, Barker KL, **Marshall DA**. Key ingredients for successful collaboration in health research: perspectives of patient research partners. *Research Involvement and Engagement*, BMC Open Access, June 2024;10(52):1-8
25. Budarick AR, Hubley-Kozey CL, Li LC, Theou O, Stanish WD, Moyer RF. Quality of Non-Surgical and Non-Pharmacological Knee Osteoarthritis Care in the Maritimes. *Musculoskeletal Care*. 2025 Mar;23(1):e70047. doi: 10.1002/msc.70047.
26. Bullock GS, Fallowfield J, Fisher B, **Whittaker JL**, Gafari O, Bilzon JLJ. Prioritizing Knowledge User Engagement: Engaging Patients and the Public in Creating Enduring Musculoskeletal Rehabilitation Research. *J Orthop Sports Phys Ther*. 2024 Dec;54(12):1-5. doi: 10.2519/jospt.2024.12668.
27. Cardwell FS, Elliott SJ, **Barber MRW**, Cheema K, George S, Boucher A, **Clarke AE**. Using photovoice to investigate patient experiences of lupus nephritis in Canada. *Lupus Sci Med*. 2024 Nov 7;11(2):e001265. doi: 10.1136/lupus-2024-001265.
28. Cardwell FS, Kobza AO, Elliott SJ, Gibson PS, Soliman N, Skeith L, **Clarke AE**, **Barber MR**. A qualitative investigation of the experiences of patients living with antiphospholipid antibodies. *Lupus*. 2024 Sep;33(10):1043-1058. doi: 10.1177/09612033241265545. Epub 2024 Jul 24.
29. Cecchi I, Radin M, Foddai SG, Barinotti A, Andrade D, Tektonidou MG, Pengo V, Ruiz-Irastorza G, Belmont HM, Lopez Pedrera C, **Fortin PR**, Gerosa M, de Jesus G, Atsumi T, Ji L, Efthymiou M, Branch DW, Nalli C, Rodriguez-Almaraz E, Petri M, Cervera R, Knight J, Artim-Esen B, Willis R, Bertolaccini ML, Cohen H, Erkan D, Sciascia S. ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the APS ACTION Clinical Database and Repository. *Rheumatology (Oxford)*. 2025 May 1;64(5):2862-2867. doi: 10.1093/rheumatology/keae583.
30. Chakraborty R, Chronopoulos J, Sun R, Morozan A, **Joy S**, Divangahi M, Lauzon AM, Martin JG. Anti-ST2 antibody reduces airway hyperresponsiveness mediated by monocyte-derived macrophages during influenza A infection. *Mucosal Immunol*. 2025 May 2:S1933-0219(25)00046-7. doi: 10.1016/j.mucimm.2025.04.008. Online ahead of print.
31. Chan SJ, Stamp LK, Treharne GJ, Cheung JMY, Dalbeth N, Grainger R, Stebbings S, **Marra CA**. Preferences for Tapering Biologic Disease-Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment. *Arthritis Care Res (Hoboken)*. 2025 Mar;77(3):349-358. doi: 10.1002/acr.25437. Epub 2024 Oct 16.
32. Chen L, Fallavollita S, Sakr L, Wang H, Pusztaszeri M, Esfahani K, Pollak MN, **Hudson M**, **Leclair V**. Case Series: The Challenge of Using Immune Checkpoint Inhibitors in Anti-Transcriptional Intermediary Factor 1  $\gamma$  Antibody-Positive Dermatomyositis. *Int J Rheum Dis*. 2025 Jan;28(1):e70087. doi: 10.1111/1756-185X.70087.
33. **Cheng V**, Sayre EC, Chang V, Garg R, Gill S, Farooq A, **De Vera MA**. Patterns of Prescription Medication Use Before Diagnosis of Early Age-Onset Colorectal Cancer:

- Population-Based Descriptive Study. *JMIR Cancer*. 2024 Jul 12:10:e50402. doi: 10.2196/50402.
34. **Cheng V, Amiri N**, Cheng V, Ellis U, Cragg JJ, **Harrison M**, Proulx L, **De Vera MA**. Pregnancy Outcomes of Targeted Synthetic Disease-Modifying Antirheumatic Drugs Among Patients With Autoimmune Diseases: A Scoping Review. *Arthritis Care Res (Hoboken)*. 2025 Feb 2. doi: 10.1002/acr.25502. Online ahead of print.
  35. **Cheng V**, Kang P, Proulx L, **Amiri N, De Vera MA**. Lessons learned from Café Scientifique public webinars on pregnancy and parenting in arthritis: perspectives from patients, clinicians, and researchers. *BMC Proc*. 2025 Apr 8;19(Suppl 7):10. doi: 10.1186/s12919-025-00323-7.
  36. **Choi MY**, Costenbader KH, Fritzler MJ. Environment and systemic autoimmune rheumatic diseases: an overview and future directions. *Front Immunol*. 2024 Sep 10;15:1456145. doi: 10.3389/fimmu.2024.1456145. eCollection 2024.
  37. Chomistek K, **Barnabe C**, Santana MJ, Stinson J, Schmelting H. Systematized Literature Review on the Effectiveness of Self-Management Programs for Juvenile Idiopathic Arthritis. *Discover Health Systems* 2025;4:4.
  38. Churipuy MM, Golchi S, **Hudson M, Hoa S**. A Bayesian adaptive feasibility design for rare diseases. *Contemp Clin Trials Commun*. 2024 Nov 9;42:101392. doi: 10.1016/j.conctc.2024.101392. eCollection 2024 Dec.
  39. Cipolletta E, Nakafero G, **McCormick N**, Yokose C, Avery AJ, Mamas MA, **Choi HK**, Tata LJ, Abhishek A. Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data. *Lancet Rheumatol*. 2024 Dec 18:S2665-9913(24)00248-0. doi: 10.1016/S2665-9913(24)00248-0. Online ahead of print.
  40. **Contreras D**, McLane P, **Barber C**, Lin K, Elliott M, **Chomistek K, McQuitty S, Davidson E**, Hildebrandt C, Katz S, Lang E, Holroyd B, **Barnabe C**. Emergency Department Utilization by Persons with Rheumatoid Arthritis: A Population-Based Cohort Study. *Rheumatology International* 2024 Sep;44(9):1691-1700. doi: 10.1007/s00296-024-05627-z. Epub 2024 Jun 8.
  41. **Contreras DG, Barber CEH, Aviña-Zubieta JA**, Quan H, Lee S, King JA, **Barnabe C**. Avoidable Hospitalizations in Persons with Rheumatoid Arthritis: A Population-Based Study Using Administrative Data. *Arthritis Care Res*. 2025 Apr 2. doi: 10.1002/acr.25541. Online ahead of print.
  42. **Couch JL**, King MG, Silva DO, **Whittaker JL**, West TJ, Bruder AM, Girdwood MA, Barton CJ, Crossley KM, Roos EM, Culvenor AG. Diagnostic performance of self-reported knee crepitus using a Knee injury and Osteoarthritis Outcome Score item. *Osteoarthritis Cartilage*. 2024 Dec 19:S1063-4584(24)01503-6. doi: 10.1016/j.joca.2024.12.004. Online ahead of print.
  43. **Couch JL**, King MG, De Oliveira Silva D, **Whittaker JL**, Bruder AM, Serighelli F, Kaplan S, Culvenor SK. Noisy Knees – knee crepitus prevalence and association

- with structural pathology: A systematic review and meta-analysis. *Br J Sports Med.* 2025 Jan 2;59(2):126-132. doi: 10.1136/bjsports-2024-108866.
44. Crosland P, Ho N, Hosseini S, Vacher C, Skinner A, Natsky AN, Rosenberg S, Hasudungan R, Huntley S, Song YJC, Lee GY, **Marshall DA**, Occhipinti J-A, Hickie IB. Cost-effectiveness of system-level mental health strategies for young people in the Australian Capital Territory: a dynamic simulation modelling study. *Lancet Psychiatry* 2024; 11(2):123-133.
  45. Crosland P, **Marshall DA**, Hosseini SH, Ho N, Vacher C, Skinner A, Nguyen KH, Iorfino F, Rosenberg S, Christine Sog YJ, Tsiachristas A, Tran K, Occhipinti J, Hickie IB. Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning. *PharmacoEconomics*, Oct 2024;1-10.
  46. Currie GR, Storek J, MacDonald KV, **Hazlewood G**, Durand C, Bridges JFP, Mosher D, **Marshall DA**. Measuring Patient Preferences to Inform Clinical Trial Design: An Example in Rheumatoid Arthritis. *Patient.* 2025 Mar;18(2):161-171. doi: 10.1007/s40271-024-00724-4. Epub 2024 Dec 12.
  47. Currie GR, Lee R, Palacios-Derflinger L, Hagel B, Black AM, Babul S, Mrazik M, **Marshall DA**, Emery CA. Correction: Reality Check 2: The cost-effectiveness of policy disallowing body checking in non-elite 13- to 14-year-old ice hockey players. *IJERPH*, Feb 2024;21(3):269.
  48. Dal Santo C, Golberg M, Carrier ME, Harel D, Kwakkenbos L, Bartlett SJ, Fortuné C, Gietzen A, Gottesman K, Guillot G, Lawrie-Jones A, Richard M, Worrón-Sauvé M, Mouthon L, Malcarne VL, Benedetti A, Thombs BD; SPIN Investigators (incl. **Fortin PR**). Evaluation of the Coping Strategies Questionnaire-Revised for fatigue in systemic sclerosis: a Scleroderma Patient-centred Intervention Network (SPIN) cohort study. *Clin Exp Rheumatol.* 2025 Mar 10. doi: 10.55563/clinexprheumatol/26zipq. Online ahead of print.
  49. Degeling K, Tagimacruz T, MacDonald KV, Seeger TA, Fooks K, Venkataramanan V, Boycott KM, Bernier FP, Mendoza-Londono R, Hartley T, Hayeems RZ, **Marshall DA**, on behalf of Care4Rare Canada. Exome sequencing in the diagnostic pathway for suspected rare genetic diseases: Does the order of testing affect its cost-effectiveness? *Applied Health Economics and Health Policy.* May 2025;23(3):453-466. <https://doi.org/10.1007/s40258-024-00936-7>
  50. Dhakal S, Merani S, Ahluwalia V, Battistella M, Borkhoff CM, **Hazlewood GS**, Lofters A, **Marshall DA**, MacKay C, Gagliardi AR. The Quality and Cultural Safety of Online Osteoarthritis Information for Affected Persons and Health Care Professionals: Content Analysis, *J Med Internet Res*, Oct 2024;26:e57698.
  51. D'Silva A, Hua N, Modayil MV, Seidel J, **Marshall DA**. Digital Health Interventions Are Effective for Irritable Bowel Syndrome Self-Management: A Systematic Review. *Dig Dis Sci.* 2025 Feb;70(2):644-664. doi: 10.1007/s10620-024-08672-7. Epub 2024 Oct 14.
  52. D'Silva A, Hua N, Wicks C, Modayil M, Seidel J, Marshall DA. E-health tools in irritable bowel syndrome management. *International Journal of Integrated Care*, April 2025;25(2):1-11.

53. Ediboglu ED, Erpek E, **Bayraktar D**, Özmen M, Solmaz D, Akar S. Major Determinants of Well-Being in Patients With Axial Spondyloarthritis: 2 Year Follow-Up. *Musculoskeletal Care*. 2024 Sep;22(3):e1942. doi: 10.1002/msc.1942.
54. Erton ZB, Leaf RK, de Andrade D, **Clarke A**, Tektonidou MG, Pengo V, Sciascia S, Pardos-Gea J, Kello N, Paredes-Ruiz D, Lopez-Pedraza C, Belmont HM, **Fortin PR**, Ramires de Jesús G, Atsumi T, Zhang Z, Efthymiou M, Branch DW, Pazzola G, Andreoli L, Duarte-García A, Rodriguez-Almaraz E, Petri M, Cervera R, Artim-Esen B, Quintana R, Shi H, Zuo Y, Willis R, **Barber MRW**, Skeith L, Radin M, Meroni P, Bertolaccini ML, Cohen H, Roubey R, Erkan D. Thrombocytopenia and autoimmune hemolytic anemia in antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid syndrome alliance for clinical trials and InternatiOnal networking (APS ACTION) clinical database and repository ("Registry"). *Lupus*. 2025 May;34(6):617-625. doi: 10.1177/09612033251332258. Epub 2025 Apr 3.
55. **Ester M**, White K, **Dhiman K**, **Zafar S**, Subdar S, Zimmermann GL, **Hoens AM**, Manske SL, **Hazlewood G**, **Lacaille D**, **Barber MRW**, Panich N, Jung M, Perry M, Twilt M, Then KL, Charlton A, **Barber C**. A theory of change for patient-initiated follow-up care in rheumatoid arthritis. *BMC Rheumatology*. Accepted. 2025.
56. **Ester M**, **Zafar S**, **Dhiman K**, **Hoens AM**, **Graveline C**, **McKinnon A**, **Barber CEH**. Online physical activity resources for individuals with rheumatoid arthritis: An environmental scan and quality appraisal. *BMJ Open*. 2025 Feb 20;15(2):e094220. doi: 10.1136/bmjopen-2024-094220.
57. Fatima S, Pope JE, Chen LR, Schieir O, Valois MF, **Bartlett SJ**, Boire G, **Hazlewood G**, Hitchon C, Tin D, Thorne C, Kuriya B, **Allard-Chamard H**, Bykerk VP, Bessette L; CATCH investigators. Higher comorbidities associated with less improvement in disease activity in early rheumatoid arthritis: results from CATCH cohort. *Rheumatology (Oxford)*. 2025 Jun 25:keaf350. doi: 10.1093/rheumatology/keaf350. Online ahead of print.
58. Feehan L, **Xie H**, **Lu N**, **Li LC**. Twenty-four hour physical activity, sedentary behaviour and sleep profiles in adults living with rheumatoid arthritis: a cross-sectional latent class analysis. *J Act Sedentary Sleep Behav*. 2024 Apr 17;3(1):10. doi: 10.1186/s44167-024-00049-5.
59. Fukui S, Okada M, Shinozaki T, Suzuki T, Nakai T, Ozawa H, Tamaki H, Kishimoto M, Hasegawa H, Matsuda T, Marrugo J, Tedeschi SK, **Choi HK**, Solomon DH. Weight Reduction and Target Serum Urate Level: A Longitudinal Study of Annual Medical Examination. *Arthritis Rheumatol*. 2024 Oct 14. doi: 10.1002/art.43027. Online ahead of print.
60. 1. Fujii U, Makita K, **Joy S**, Sun R, Dunberry S, Moroza A, Nakada E, McGovern T, Martin J. Leukotriene C4 synthase deficiency causes spontaneous emphysema in female mice. *American Journal of Respiratory Cell and Molecular Biology*. May 2025. In Press.
61. Germeni E, Fifer S, Hiligsmann M, Stein B, Tonkinson M, Joshi M, Hanna A, Liden B, **Marshall DA**. A genuine need or nice to have? Understanding HTA

- representatives' perspectives on the use of patient preference data. *Int J Technol Assess Health Care*. 2024 Nov 20;40(1):e60. doi: 10.1017/S026646232400463X.
62. Ginn C, Ginn CWC, **Barnabe C**, Dumont D/Bergum V, Gentes J, Tatrallyay P. How do health, spirituality and well-being intersect in the Metis Nation of Alberta (MNA) Region 3? A Metis-guided, community-based, participatory study. *BMJ Open* 2025;15:e089503.
  63. **Githumbi R**, Katz SJ, Widdifield J, **Barber CEH**. Update to a Systematic Review on Quality Measures for Rheumatoid Arthritis. *J Rheumatol*. April 2025. Epub ahead of print. DOI: <https://doi.org/10.3899/jrheum.2024-1314>
  64. **Githumbi R, Barber CEH, Bartlett SJ**, Toupin-April, Twilt M, **Lacaille D, Barnabe C, Dhiman K, Hoens AM**, Grebowicz A, McMillan T, Widdifield J. Canadian Rheumatology Association Guidance for Developing & Endorsing Quality Measures to Support Learning Health Systems. *J Rheumatol*. April 15 2025, jrheum.2024-1065; DOI: <https://doi.org/10.3899/jrheum.2024-1065>
  65. Goubran M, Spaner C, Stukas S, Zoref-Lorenz A, **Shojania K**, Beckett M, Li A, Peterson E, Sekhon M, Grey R, Wellington C, Cheng CV, Biggs CM, Mattman A, Jordan MB, Chen LYC, Setiadi A. The role of C-reactive protein and ferritin in the diagnosis of HLH, adult-onset still's disease, and COVID-19 cytokine storm. *Sci Rep*. 2024 Dec 28;14(1):31306. doi: 10.1038/s41598-024-82760-6.
  66. Gulcernal MO, Sarac DC, Alp G, Duran G, Gucenmez S, Solmaz D, Akar S, Bayraktar D. Effects of video-based cervical stabilization home exercises in patients with rheumatoid arthritis: a randomized controlled pilot study. *Z Rheumatol*. 2024 Dec;83(Suppl 3):352-358. doi: 10.1007/s00393-024-01543-6. Epub 2024 Jul 1.
  67. Gupta A, Johnson S, Barraclough M, Su J, Bingham K, Knight AM, Diaz Martinez JP, Kakvan M, Tartaglia MC, Ruttan L, Marzouk S, Wither J, **Choi M**, Bonilla D, Appenzeller S, Beaton D, Katz P, Green R, Touma Z. Outcome clusters and their stability over 1 year in patients with SLE: self-reported and performance-based cognitive function, disease activity, mood and health-related quality of life. *Lupus Sci Med*. 2024 Jul 11;11(2):e001006. doi: 10.1136/lupus-2023-001006.
  68. Habib R, Dayam RM, Hitchon C, Chandran V, **Fortin PR**, Boire G, Bowdish DME, Gingras AC, Flamand L, Larché MJ, **Colmegna I**, Lukusa L, Lee JLF, Pereira D, Bernstein CN, Lalonde N, Turnbull E, Bernatsky S; SUCCEED investigative team. Duration of Postvaccination Neutralizing Antibodies to SARS-CoV-2 and Medication Effects: Results from the Safety and Immunogenicity of COVID-19 Vaccination in Systemic Immune-Mediated Inflammatory Diseases Cohort Study. *ACR Open Rheumatol*. 2024 Sep;6(9):581-586. doi: 10.1002/acr2.11697. Epub 2024 Jul 1.
  69. **Hassen N, Moolooghy K, Kopec J, Xie H**, Khan KM, **Lacaille D**. Determinants of health-related quality of life in adults living with rheumatoid arthritis: a systematic review. *Sem Arth Rheum*. August 2025. Vol 73.
  70. Hermansen A, Pollard S, McGrail K, **Bansback N**, Regier DA. Heuristics Identified in Health Data-Sharing Preferences of Patients With Cancer: Qualitative Focus Group Study. *J Med Internet Res*. 2024 Dec 17;26:e63155. doi: 10.2196/63155.

71. Hickie KL, Neufeld ME, Howard LC, **Greidanus NV**, Masri BA, **Garbuz DS**. Long-term outcomes of revision total hip arthroplasty with the Zimmer Modular Revision hip system. *Bone Joint J.* 2024 May 1;106-B(5 Supple B):112-117. doi: 10.1302/0301-620X.106B5.BJJ-2023-0733.R1.
72. Hiligsmann M, Liden B, Beaudart B, Germeni E, Hanna A, Joshi M, Koola CP, Stein B, Tonkinson M, **Marshall DA**, Fifer S. HTA community perspectives on the use of patient preference information: lessons learned from a survey with members of HTA bodies. *International Journal of Technology Assessment in Health Care*, March 2024;40(1):e27.
73. Hitchon CA, Bowdish DME, Boire G, **Fortin PR**, Flamand L, Chandran V, Dayam RM, Gingras AC, Card CM, **Colmegna I**, **Larché MJ**, Kaplan GG, Lukusa L, Lee JLF, Bernatsky S, On Behalf Of The Succeed Investigative Team. Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study. *Vaccines (Basel)*. 2024 Sep 17;12(9):1061. doi: 10.3390/vaccines12091061.
74. **Hoa S**, Berger C, Lahmek N, **Larche M**, Osman M, **Choi M**, Pope J, Thorne C; Canadian Scleroderma Research Group; Hudson M. Characterisation of incident interstitial lung disease in late systemic sclerosis. *Arthritis Rheumatol.* 2025 Apr;77(4):450-457. doi: 10.1002/art.43051. Epub 2025 Jan 7.
75. **Howren A**, Sayre EC, **Aviña-Zubieta JA**, Puyat JH, **Da Costa D**, **Xie H**, **Davidson E**, Gupta A, **De Vera MA**. Do individuals with inflammatory arthritis receive minimally adequate treatment for incident depression and anxiety? A population-based study. *Arthritis Research & Therapy.* 23 Dec 2024. 2025 Jan 21;27(1):13. doi: 10.1186/s13075-024-03466-8.
76. Hu A, Blumenauer B, Kazem M, Baldwin C, **Kherani RB**, **Jamal S**, Day H, Stewart J, Wright G, Melton G, **Shojania K**, **Lacaille D**, **Carruthers M**. Explaining the gender pay gap: Lessons from rheumatology. *BCMJ.* 2024;(67)1.
77. Hudon A, Miciak M, Slade T, Lovo S, **Whittaker JL**, Côté D, Feldman DE, Kairy D, Laberge M, McKeen B, Cooper L, Gross DP. What are the Perceptions and Lived Experiences of Canadian Injured Workers about the Provision of Physiotherapy Services using Telerehabilitation? *J Occup Rehabil.* 2024 Dec 15. doi: 10.1007/s10926-024-10261-4. Online ahead of print.
78. Iziduh S, Abenoja A, Theodorlis M, Ahluwalia V, Battistella M, Borkhoff CM, Hazlewood GS, Lofters A, MacKay C, **Marshall DA**, Gagliardi AR. Priority strategies to reduce socio-gendered inequities in access to person-centred osteoarthritis care: Delphi survey. *BMJ Open*, Feb 2024;14(2):e080301.
79. Johnson D, **Jamal S**, Hung RW, Ye C. False-positive Findings of Large Vessel Vasculitis on FDG-PET in Patients Treated with Immune Checkpoint Inhibitors. *J Immunother.* 2024 Sep 1;47(7):275-278. doi: 10.1097/CJI.0000000000000527. Epub 2024 May 20.
80. Johnson JA, Itiola A, Rahman S, Smith C, Sporovich A, Wozniak LA, **Marshall DA**. Exploring patient perspectives on EQ-5D-5L data visualization within an

- individualized decision aid for total knee arthroplasty (TKA) in Alberta, Canada. *BMC Musculoskeletal Disorders*, March 2024;25(1):183.
81. **Jones, CA**, Guy P, **Xie H**, Sayre E, **Zhao K**, **Lacaille D**. Incidence of and risk of mortality after hip fractures in Rheumatoid Arthritis relative to the general population. *Arthritis Care Res. (Hoboken)*. 2025 May;77(5):604-613. doi: 10.1002/acr.25466. Epub 2024 Dec 22.
  82. **Jones C**, **Hamilton C**, Tugwell P, Grosskleg S, Hoffstetter C, Horgan B, **Hoens AM**, Beaton D. Implementing the PEIR Framework and PEIRS-22 Scale to facilitate improved and sustainable patient engagement in OMERACT. *Semin Arthritis Rheum*. 2025 Jun;72:152704. doi: 10.1016/j.semarthrit.2025.152704. Epub 2025 Feb 27. 2025 <https://doi.org/10.1016/j.semarthrit.2025.152704>
  83. Kao D, Wong K, Jijon H, Moayyedi P, Franz R, McDougall C, Hotte N, Panaccione R, Semlacher E, Kroeker KI, Peerani F, MacDonald KV, Xu H, Narula N, Turbide C, **Marshall DA**, Madsen KL. Preliminary Results From a Multicenter, Randomized Trial Using Fecal Microbiota Transplantation to Induce Remission in Patients With Mild-to-Moderate Crohn's Disease. *Am J Gastroenterol*. June 2025;120(6):1334–44. doi:10.14309/ajg.0000000000003196.
  84. **Karacabeyli D**, **Lacaille D**, **Lu N**, **McCormick N**, **Xie H**, **Choi H**, **Aviña-Zubieta JA**. Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: a population-based study. *Plos One*. 2024 Aug 8;19(8):e0308533. doi: 10.1371/journal.pone.0308533. eCollection 2024.
  85. Kawano-Dourado L, Kristianslund EK, Zeraatkar D, Jani M, Makharia G, **Hazlewood G**, Smith C, Jess T, Stabell C, Schatten A, Owen A, Gehin J, Katsidzira L, Weinberg D, Bauer-Ventura I, Tugwell P, Moayyedi P, Cecchi AVW, Shimabuco A, Seterelv S, Gyuatt G, Agoritsas T, Vandvik PO. Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline. *BMJ*. 2024 Oct 28;387:e079830. doi: 10.1136/bmj-2024-079830.
  86. Kayani B, Neufeld ME, Bautista M, Howard LC, Abdelmalek M, **Greidanus NV**, Masri BA, **Garbuz DS**. The Wagner Cone Stem for Atypical Femoral Anatomy in Total Hip Arthroplasty: A Report of 320 Cases with Minimum 5-Year Follow-up. *J Bone Joint Surg Am*. 2024 Aug 21;106(16):1461-1469. doi: 10.2106/JBJS.23.00849. Epub 2024 May 30.
  87. Kayani B, Howard LC, Neufeld ME, **Greidanus NV**, Masri BA, **Garbuz DS**. Porous Tantalum Metaphyseal Cones for Severe Femoral and Tibial Bone Defects in Revision Total Knee Arthroplasty are Reliable for Fixation at Mean 5-Year Follow-Up. *J Arthroplasty*. 2024 Sep;39(9S2):S374-S379. doi: 10.1016/j.arth.2024.03.022. Epub 2024 Mar 18.
  88. Kennedy KM, DeJong EN, Chan AWY, Kennedy AE, Jamal A, Surette MG, **Larché MJ**, Larché M, Hambly N, Ask K, Atkinson SA, McNicholas PD, McGeer A, Coleman BL, Bowdish DME. Mapping the intersection of demographics, behavior, and

- government response to the COVID-19 pandemic: an observational cohort study. *BMC Glob Public Health*. 2025 Jun 11;3(1):52. doi: 10.1186/s44263-025-00162-w.
89. Khorshidi HA, **Marshall DA**, Goranitis I, Schroeder B, IJzerman M. System Dynamics Simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual Model. *Expert Review of Pharmacoeconomics & Outcomes Research*, Jan 2024;24(1):37-47.
  90. Koehn S, **Jones CA**, **Barber C**, Jasper L, Pham A, Lindeman C, Drummond N. Candidacy 2.0 (CC) – an enhanced theory of access to healthcare for chronic conditions: lessons from a Critical Interpretive Synthesis on access to Rheumatoid Arthritis care. *BMC Health Service Research*. 2024; 24(1):986.
  91. Kuspinar A, Na E, Hum S, **Jones A**, Mayo N. Use of advanced topic modeling to generate domains for a preference-based index in osteoarthritis. *Health Qual Life Outcomes*. 2024 Dec 31;22(1):113. doi: 10.1186/s12955-024-02331-1.
  92. Kwakkenbos L, Levis B, Henry RS, Virgili-Gervais G, Carrier ME, **Bartlett SJ**, Gietzen A, Gottesman K, Guillot G, Lawrie-Jones A, Hummers LK, Malcarne VL, Mayes MD, Richard M, Wojeck RK, Worrion-Sauvé M, **Hudson M**, Mouthon L, Benedetti A, Thombs BD. Fatigue levels and associated factors in systemic sclerosis: a cross-sectional study of 2,385 SPIN Cohort participants. *Rheumatology (Oxford)*. 2025 May 1;64(5):2810-2820. doi: 10.1093/rheumatology/keae570.
  93. Kwok T, Lake S, **Barber CEH**, Hitchon C, Katz S, Jilkin K, Collins D, Lyddell C, Milne A, Stein M, Deslauriers JP, Lazovskis J, Goudie S, Morais S, King L, Widdifield J. Inequities in Fee-For-Service Remuneration Affecting Rheumatologists and Patient Centred Care Across Canada: An Environmental Scan. 2025. *J Rheumatol*. March 1 2025, jrheum.2024-1170; DOI: <https://doi.org/10.3899/jrheum.2024->.
  94. La Bella S, Bayraktar D, Porreca A, **Li LC**, Attanasi M, Aliyev E, Migowa AN, Scott C, Thakare DR, Bayindir Y, Consolaro A, Feldman BM, Ozen S. Global variations in artificial intelligence-generated information on juvenile idiopathic arthritis. *Rheumatology (Oxford)*. 2025 Jun 12:keaf329. doi: 10.1093/rheumatology/keaf329. Online ahead of print.
  95. Ladouceur A, **Jamal S**, Saltman A, Himmel M, **Hudson M**, Pope J, **Ho S**, **Roberts J**, **Colmegna I**, Gonzalez Arreola L, Nevskaya T, Karmali A, Moon D, Schmidt E, Cho L, Toban N, Barnette T, Ye C. Chronicity of Immune Checkpoint Inhibitor Associated Inflammatory Arthritis after Immunotherapy Discontinuation: Results from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) Database. *ACR Open Rheumatology*. Vol. 7, No. 2, February 2025, e70002. DOI 10.1002/acr2.70002.
  96. LaPlante E, Rosychuk RJ, Curtin KD, **Barnabe C**, Rittenbach K, Holroyd BR, Bill L, Healy B, Louis E, McLane P. Emergency Department Visits Among First Nations Female Adults in Alberta: A Population-Based Study. *Canadian Journal of Emergency Medicine*. Accepted March 28, 2025.
  97. Lee J, **Barber CEH**, Jung M, Kaminska E, **Bansback N**, Richards D, Proulx L, Rebutoc A, **Hazlewood GS**. Decision Aid-Led Tapering of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A

- Qualitative Study. *J Rheumatol.* 2024 Nov 1;51(11):1077-1083. doi: 10.3899/jrheum.2024-0383.
98. Lee JE, Mendel A, Malhamé I, **Barber MRW, Clarke AE, Fortin PR**, Hanly JG, **Legge A**, Peschken C, Laskin CA, Touma Z, Urowitz MB, Bernatsky S, Vinet É. An educational tool to improve PREeclamPsia knowledge and Aspirin adheRence in lupus prEgnancies: the PREPARE trial. *Rheumatology (Oxford)*. 2025 Jun 20:keaf334. doi: 10.1093/rheumatology/keaf334. Online ahead of print.
  99. Lee L, Zhao EJ, Schmidt R, Abdulla A, Sreenivasan G, Ambler K, Hiltz M, Foltz L, Chan V, **Legge A**, Yuen M, Lee L, Yenson P, Nevill TJ, Deghan N, Chen LY, Stubbins RJ. Real-world outcomes of Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome at a tertiary referral center. *British Journal of Hematology*. 2025 May 13. doi: 10.1111/bjh.20153.
  100. **Legge AC**, Hanly JG. Recent advances in the diagnosis and management of neuropsychiatric lupus. *Nat Rev Rheumatol.* 2024 Nov;20(11):712-728. doi: 10.1038/s41584-024-01163-z. Epub 2024 Oct 2.
  101. **Legge A**. Treating antineutrophil cytoplasmic antibody-associated vasculitis in frail older adults. *Lancet Rheumatol.* 2024 Nov;6(11):e737-e739. doi: 10.1016/S2665-9913(24)00272-8. Epub 2024 Sep 18.
  102. Leung E, Pryma C, Murphy S, Harrison R, Peterson E, Tsang PWK, Varghese J, You XJ, Slack GW, Skinnider BF, Ng T, Young S, Burrell S, Stubbins R, Lim H, **Carruthers M, Dutz J**, Diamond EL, Chen LYC. Rosai-Dorfman-Destombes disease in adults: a single center experience. *Ann Hematol.* 2024 Nov;103(11):4467-4476. doi: 10.1007/s00277-024-06019-w. Epub 2024 Sep 27.
  103. Li J, **Hudson M**, Ye C, **Roberts J**, Fifi-Mah A, **Choi MY, Hoa S**, Appleton CT, Pope J, Maltez N, **Arreola LG, Obrzut A, Jamal S**; Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO). Effect of Age on Rheumatic Immune-related Adverse Events: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO). *J Rheumatol.* 2025 Apr 1;52(4):389-395. doi: 10.3899/jrheum.2024-0603.
  104. Lora M, Ménard HA, Nijnik A, Langlais D, **Hudson M, Colmegna I**. Low Dose Methotrexate Has Divergent Effects on Cycling and Resting Human Hematopoietic Stem and Progenitor Cells. *Clin Transl Sci.* 2025 May;18(5):e70233. doi: 10.1111/cts.70233.
  105. **Losciale JM, Truong LK**, Ward P, Collins GS, Bullock GS. Limitations of Separating Athletes into High or Low-Risk Groups based on a Cut-Off. A Clinical Commentary *Int J Sports Phys Ther.* 2024 Sep 1;19(9):1151-1164. doi: 10.26603/001c.122644. eCollection 2024.
  106. **Losciale JM, Truong LK, Zhang K, Silvester-Lee**, Miciak M, Pajkic A, **Le CY, Xie H, Hoens AM**, Mosewich A, **Hunt MA, Li LC**, Roos EM, **Whittaker JL**. Assessing the efficacy of the Stop OsteoARthritis (SOAR) program: A randomized delayed-controlled trial in persons at increased risk of early-onset post-traumatic knee osteoarthritis. *Osteoarthritis Cartilage* April 32(8) doi: 10.1016/j.joca.2024.04.003 PM.

107. **Losciale JM, Le CY**, Jansen NEJ, **Lu L, Xie H**, Mitchell C, Hunt MA, **Whittaker JL**. Strength Setbacks: The Impact of Youth Sport-Related Knee Joint Injuries on Thigh Muscle Strength. A 24-Month Prospective Cohort Study. *J Orthop Sports Phys Ther*. 2025 Feb;55(2):137-147. doi: 10.2519/jospt.2024.12663.
108. Lu J, Vulesevic B, Burchell AN, Singer J, Needham J, Yang Y, Qian H, Chambers C, Samji H, **Colmegna I**, del Canto S, Godin GH, Habanyama M, Hui SSC, Kroch A, Mandarino E, Margolese S, Martin C, Owino M, Lau E, Mohammadi T, **Zhang W**, Pelaez S, Kovacs C, Benko E, Cooper CL, **Anis AH**, Costiniuk CT for the COVAXHIV Study Group. Sex differences in COVID-19 vaccine confidence in people living with HIV in Canada. *Vaccine: X*. 2024;100566. doi: <https://doi.org/10.1016/j.jvacx.2024.100566>.
109. Lytvyn Y, Himmel ME, **Ye C, Jamal S**, Saltman AP, on behalf of the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO). Acrocyanosis After Immunotherapy: Vasculitis or Vasculopathy? New Iatrogenic Disease Case Series From CanRIO. *J Rheumatol*. April 15 2025, jrheum.2024-0486; DOI: <https://doi.org/10.3899/jrheum.2024-0486>
110. Ma Y, Lessard D, Vicente S, Engler K, Rodriguez Cruz A, Laymouna M; Opal-COVID Patient Expert Committee; Hijal T, Del Balso L, Thériault G, Paisible N, Kronfli N, Pomey MP, Peiris H, Barkati S, Brouillette MJ, Klein M, Cox J, de Pokomandy A, Asselah J, **Bartlett SJ**, Lebouché B. Implementing a Patient Portal for the Remote Follow-Up of Self-Isolating Patients With COVID-19 Infection Through Patient and Stakeholder Engagement (the Opal-COVID Study): Mixed Methods Pilot Study. *J Particip Med*. 2024 Dec 4;16:e48194. doi: 10.2196/48194.
111. MacDonald KV, Nguyen GC, Barker KL, Harris M, Sewitch MJ, **Marshall DA**. Identifying fraudulent respondents in preference surveys: An example in Inflammatory Bowel Disease. *The Patient*. Sept 2024;17: 719-720. (IAHPR oral presentation / publication).
112. MacDonald KV, Nguyen GC, Sewitch MJ, **Marshall DA**. Identifying and Managing Fraudulent Respondents in Online Stated Preferences Surveys: A Case Example from Best-Worst Scaling in Health Preferences Research. *Patient*. 2025 May 3. doi: 10.1007/s40271-025-00740-y. Online ahead of print.
113. MacKenzie NE, Chambers CT, Marshall DA, Cassidy CE, Corkum PV, McGrady ME, Parker JA, MacDonald KV, Birnie KA. Unique and shared partner priorities for supporting engagement in knowledge mobilization: a best worst scaling experiment. *BMC Health Research Policy and Systems*. April 2025;23(1):49.
114. MacLean D, Curtin KD, **Barnabe C**, Bill L, Healy B, Holroyd BR, Khangura JK, McLane P. Interventions to improve equity in emergency departments for Indigenous people: A scoping review. *Academic Emergency Medicine* 2024;26:488-498. doi: 10.1111/acem.14987. Online ahead of print.
115. Madanipour S, Howard LC, Masri BA, **Greidanus NV, Garbuz DS**, Neufeld ME. Outcomes of Liner Exchange Versus Component Revision for the Treatment of Stiffness Following Primary Total Knee Arthroplasty. *J Arthroplasty*. 2024 Oct 16:S0883-5403(24)01027-1. doi: 10.1016/j.arth.2024.10.014. Online ahead of print.

116. Mainville L, Veillette H, **Fortin PR**. Drug Insurance and Psoriasis Severity: A Retrospective Cohort Study. *J Health Econ Outcomes Res*. 2025 Feb 7;12(1):51-57. doi: 10.36469/001c.127820. eCollection 2025.
117. Major TJ, Takei R, Matsuo H, Leask MP, Sumpter NA, Topless RK, Shirai Y, Wang W, Cadzow MJ, Phipps-Green AJ, Li Z, Ji A, Merriman ME, Morice E, Kelley EE, Wei WH, McCormick SPA, Bixley MJ, Reynolds RJ, Saag KG, Fadason T, Golovina E, O'Sullivan JM, Stamp LK, Dalbeth N, Abhishek A, Doherty M, Roddy E, Jacobsson LTH, Kapetanovic MC, Melander O, Andrés M, Pérez-Ruiz F, Torres RJ, Radstake T, Jansen TL, Janssen M, Joosten LAB, Liu R, Gaal OI, Crişan TO, Rednic S, Kurreeman F, Huizinga TWJ, Toes R, Lioté F, Richette P, Bardin T, Ea HK, Pascart T, McCarthy GM, Helbert L, Stibůrková B, Tausche AK, Uhlig T, Vitart V, Boutin TS, Hayward C, Riches PL, Ralston SH, Campbell A, MacDonald TM; FAST Study Group; Nakayama A, Takada T, Nakatochi M, Shimizu S, Kawamura Y, Toyoda Y, Nakaoka H, Yamamoto K, Matsuo K, Shinomiya N, Ichida K; Japan Gout Genomics Consortium; Lee C; Asia Pacific Gout Consortium; Bradbury LA, Brown MA, Robinson PC, Buchanan RRC, Hill CL, Lester S, Smith MD, Rischmueller M, **Choi HK**, Stahl EA, Miner JN, Solomon DH, Cui J, Giacomini KM, Brackman DJ, Jorgenson EM; GlobalGout Genetics Consortium; Liu H, Susztak K; 23andMe Research Team; Shringarpure S, So A, Okada Y, Li C, et al. A genome-wide association analysis reveals new pathogenic pathways in gout. *Nat Genet*. 2024 Nov;56(11):2392-2406. doi: 10.1038/s41588-024-01921-5. Epub 2024 Oct 15.
118. Maksymowych WP, Carmona R, Weber U, Aydin SZ, Yeung J, Reis J, Masetto A, Rohekar S, Mosher D, Zouzina O, Martin L, Keeling SO, Paschke J, Dadashova R, Carapellucci A, Wichuk S, Lambert RG, **Chan J**. Features of Axial Spondyloarthritis in Two Multicenter Cohorts of Patients with Psoriasis, Uveitis, and Colitis Presenting with Undiagnosed Back Pain. *Arthritis Rheumatol*. 2025 Jan;77(1):47-58. doi: 10.1002/art.42967. Epub 2024 Sep 3.
119. Maleyeff L, Golchi S, Moodie EEM, **Hudson M**. An adaptive enrichment design using Bayesian model averaging for selection and threshold-identification of predictive variables. *Biometrics*. 2024 Oct 3;80(4):ujae141. doi: 10.1093/biometc/ujae141.
120. **Marshall DA**, Suryaprakash N, Lavallee DC, McCarron TL, Zelinsky S, Barker KL, MacKean G, Santana MJ, Moayyedi P, Bryan S. Studying how patient engagement influences research: A mixed methods study. *The Patient – The Patient-Centered Outcomes Research*, March 2024;17(1):379-395.
121. **Marshall DA**, Suryaprasash N, Bryan S, McCarron T, MacKean G, Barker K, Lavallee D, Zelinsky S, Santana M, Moayyedi P. Measuring the impact of patient engagement in health research: an exploratory study using multiple survey tools. *Journal of the Canadian Association of Gastroenterology*, April 2024;7(1):177-187.
122. **Marshall DA**, Hua N, Buchanan J, Christensen KD, Frederix GW, Goranitis I, Ijzerman M, Jansen JP, Lavelle TA, Regier DA, Smith HS, Ungar WJ, Weymann D, Wordsworth S, Phillips KA. Paving the path for implementation of clinical genomic sequencing globally: Are we ready? *Health Affairs Scholar*, May 2024;2(5):1-7.

123. **Marshall DA**, MacDonald KV, Kao D, Bernstein CM, Kaplan GG, Jijon H, Hazlewood G, Panaccione R, Nasser Y, Raman M, Moayyedi P; on behalf of the IMAGINE Network. Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation. *Therapeutic Advances in Chronic Disease*, March 2024;15(1):1-19.
124. **Marshall DA**, Veldwijk J, Janssen EM, Reed SD. Stated-preference survey design and testing in health applications. *Patient* 2025 May;18(3):187-197. doi: 10.1007/s40271-023-00671-6. Epub 2024 Jan 31.
125. **Marshall DA**, Gerber B, Currie GR, Antón J, De Somer L, Dey M, Egert T, Egert Y, Henan L, Klotsche J, Mifsut LM, Minden K, Normand C, Porte D, Saurenmann RK, Swart JF, Uziel Y, Wilson J, Wouters C, Ziv A, **Benseler SM**; PAVE Consortium. Uncovering the hidden socioeconomic impact of juvenile idiopathic arthritis and paving the way for other rare childhood diseases: an international, cross-disciplinary, patient-centered approach (PAVE Consortium). *Pediatr Rheumatol Online J*. 2024 Aug 9;22(1):74. doi: 10.1186/s12969-024-01012-z.
126. Mazzei DR, **Whittaker JL**, Faris P, Wasylak T, **Marshall DA**. Estimating the Budget Impact and Joint Replacement Avoidance by Implementing a Standardized Education and Exercise Therapy Program for Hip and Knee Osteoarthritis in a Publicly Insured Healthcare System. *Arthritis Care Res (Hoboken)*. June 2025;77(6):744-752 <https://doi.org/10.1002/acr.25492>
127. Mazzei DR, **Whittaker JL**, Faris P, Wasylak T, **Marshall DA**. Real-World Cost-Effectiveness of a Standardized Education and Exercise Therapy Program Hip and Knee Osteoarthritis Compared to Usual Care. *Arthritis Care Res*. April 2025 Online ahead of print.
128. **McCormick N**, Joshi AD, Yokose C, Yu B, Tin A, Terkeltaub R, Merriman TR, Zeleznik O, Eliassen AH, Curhan GC, Ea HK, Naylor M, Raffield LM, **Choi HK**. Prediagnostic Amino Acid Metabolites and Risk of Gout, Accounting for Serum Urate: Prospective Cohort Study and Mendelian Randomization. *Arthritis Care Res (Hoboken)*. 2024 Dec;76(12):1666-1674. doi: 10.1002/acr.25420. Epub 2024 Oct 16.
129. **McCormick N**, Yokose C, **Lu N**, Wexler DJ, **Aviña-Zubieta JA**, **De Vera MA**, Chigurupati S, Tan K, Chen C, McCoy R, Curhan GC, **Choi HK**. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies. *BMJ*. 2024 Oct 30;387:e080035. doi: 10.1136/bmj-2024-080035.
130. **McCormick N**, Burrack N, Yokose C, **Lu N**, Wexler D, **Rai S**, Challener G, **Aviña-Zubieta JA**, McCoy RG, Abuhasira R, **Choi H**. Gout-Related Medication Use After Initiating Sodium Glucose Co-Transporter-2 Inhibitors in Patients with Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies. *Arthritis Rheum*. May 2025 Accepted.
131. McMullen EP, Grewal RS, Storm K, Mbuagbaw L, Maretzki MR, **Larché MJ**. Can machine learning assist in systemic sclerosis diagnosis and management? A scoping review. *J Scleroderma Relat Disord*. 2024 Oct;9(3):171-177. doi: 10.1177/23971983241253718. Epub 2024 May 24.

132. Mehrabadi A, Austin N, Keyes KM, **De Vera MA**. It's personal: navigating research questions that stem from our lived experiences. *Int J Epidemiol*. 2024 Oct 13;53(6):dyae132. doi: 10.1093/ije/dyae132.
133. Meng CF, Lee YC, Schieir O, Valois MF, Butler MA, Boire G, **Hazlewood G**, **Allard-Chamard H**, Hitchon C, Bindee K, Tin D, Thorne C, Bessette L, Pope J, **Bartlett SJ**, Bykerk VP; Canadian Early Arthritis Cohort Investigators. Characterizing Nonarticular Pain at Early Rheumatoid Arthritis Diagnosis: Evolution Over the First Year of Treatment and Impact on Remission in a Prospective Real-World Early Rheumatoid Arthritis Cohort. *Arthritis Rheumatol*. 2025 Apr;77(4):405-413. doi: 10.1002/art.43049. Epub 2024 Nov 21.
134. **Merry K**, MacPherson MM, Holsti L, Napier C, **Whittaker JL**, Scott A. An exercise-based precision medicine tool and smartphone app for managing Achilles tendinopathy: user-centered development of the PhysViz. *JMIR Hum Factors*. 2024. Nov 13;11:e57873. doi: 10.2196/57873.
135. Mirza RM, Salim S, Bell JAH, Esplen MJ, MacDonald KV, Stein BD, **Marshall DA**. Exploring How Values of Colorectal Cancer Patients and their Caregivers Influence Treatment Decision-Making. *Patient*. 2024 Sep 18. doi: 10.1007/s40271-024-00716-4. Online ahead of print.
136. Mocanu V, **Barber C**, McLane P, Chomistek K, **Davidson E**, Elliott M, Hildebrandt C, Katz S, Lin K, **McQuitty S**, Russon N, Holroyd B, Lang E, **Barnabe C**. Potentially Avoidable Emergency Department Utilization by Persons with Psoriatic Arthritis and Ankylosing Spondylitis: A Population-Based Cohort Study. *The JRheumatol*. 2025 Mar 1;52(3):243-250. doi: 10.3899/jrheum.2024-1113.
137. Molyneux P, Bowen C, Ellis R, Rome K, Fitzgerald K, Clark P, **Whittaker JL**, Dando C, Richard G, Carroll M. Development of an ultrasound imaging atlas (AUTUSI atlas) for grading osteoarthritis in the first metatarsophalangeal joint, *Arthritis Care Res (Hoboken)*. 2024 Nov;76(11):1501-1510. doi: 10.1002/acr.25407. Epub 2024 Aug 10.
138. Morton E, Hole R, O'Brien H, **Li LC**, Barnes SJ, Michalak EE. The experience of self-monitoring using the PolarUs bipolar disorder self-management app: a qualitative report of impacts and unmet needs. *J Affect Disord*. 2025 Aug 15;383:374-384. doi: 10.1016/j.jad.2025.04.107. Epub 2025 Apr 24.
139. Murray A, Campbell EJ, **Clarke AE**, **Barber MRW**, Pannu T, Fritzler MJ, Jung M, St Pierre Y, Skeith L. Non-criteria antiphospholipid antibody profiles and thrombotic outcomes in a cohort of patients with systemic lupus erythematosus. *Lupus Sci Med*. 2024 Dec 12;11(2):e001174. doi: 10.1136/lupus-2024-001174.
140. Murphy M, Coventry M, Taylor JL, Rio E, Mosler A, **Whittaker JL**, Latella C. People with hip osteoarthritis have reduced quadriceps voluntary activation and altered motor cortex function: a cross-sectional study. *Journal of Sport and Health Science* September 20, 2024 [doi:10.1016/j.smhs.2024.09.005](https://doi.org/10.1016/j.smhs.2024.09.005)
141. Nassar EL, Virgili-Gervais G, Carrier ME, Kwakkenbos L, Henry RS, Hu S, Provencher S, Golberg M, **Bartlett SJ**, Mouthon L, Patten SB, Varga J, Benedetti A, Thombs BD; Scleroderma Patient-centered Intervention Network (SPIN) COVID-19

- Patient Advisory Team, on behalf of the SPIN Investigators. Experiences of telehealth during and after the COVID-19 pandemic and preferences for future care of people with systemic sclerosis: a cross-sectional study. *Lancet Rheumatol.* 2024 Oct;6(10):e660-e663. doi: 10.1016/S2665-9913(24)00166-8. Epub 2024 Jun 26.
142. Naye F, Légaré F, Cachinho C, Gérard T, Toupin-April K, Sasseville M, Paquette JS, LeBlanc A, Gaboury I, Poitras ME, **Li LC, Hoens AM**, Poirier MD, Tousignant-Laflamme Y, Décary S. People living with chronic pain in Canada face difficult decisions and decisional conflict concerning their care: data from the national DECIDE-PAIN survey. *BMC Prim Care.* 2024 Dec 19;25(1):424. doi: 10.1186/s12875-024-02667-z.
143. Naye F, Tousignant-Laflamme Y, Sasseville M, Cachinho C, Gerard T, Toupin-April K, Dubois O, Paquette JS, LeBlanc A, Gaboury I, Poitras ME, Li LC, **Hoens A**, Poirier MD, Légaré F, & Décary S. People living with chronic pain experience high prevalence of decision regret in Canada: a pan-Canadian online survey. *Medical Decision Making.* 2025 May;45(4):462-479. doi: 10.1177/0272989X251326069. Epub 2025 Mar 22.
144. Neufeld ME, Sheridan GA, MacDonell T, Howard LC, Masri BA, Keown P, Sherwood K, **Garbuz DS**. The John Charnley Award: The Impact of Human Leukocyte Antigen Genotype on Bacterial Infection Rates and Successful Eradication in Total Hip Arthroplasty. *J Arthroplasty.* 2024 Sep;39(9S1):S17-S23.e4. doi: 10.1016/j.arth.2024.05.076. Epub 2024 Jun 1.
145. Nguyen N, Leclair V, Kaedbey R, **Hudson M**. Failure of daratumumab in the treatment of anti-synthetase syndrome: A case report. *SAGE Open Med Case Rep.* 2025 Apr 29;13:2050313X251336022. doi: 10.1177/2050313X251336022. eCollection 2025.
146. Nguyen N, Bernatsky S, **Colmegna I**, Berger C, Carrier N, **Allard-Chamard H**, Liang P, Roux S, Boire G, **Hudson M**. Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Using an Extended Set of Clinical Variables: An Unmet Need. *Int J Rheum Dis.* 2025 May;28(5):e70281. doi: 10.1111/1756-185X.70281.
147. Nielsen W, Kharouf F, munoz Grajales C, Thayaparan A, Anderson M, Strand V, Simon L, Bonilla D, Morand E, et al. (including **Legge A**), OMERACT SLE Working Group. Scoping literature review to identify candidate domains for the OMERACT systemic lupus erythematosus core outcome set. *Seminars in Arthritis and Rheumatism.* 2025;72:152684.
148. Nikolic RPA, Pardo JP, Pope JE, **Barber CEH, Barnabe C**, Schieir O, Jamal S, **Legge A**, Kuriya B, Akhavan P, Thorne JC, Bombardier C, Taylor-Gjevre R, Bykerk V, Khraishi M, Proulx L, Richards DP, Tugwell P, Agarwal A, **Bansback N, Hazlewood GS**. Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #2. *J Rheumatol.* 2024 Sep 1;51(9):940-941. doi: 10.3899/jrheum.2024-0540.
149. Nind J, **Marra CA**, Scahill S, Siermans C, Smith A. Does the type of pharmacy used influence medication adherence? A retrospective observational study in

- Aotearoa, New Zealand. *Can Pharm J (Ott)*. 2024 Jul 28;157(5):261-270. doi: 10.1177/17151635241267025. eCollection 2024 Sep-Oct.
150. Nind J, **Marra CA**, Scahill S, Mather D, Smith A. The effects of free prescriptions on community pharmacy selection: A discrete choice experiment. *Res Social Adm Pharm*. 2024 Dec;20(12 Pt A):1089-1095. doi: 10.1016/j.sapharm.2024.08.089. Epub 2024 Aug 24.
  151. Nosrati Z, Chen YA, Bergamo M, Rodríguez-Rodríguez C, **Chan J, Shojania K, Kherani RB**, Chin C, Kelsall JT, Dehghan N, Colwill AM, Collins D, Saatchi K, Häfeli UO. Prodrug Nanomedicine for Synovium Targeted Therapy of Inflammatory Arthritis: Insights from Animal Model and Human Synovial Joint Fluid. *Adv Healthc Mater*. 2024 Dec;13(30):e2401936. doi: 10.1002/adhm.202401936. Epub 2024 Oct 9.
  152. Nowrouzi-Kia B, Howe AS, Li A, **Tan J**, Saade-Cleves N, Jules K, Sadek M, Bani-Fatemi A, **Aviña-Zubieta A**, Fox MT, Shaw W, Haaland D, Pope J, **Fortin PR**, Bingham KS, Peschken C, Reynolds J, Ivory C, Gladman DD, Urowitz MB, Sanchez-Guerrero J, Lim LSH, Keeling S, Katz P, Kavkan M, Bonilla D, Nielsen W, Touma Z. Functional work disability from the perspectives of persons with systemic lupus erythematosus: a qualitative thematic analysis. *Arthritis Res Ther*. 2025 May 26;27(1):114. doi: 10.1186/s13075-025-03572-1.
  153. Oakes EG, Ellrodt J, Guan H, Yee J, **Choi MY**, Costenbader KH. Increased risk of adverse events among patients with vs. without systemic autoimmune rheumatic disease prescribed sodium-glucose cotransporter 2 inhibitors: a retrospective cohort study. *Clin Rheumatol*. 2024 Dec;43(12):3839-3847. doi: 10.1007/s10067-024-07206-w. Epub 2024 Oct 25.
  154. Oakes EG, Dillon E, Buhler KA, Guan H, Paudel M, Marks K, Adejorin I, Yee J, Ellrodt J, Tedeschi S, Sparks J, Case SM, Hsu T, Solomon DH, Jonsson AH, Alexander RV, Rao DA, **Choi MY**, Costenbader KH. Earlier vs. later time period of COVID-19 infection and emergent autoimmune signs, symptoms, and serologies. *J Autoimmun*. 2024 Sep;148:103299. doi: 10.1016/j.jaut.2024.103299. Epub 2024 Aug 2.
  155. O'Brien D, Rabey M, Reid D, Ellis R, Uluinayau TW, **Whittaker JL**. The well-being of people with anterior cruciate ligament rupture-related post-traumatic osteoarthritis in Aotearoa New Zealand. *BMC Musculoskelet Disord*. 2025 Mar 3;26(1):216. doi: 10.1186/s12891-025-08421-5.
  156. O'Brien M, Best KL, **Barnabe C**, Routhier F, Miller WC, Manocha RHK. Feasibility of an interactive video-based training program for learning and reviewing walking aid skills. *Archives of Physical Medicine and Rehabilitation*. Accepted April 14, 2025.
  157. Ohinmaa A, Wen J, Currie GR, **Benseler SM**, Swart JF, Vastert SJ, Yeung RSM, **Marshall DA**. Validation of the EQ-5D-Y-5L parent-proxy version among children with juvenile idiopathic arthritis. *Qual Life Res*. 2024 Oct;33(10):2677-2691. doi: 10.1007/s11136-024-03682-4. Epub 2024 Aug 14.
  158. Olson JL, Palumbo A, Desjardins C, Wicks C, Bhopa S, Cheyne K, D'Silva A, Graff LA, Narula N, Rodrigues DM, Fernandes A, Marshall DA, Moayyedi P, Presseau J.

- Perspectives on the sustained engagement with digital health tools: protocol for a qualitative interview study among people living with Inflammatory Bowel Disease or irritable bowel syndrome. *BMJ Open*. 2024 Nov 9;14(11):e089220. doi: 10.1136/bmjopen-2024-089220.
159. O'Sullivan O, Bennett A, Crossley KM, Cameron K, Driban J, Ladlow P, Macri E, Schmitt L, Teyhen DS, Wellsandt E, **Whittaker JL**, Rhon D. Preventing post-traumatic osteoarthritis in the Military: Relevance of OPTIKNEE and Osteoarthritis Action Alliance recommendations. *BMJ Military Health* October 8, 2024. doi: [10.1136/military-2024-002813](https://doi.org/10.1136/military-2024-002813)
  160. Pascart T, Latourte A, Tedeschi SK, Dalbeth N, Neogi T, Adinolfi A, Arad U, Andres M, Becce F, Bardin T, Cipolletta E, Ea HK, Filippou G, Filippucci E, FitzGerald J, Iagnocco A, Jansen TL, Janssen M, Lioté F, So A, McCarthy GM, Ramonda R, Richette P, Rosenthal A, Scirè C, Silvagni E, Sirotti S, Sivera F, Stamp LK, Taylor WJ, Terkeltaub R, **Choi HK**, Abhishek A. Features Associated With Different Inflammatory Phenotypes of Calcium Pyrophosphate Deposition Disease: A Study Using Data From the International American College of Rheumatology/EULAR Calcium Pyrophosphate Deposition Classification Criteria Cohort. *Arthritis Rheumatol*. 2024 Dec;76(12):1780-1788. doi: 10.1002/art.42962. Epub 2024 Aug 22.
  161. Peremans L, Twilt M, **Benseler SM**, Grisaru S, Kirton A, Myers KA, Hamiwka L. Real-World Biomarkers for Pediatric Takayasu Arteritis. *Int J Mol Sci*. 2024 Jul 4;25(13):7345. doi: 10.3390/ijms25137345.
  162. Peterson JM, **Leclair V**, Oyebode OE, Herzallah DM, Nestor-Kalinoski AL, Morais J, Zahedi RP, Alamr M, Di Battista JA, **Hudson M**. A window into intracellular events in myositis through subcellular proteomics. *Inflamm Res*. 2025 Jan 31;74(1):31. doi: 10.1007/s00011-025-01996-8.
  163. Pham ANQ, **Barber CEH**, Drummond N, Jasper L, Klein D, Lindeman C, Widdifield J, Williamson T, **Jones CA**. Development and validation of a rheumatoid arthritis case definition: a machine learning approach using data from primary care electronic medical records. *BMC Med Inform Decis Mak*. 2024 Nov 27;24(1):360. doi: 10.1186/s12911-024-02776-w.
  164. Pianarosa E, Roach P, Barber CEH, Holroyd BR, McLane P, Katz SJ, Elliott MJ, Russon N, Hildebrandt C, Chomistek K, Davidson E, Keeling S, Barnabe C. Deciding to Attend the Emergency Department: Experiences of Patients With Inflammatory Arthritis. *J Rheumatol*. 2024 Oct 1;51(10):1015-1022. doi: 10.3899/jrheum.2024-0111.
  165. Pierobon A, Taylor W, Siegert R, Willink R, Bennell K, Allen K, **Whittaker J**, Pearson J, Norton M, Clark J, Tay HA, Schiphof D, Darlow B. Exploring the Perceived Difficulty and Importance of Lower Limb Physical Activities for People With and Without Osteoarthritis: A Discrete Choice Experiment. *Musculoskeletal Care*. 2024 Dec;22(4):e70011. doi: 10.1002/msc.70011.
  166. Piga M, Parodis I, Touma Z, **Legge A**, Ugarte-Gil MF, Hmamouchi I, Gomez Puerta JA, Devilliers H, Zen M, Cho J, Ziade N, Mucke J, Toro-Gutierrez CE, Izuka S, Korsten P, Kane BSY, Golder V, Chong BF, Pons-Estel G, Chasset F, Arnaud L.

- Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force. *Autoimmunity Reviews*. 2025;24(5):103773.
167. Pope J, **Karacabeyli D**, **Aviña-Zubieta JA**. Target Trial Emulations of Sodium-Glucose Cotransporter 2 Inhibitors in Systemic Lupus Erythematosus. *Arthritis Rheumatol*. 2025 Apr;77(4):390-392. doi: 10.1002/art.43130. Epub 2025 Feb 20.
  168. Powelske B, Kongsted A, **Jones A**, Kawchuk G. The Alberta Back Care Pathway: The feasibility of implementing a novel care pathway to improve low back pain management for family physicians in primary care. *PLoS One*. 2024 Nov 27;19(11):e0312737. doi: 10.1371/journal.pone.0312737. eCollection 2024.
  169. Qi W, Robert A, Singbo N, Ratelle L, **Fortin PR**, Bessette L, Brown JP, **Michou L**. Characteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study. *Adv Rheumatol*. 2024 Aug 6;64(1):55. doi: 10.1186/s42358-024-00396-6.
  170. Rahman P, Garrido-Cumbrera M, Rohekar S, Mallinson MG, Karam E, Jovaisas AV, Haroon N, Beach J, de Brum-Fernandes AJ, Cohen M, **Chan J**, Correa-Fernández J, Leclerc P, Inman RD. Canadian Patients With Axial Spondyloarthritis Require Almost a Decade To Be Diagnosed Leading to Severe Functional Limitation. Results From the International Map of Axial Spondyloarthritis (IMAS). *Musculoskeletal Care*. 2024 Dec;22(4):e70010. doi: 10.1002/msc.70010.
  171. **Rebić N**, Cheng L, Law MR, Cragg JJ, Brotto LA, **De Vera MA**. Predictors of cost-related medication nonadherence in Canada: a repeated cross-sectional analysis of the Canadian Community Health Survey. *CMAJ*. 2024 Nov 24;196(40):E1331-E1340. doi: 10.1503/cmaj.241024.
  172. Roa L, Larouche M, Hyakutake M, Brennand EA, Malabarey O, Koenig N, Lee T, Singer J, **Zhang W**, Brotto LA, Geoffrion R. COMET (Composite Outcomes of Mesh vs suture Techniques for prolapse repair)- Protocol for a single blind randomized controlled multicenter trial testing surgical innovation in female pelvic surgery. *PLOS ONE*. 2024;19(10):e0308926. doi: 10.1371/journal.pone.0308926.
  173. **Roberts J**, Barmettler S, Murray J, Melvin JE, Ye C. Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis. *Immunotherapy*. 2024;16(20-22):1247-1254. doi: 10.1080/1750743X.2024.2436838.
  174. **Roberts J**, **Jamal S**, **Hudson M**, Katz S, Ennis D, Maltez N, Lau K, Ye C. Improving knowledge dissemination of rheumatic toxicities of cancer immunotherapy: a web-based educational initiative. *Musculoskeletal Care*. 2025 Mar;23(1):e70065. doi: 10.1002/msc.70065.
  175. **Roberts J**, Gunn C, MacKinnon J, Parlee S, Bakowsky V, Taylor T, **Barber CEH**, Hanly JG, **Legge A**. Letter to the editor regarding physiotherapist-led rheumatology triage. *Journal of Rheumatology* 2025;52(2):195-196.

176. **Roberts J.** Determining fracture risk in patients exposed to immune checkpoint inhibitors: the time is now. *British Medical Journal of Oncology* 2024 Aug 22;3(1). <https://doi.org/10.1136/bmjonc-2024-000559>
177. Roberts ET, **Bansback N**, Tseng CW, Shiboski S, Li J, Schmajuk G, Yazdany J. Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registry. *Health Serv Res.* 2024 Dec 1. doi: 10.1111/1475-6773.14410. Online ahead of print.
178. Roberts ET, Li J, **Bansback N**, Tseng CW, Shiboski S, Schmajuk G, Yazdany J. Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022. *Arthritis Rheumatol.* 2024 Dec;76(12):1739-1742. doi: 10.1002/art.42963. Epub 2024 Aug 13.
179. Salma J, Yamamoto S, Salbach NM, Barclay R, **Jones A.** An Outdoor Walking Program for Immigrant Muslim Older Adults: A Community-Based Participatory Intervention. *Nurs Open.* 2024 Dec;11(12):e70051. doi: 10.1002/nop2.70051.
180. Sammaritano LR, Askanase A, Bermas BL, Dall-Era M, Duarte-Garcia A, Hiraki LT, Robin B, **Legge A**, et al. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. *Arthritis Care Res.* March 2025. *Arthritis & Rheumatology.* 2025 May 7. doi: 10.1002/art.43212.
181. Sarac DC, Durak Ediboglu E, Ozer Kaya D, Duran G, Akatay EA, Gucenmez S, Akar S, **Bayraktar D.** Validity and reliability of the Turkish version of Exercise Benefits/ Barriers Scale: Perceived exercise benefits and barriers of patients with different axial spondyloarthritis subtypes. *Arch Rheumatol.* 2024 Aug 26;39(3):447-458. doi: 10.46497/ArchRheumatol.2024.10720. eCollection 2024 Sep.
182. Sarac DC, Cinakli H, Coban MB, Tosun S, Altin SD, Yarbuz AE, Porreca A, Solmaz D, Akar S, **Bayraktar D.** Evaluation of the Turkish version of measure of activity performance of the hand (MAP-Hand) in people with rheumatoid arthritis. *Physiother Theory Pract.* 2024 Oct 13:1-8. doi: 10.1080/09593985.2024.2415967. Online ahead of print.
183. Satirer Ö, Henes JC, Döring M, Lesk T, **Benseler S**, Kuemmerle-Deschner JB. Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children. *RMD Open.* 2024 Jul 14;10(3):e004381. doi: 10.1136/rmdopen-2024-004381.
184. Satirer Ö, Welzel T, Zapf B, **Benseler SM**, Kuemmerle-Deschner JB. Refining Treat-to-Target (T2T) strategies in Cryopyrin-Associated Periodic Syndromes (CAPS): The role of inflammatory markers. *Rheumatology (Oxford).* 2025 Mar 1;64(3):1523-1527. doi: 10.1093/rheumatology/keae340.
185. Scime NV, Velez MP, **Choi MY**, Ray JG, Boblitz A, Brown HK. Association between infertility and incident onset of systemic autoimmune rheumatic disease after childbirth: a population-based cohort study. *Hum Reprod.* 2025 Jan 1;40(1):157-166. doi: 10.1093/humrep/deae253.

186. Scime NV, Grandi SM, Ray JG, Dennis CL, **De Vera MA**, Banack HR, Vigod SN, Boblitz A, Brown HK. Pregnancy complications and new-onset maternal autoimmune disease. *Int J Epidemiol*. 2024 Aug 14;53(5):dyae115. doi: 10.1093/ije/dyae115.
187. Shantz E, Elliott SJ, Sperling C, Buhler K, Costenbader KH, **Choi MY**. Towards an understanding of the biopsychosocial determinants of CVD in SLE: a scoping review. *Lupus Sci Med*. 2024 Jul 24;11(2):e001155. doi: 10.1136/lupus-2024-001155.
188. Sharma K, Cheng L, Dormuth CR, McGrail KM, **De Vera MA**, Clement F, McCracken RK, Mamdani M, Law MR. The impact of eliminating out-of-pocket payments for medicines on low-income households: a controlled interrupted time series analysis using linked administrative data from British Columbia. *Health Policy*. 2025 May;155:105270. doi: 10.1016/j.healthpol.2025.105270. Epub 2025 Feb 17.
189. Sheng J, Zhang A, Moyer H, **Hudson M, Hazlewood G**, Strand V, Kimmelman J. Explanation for substandard of care comparators in rheumatology randomised trial protocols. *Lancet Rheumatol*. 2024 Nov;6(11):e743-e745. doi: 10.1016/S2665-9913(24)00277-7.
190. Sheridan GA, Neufeld ME, Howard LC, **Garbuz DS**, Masri BA. Short-term survival of the cementless triathlon total knee arthroplasty in a young patient cohort. *Arch Orthop Trauma Surg*. 2024 Sep;144(9):4109-4114. doi: 10.1007/s00402-024-05481-5. Epub 2024 Sep 9.
191. Sidhu SP, Howard LC, Levesque G, **Greidanus NV**, Masri BA, **Garbuz DS**, Neufeld ME. Risk factors for failure of manipulation under anesthesia after total knee arthroplasty. *Eur J Orthop Surg Traumatol*. 2024 Aug;34(6):3061-3066. doi: 10.1007/s00590-024-03974-y. Epub 2024 Jun 21.
192. Smith HS, Reiger DA, Goranitis I, Bourke M, Ijzerman MJ, Degeling K, Montgomery T, Philips KA, Wordsworth S, Buchanan J, **Marshall DA**. Approaches to incorporation of preferences into health economic models of genomic medicine: A critical interpretive synthesis and conceptual framework. *Applied Health Economics and Health Policy*, May 2025;23(3):337-358 10.1007/s40258-025-00945-0
193. Smith-Turchyn J, Farley C, Newman ANL, Pannu J, Rochweg B, Mukherjee SD, Beauchamp M, **Li LC**, Mian H, Kho ME. A Qualitative Study Exploring the Rehabilitation Experience of Individuals with a Previous Diagnosis of Cancer and/or Sepsis, Their Caregivers, and Health Providers. *Healthcare (Basel)*. 2025 Apr 4;13(7):822. doi: 10.3390/healthcare13070822.
194. Starkey SY, Akuffo-Addo E, Johnston L, Mar K, Kashetsky N, AlHalees Z, **Dutz J**, Mukovozov I. Treatment Outcomes of IgA Vasculitis in Adults: A Review. *J Cutan Med Surg*. 2024 Nov-Dec;28(6):588-589. doi: 10.1177/12034754241269197. Epub 2024 Aug 6.
195. Tadrous M, Aves T, Fahim C, Riad J, Mittmann N, Prieto-Alhambra D, Rivera DR, Chan K, Lix LM, Kent S, Dawoud D, Guertin JR, McDonald JT, Round J, Klarenbach S, Stanojevic S, **De Vera MA**, Strumpf E, Platt RW, Husein F, Lambert L, Hayes KN. Development of a Canadian Guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision-making. *J Clin Epidemiol*. 2024 Dec;176:111545. doi: 10.1016/j.jclinepi.2024.111545. Epub 2024 Sep 23.

196. Tam ACT, Badesha J, Guh DP, **Bansback N**, Peter KK, Hollis A, Grootendorst P, Bae SC, **Anis AH, Zhang W**. Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries. *BioDrugs*. 2025 May;39(3):461-476. doi: 10.1007/s40259-025-00709-1. Epub 2025 Feb 25.
197. Tamblyn R, Habib B, Buckeridge DL, Weir DL, Frolova E, Alattar R, Rogozinsky J, Beauchamp C, Pupo R, **Bartlett SJ**, McDonald E. Evaluating the effectiveness of the Smart About Meds (SAM) mobile application among patients discharged from hospital: protocol of a randomised controlled trial. *BMJ Open*. 2024 Nov 24;14(11):e084492. doi: 10.1136/bmjopen-2024-084492.
198. **Tan J**, Bernatsky S, Lee JLF, **Fortin PR**, Dayam RM, Gingras AC, **Colmegna I**, Bowdish DME, Berger C, Chan D, **Larché MJ**, Richards DP, **Gonzalez Arreola L**, Hitchon CA, **Lalonde N, Aviña-Zubieta JA**. COVID-19 Breakthrough Infections in Immune-Mediated Inflammatory Diseases: Data from the SUCCEED (Safety and Immunogenicity of COVID-19 Vaccines in Systemic Autoimmune-Mediated Inflammatory Diseases) Study. *Vaccines (Basel)*. 2025 Jan 22;13(2):104. doi: 10.3390/vaccines13020104.
199. **Thomas M, Harrison M, Barnabe C**, Ronquillo CE, **Aviña-Zubieta JA**, Samson A, **Kuluva, M, Trehan, N, De Vera MA**. “It’s Just Good Science”: A Qualitative Study Exploring Equity, Diversity and Inclusion in Canadian Arthritis Research. *Arthritis Care & Research*. November 2024. 2024 Dec 26. Doi:10.1002/acr.25487.
200. Thombs BD, Adams C, Nassar EL, Carrier ME, Golberg M, Bharthi K, Wurz A, South A, Kwakkenbos L, Hoa S, Rice DB, Guillot G, Lawrie-Jones A, Sauvé M, **Bartlett SJ**, Fortune C, Gietzen A, Gottesman K, **Hudson M**, Hummers LK, Malcarne VL, Mayes MD, Richard M, Stempel J, Wojeck RK, Blaggrave K, Boruff JT, Cook V, Culos-Reed N, Fröbert O, Gillies K, Granikov V, Hemkens LG, Jimenez EY, Kocher A, Leite C, Lim MAWT, Maltez N, Michalski J, Mieszczak T, Ndosu M, Pope J, Rannou F, Rozee K, Straus SE, Sydes MR, Thabane L, Varga J, Yap T, Zwarenstein M, Mouthon L, Benedetti A; SPIN Investigators. Master protocol for a series of cohort-based randomized controlled trials to test tools to communicate research results to study participants and others with relevant lived experience: the SPIN-CLEAR Trials. *Trials*. 2025 May 8;26(1):149. doi: 10.1186/s13063-025-08846-2.
201. Toor KK, Chen A, Cabral DA, Mammen C, Bosman ES, Shen Y, Bone JN, Noone D, Al-Abadi E, **Benseler S**, Berard R, Bohm M, Charuvanij S, Cook K, Dancey P, Deepak S, Duffy C, Eberhard B, Elder M, Foell D, Gerstbacher D, Heshin-Bekenstein M, Huber A, James KE, Kim S, Klein-Gitelman M, Martin N, McErlane F, Moorthy LN, Myrup C, Riley P, Shenoi S, Sivaraman V, Tanner T, Tarvin S, Wagner-Weiner L, Yeung RSM, Brown KL, Morishita KA; PedVas Investigator's Network. Evaluating renal disease in pediatric-onset anti-neutrophil cytoplasmic antibody-associated vasculitis: disease course, outcomes, and predictors of outcome. *Arthritis Rheumatol*. 2025 May;77(5):606-614. doi: 10.1002/art.43071. Epub 2025 Jan 14.
202. Trenaman L, Guh D, McGrail K, Karim ME, Sawatzky R, Bryan S, **Li LC**, Parker M, Wheeler K, **Harrison M**. Longitudinal trajectories of healthcare costs among high-need high-cost patients: a population-based retrospective cohort study in British

- Columbia, Canada. *BMJ Open*. 2025 Apr 25;15(4):e089693. doi: 10.1136/bmjopen-2024-089693.
203. **Truong LK**, Mosewich AD, Miciak M, **Losciale JL**, **Li L**, **Whittaker JL**. Social support and therapeutic relationships intertwine to influence exercise behaviour in people with sport-related knee injuries. *Physiotherapy Theory and Practice* Feb 19:1-14. doi: [10.1080/09593985.2024.2315520](https://doi.org/10.1080/09593985.2024.2315520) PMID **38374585**
204. Tseng OL, Brar S, Dawes M, Ranchod H, **Lacaille D**, Su VCH, Mitton C. Are Canadian Clinical Practice Guidelines Accounting for Adults With Multiple Chronic Diseases? A Systematic Review. *J Eval Clin Pract*. 2025 Jun;31(4):e70143. doi: 10.1111/jep.70143.
205. Tsyruk O, Kaplan GG, **Fortin PR**, Hitchon CA, Chandran V, Larché MJ, **Aviña-Zubieta JA**, Boire G, **Colmegna I**, **Lacaille D**, **Lalonde N**, Proulx L, Richards DP, Boivin N, DeBow C, Kovalova-Wood L, Paleczny D, Wilhelm L, Lukusa L, Pereira D, Lee JLF, Bernatsky S, and SUCCEED investigative team. How Safe Are COVID-19 Vaccines in Individuals with Immune-Mediated Inflammatory Diseases? The SUCCEED Study. *Vaccines (Basel)* 2024 Sep 8;12(9):1027. doi: 10.3390/vaccines12091027.
206. Van MT, Loewen P, Sadatsafavi M, **Zhang W**, Hawkins N, Turgeon RD. Pharmacotherapy sequencing strategies for heart failure with reduced ejection fraction: A cost-utility analysis. *CMAJ*. 2024; 196 (36) E1221-E1231; doi: <https://doi.org/10.1503/cmaj.240116>. [SA]
207. Van Compernelle K, Selleslag D, **Hazlewood GS**, Storek J, van Laar JM, Piette Y. Allogeneic stem cell transplantation in difficult-to-treat rheumatoid arthritis. *Clin Exp Rheumatol*. 2025 Mar;43(3):545. doi: 10.55563/clinexprheumatol/qonstg. Epub 2024 Oct 17.
208. van Gaal SC, Alimohammadi A, Karim ME, **Zhang W**, Sutherland J. Investigation of treatment delay in a complex healthcare process using physician insurance claims data: an application to symptomatic carotid artery stenosis. *BMC Health Serv Res*. 2024 Nov 29;24(1):1507. doi: 10.1186/s12913-024-11860-w.
209. Van Steenberg HW, Doornkamp F, Alivernini S, Backlund J, Codreanu C, Cohen SB, Combe B, Cope AP, Deane KD, England BR, Falahee M, de Jong PHP, Kleyer A, **Lacaille D**, Maat B, Mankia K, van Mulligen E, Nagy G, O'Neil LJ, Rodamaker L, Sahbudin I, van Schaardenburg D, Sepriano A, da Silva JAP De Smet L, Sparks JA, Steyerberg EW, Studenic P, Wethington E, Landewe RL, Raza K, van der Helm-van Mil AHM. EULAR/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia. *Arthritis Rheumatol*. May 2025. 2025 May 8. doi: 10.1002/art.43218. Online ahead of print.
210. van Steenberg HW, Doornkamp F, Alivernini S, Backlund J, Codreanu C, Cohen SB, Combe B, Cope AP, Deane KD, England BR, Falahee M, de Jong PHP, Kleyer A, **Lacaille D**, Maat B, Mankia K, van Mulligen E, Nagy G, O'Neil LJ, Rodamaker L, Sahbudin I, van Schaardenburg D, Sepriano A, da Silva JAP, De Smet L, Sparks JA, Steyerberg EW, Studenic P, Wethington E, Landewé RL, Raza K, van der Helm-van

- Mil AHM. EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia. *Ann Rheum Dis*. 2025 May 8:S0003-4967(25)00076-7. doi: 10.1016/j.ard.2025.01.021. Online ahead of print.
211. Venerito V, Del Vescovo S, Prieto-González S, Fornaro M, Cavagna L, Iannone F, Kuwana M, Agarwal V, Day J, Joshi M, Saha S, Jagtap K, Katchamart W, Akarawatcharangura Goo P, Vaidya B, Velikova T, Sen P, Shinjo SK, Tan AL, Ziade N, Milchert M, Edgar Gracia-Ramos A, Caballero-Uribe CV; COVAD Study; **Hudson M**, Chinoy H, Gupta L, Agarwal V. Disease burden in inflammatory arthritis: an unsupervised machine learning approach of the COVAD-2 e-survey dataset. *Rheumatol Adv Pract*. 2025 Apr 18;9(2):rkaf031. doi: 10.1093/rap/rkaf031. eCollection 2025.
212. Virgili-Gervais G, Matthews B, Nassar EL, Carrier ME, Kwakkenbos L, Pauling JD, **Bartlett SJ**, Gietzen A, Gottesman K, Guillot G, **Hudson M**, Hummers LK, Lawrie-Jones A, Malcarne VL, Mayes MD, Richard M, Sauvé M, Wojeck RK, Mouthon L, Benedetti A, Thombs BD, **Fortin PR**; Scleroderma Patient-centered Intervention Network investigators. The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study. *Lancet Rheumatol*. 2024 Oct;6(10):e684-e692. doi: 10.1016/S2665-9913(24)00189-9. Epub 2024 Aug 28.
213. Virgili-Gervais G, Henry RS, Kwakkenbos L, Carrier ME, Patten S, **Bartlett SJ**, Mouthon L, Varga J, Benedetti A, Thombs BD; SPIN COVID-19 Patient Advisory Team; SPIN Investigators. Association of COVID-19 vaccination and anxiety symptoms: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort longitudinal study. *J Psychosom Res*. 2024 Sep;184:111852. doi: 10.1016/j.jpsychores.2024.111852. Epub 2024 Jun 23.
214. Wang L, Novoa-Laurentiev J, Cook C, Srivatsan S, Hua Y, Yang J, Miloslavsky E, **Choi HK**, Zhou L, Wallace ZS. Identification of an ANCA-Associated Vasculitis Cohort Using Deep Learning and Electronic Health Records. *Int J Med Inform*. 2025 Apr;196:105797. doi: 10.1016/j.ijmedinf.2025.105797. Epub 2025 Jan 17.
215. **Whittaker JL**, Kalsoum R, Bilzon J, Conaghan PG, Crossley K, Dodge GR, Detgood A, Li X, Losina E, Mason DJ, Pietrosimone, Risberg MA, Roemer F, Felson D, Culvenor A, Meuffels D, Gerwon N, Simon LS, Lohmander LS, Englund M Watt FE. (2024). Toward designing human intervention studies to prevent osteoarthritis after knee injury: A report from an interdisciplinary OARSI 2023 workshop *Osteoarthritis and Cartilage Open* Feb 23;6(2):100449 doi: 10.1016/j.ocarto.2024.100449 [PMID 38440780](#)
216. **Whittaker JL**, Cammalleri A, Archibald C, Brooks-Hill A, Chin P, Clark S, Davis JC, **Hoens AM**, Hunt MA, Kausky K, Ko A, Leveille L, Li LC, Lodhia P, Losciale JM, Miciak M, Mosewich AD, Sheikh A, **Silvester-Lee T**, Truong LK, Wade D, Wilson DR, **Xie H**, Roos EM. Digital education and exercise-therapy versus minimal intervention for young people at high risk of early onset knee osteoarthritis after ACL reconstruction: a study protocol for the Stop OsteoARthritis (SOAR) randomized

- controlled trial BMC Trials. 2025 Jun 20;26(1):213. doi: 10.1186/s13063-025-08896-6.
217. Yan XH, **Losciale JM**, Charlton JM, Mitchell C, Hunt MA, **Whittaker JL**. Explosive neuromuscular performance of the quadriceps muscles following anterior cruciate ligament reconstruction: cross-sectional study protocol. Journal of Orthopaedic and Sports Physical Therapy Methods. 2025. 1 (1): 8-16 [doi/10.2519/josptmethods.2024.0102](https://doi.org/10.2519/josptmethods.2024.0102)
218. Yee J, Feldman CH, Oakes EG, Ellrodt J, Guan H, **Choi MY**, Karlson EW, Costenbader KH. Cost-Related Medication Behaviors for Patients With and Without Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res (Hoboken). 2025 Apr;77(4):545-555. doi: 10.1002/acr.25442. Epub 2024 Oct 27.
219. Yokose C, **McCormick N**, **Lu N**, Jiang B, Tan K, Chigurupati S, **Rai S**, Challener G, **Aviña-Zubieta JA**, Cipolletta E, Abhishek A, Gaffo A, Januzzi JL, Zhang Y, **Choi HK**. Comparative Cardiovascular Safety of NSAID versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients with Gout: Target Trial Emulations. Arthritis Rheumatol. 2025 May 26. doi: 10.1002/art.43259. Online ahead of print.
220. **Zhang W**, Sun H, Guh DP, Grootendorst P, Hollis A, **Anis AH**. The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study. CMAJ. 2024 May 26;196(20):E691-E701. doi: 10.1503/cmaj.231485.
221. **Zhang W**, Guh DP, Grootendorst P, Hollis A, **Anis AH**. The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis. Health Policy. 2024 Jun;144:105064. doi: 10.1016/j.healthpol.2024.105064. Epub 2024 Apr 7.
222. **Zhou V**, **Lacaille D**, **Zheng Y**, Qian Y, Nosyk B, **Xie H**. The impact of healthcare utilization among new users of etanercept for inflammatory arthritis: a population-based regression discontinuity analysis. Lancet Reg Health Am. 2025 Apr 11;45:101058. doi: 10.1016/j.lana.2025.101058. eCollection 2025 May.

## ABSTRACTS

1. Abuhasira R, Hazan I, Yokose C, **McCormick N**, **Choi HK**. Serum urate levels and recurrent gout flare events and gout-primary hospitalisations: general population-based inception cohort of >62,000 newly-diagnosed gout patients. *Ann Rheum Dis*. 2025;84(Suppl 1);1297.
2. Ajlil Y, Gauvreau A, Moulin V, Maaroufi H, Fournier F, Ratelle L, Keyaert D, Gagnon E, Beaudreuil J, Petit-Teixeira E, Droit A, **Michou L**. Identification de variants génétiques rares dans les formes familiales de la maladie de Dupuytren (Identification of rare genetic variants in familial forms of Dupuytren's disease). Presented at the Laurentian Conference of Rheumatology, May 9-10 2025, Estérel, Quebec, Canada
3. **Amiable N**, **Colmegna I**, Harel F, Julien AS, Benlarbi M, Dubé M, Thériault SL, Godbout A, Delgado G, Duchesne M, Cloutier R, Perreault J, Gravel A, Fournier L, Alfonso G, Bourré-Tessier J, **Hudson M**, Richard N, Makhzoum JP, Mendel A, Bernatsky S, Dionne M, Libman M, De Serres G, Dieudé M, Flamand L, Kaufmann D, Finzi A, Bazin R, **Fortin PR**. Comparing Immunogenicity with Protein Subunit and Mrna Covid-19 Vaccines in Patients with Rheumatic Diseases on Rituximab (Covbird Study). 2025. *J Rheumatol*. In Press.
4. **Amiable N**, **Colmegna I**, Harel F, Julien AS, Benlarbi M, Dubé M, Thériault SL, Godbout A, Delgado G, Duchesne M, Cloutier R, Perreault J, Gravel A, Fournier L, Alfonso G, Bourré-Tessier J, **Hudson M**, Richard N, Makhzoum JP, Mendel A, Bernatsky S, Dionne M, Libman M, De Serres G, Dieudé M, Flamand L, Kaufmann D, Finzi A, Bazin R, **Fortin PR**. Safety of Covid-19 Boosters in People with Systemic Autoimmune Rheumatic Diseases on Rituximab (Covbird Study). *J Rheumatol*. In Press.
5. Askanase A, **Clarke AE**, Gladman DD, Werth VP, Yusof Y, Gaiha-Rohrbach J, Jimenez T, Koch ED, Koncz A, Nelde A, Van Vollenhoven R. Improvements observed in skin and joint manifestations of systemic lupus erythematosus with dapirolizumab pegol treatment: results from a phase 3 trial. *J Rheumatol*. May 21 2025, 52;(Suppl 1):33; DOI: <https://doi.org/10.3899/jrheum.2025-0390.O035>.
6. Audet T, Carrier N, Boire G, **Allard-Chamard H**, Roux S. Management of Osteoporosis in Patients with Rheumatoid Arthritis: Insights from a Canadian Academic Division of Rheumatology. *J Rheumatol*. In Press.
7. **Aviña-Zubieta JA**, **Hoque RM**, **Lacaille D**, **De Vera M**, Qian Y, McCandless L, **Xie H**, **Esdale JM**. Trajectories of antimalarial adherence among newly diagnosed rheumatoid arthritis and systemic lupus erythematosus patients: a population-based cohort study. 2024 *Lupus Science and Medicine*. In Press.
8. Bae S, Sambataro G, Ventura J, Bozan F, Dourado E, Faghihi-Kashani S, Loganathan A, Rivero Gallegos D, Yoshida A, Zanframundo G, Bonella F, Corte TJ, Doyle TJ, Forentino D, Gonzalez-Gay MA, **Hudson M**, Kuwana M, Mammen A, McHugh N, Miller F, Montecucco C, Notarnicola A, Oddis C, Rojas-Serrano J, Schmidt J, Scire CA, Gil-Vila A, Werth V, Cavagna L, Aggarwal R. Cardiac Manifestations in Patients with Anti-Synthetase Syndrome: Analysis from the “Classification Criteria for Anti-

synthetase Syndrome (CLASS)" Project Database. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):649-652.

9. Bae S, Bozan F, Rivero Gallegos D, Zanframundo G, Faghihi-Kashani S, Ventura J, Dourado E, Loganathan A, Sambataro G, Yoshida A, Bonella F, Corte TJ, Doyle TJ, Forentino D, Gonzalez-Gay MA, **Hudson M**, Kuwana M, Notarnicola A, Mammen A, McHugh N, Miller F, Montecucco C, Oddis C, Rojas-Serrano J, Schmidt J, Scire C, Selva-O'Callaghan A, Werth V, Cavagna L, Aggarwal R. Anti-synthetase Syndrome (ASSD) Related Interstitial Lung Disease (ILD) in Comparison to Non-ASSD Related ILDs: Analysis from the "Classification Criteria for Anti-synthetase Syndrome (CLASS)" Project Database. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):2361-2363.
10. **Barber MRW**, Hanly J, Urowitz M, Bruce I, St. Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg D, Rahman A, Merrill J, **Fortin PR**, Gladman DD, Petri M, Ginzler E, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, Van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DK, Askanase A, **Clarke AE**. Direct and indirect costs associated with damage accrual: results from the systemic lupus international collaborating clinics (SLICC) inception cohort. LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
11. **Barber MRW**, **Clarke AE**, Skeith L. Acute care utilization in patients with antiphospholipid syndrome and/or systemic lupus erythematosus. *J Rheumatol.* May 21 2025, 52;(Suppl 1):
12. **Barber MRW**, Mydlarski R. Derm in the Rheum: Clinical Pearls in Lupus and Dermatomyositis. 2025. *J Rheumatol.* In Press.
13. **Barber MRW** St-Pierre Y, Bernatsky S, Vinet E, Urowitz M, Gladman D, Peschken C, Hanly J, **Legge A**, **Fortin P**, **Clarke A**. The Forgotten Costs of SLE: Estimating Indirect Costs in a National SLE Cohort. 2025. *J Rheumatol.* In Press.
14. Barraclough M, Mckie S, Rittner L, Knight A, Katz P, Hanly K, **Legge A**, Mackay M, Dobrowolski C, Brunner H, Ogbu E, Wincup C, Govoni M, Bortoluzzi A, Silvagni E, Ruttan L, Bingham E, Green R, Tartaglia C, Lee S, Fisk J, Uludag K, Tang C, Valdés Cabrera D, Anderson E, Difrancesco M, Hoi A, Raghunath S, Kozora E, He Z, Elliott R, Parker B, Bruce I, Touma Z, Appenzeller S. International effort in harmonising cognitive impairment research in systemic lupus erythematosus. LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
15. Barreth N, Krustev E, **Clarke A**, Moran Toro C, St. Pierre Y, Sciore P, Fritzler MJ, **Hudson M**, **Leclair V**, **Choi MY** on behalf of the Canadian Inflammatory Myopathy Study (CIMS) group. Sialic Acid Binding Ig-Like Lectin 1 is a Biomarker of Disease Activity in Autoimmune Inflammatory Myopathies. 2025. *J Rheumatol.* In Press.
16. **Bartlett SJ**, Schieir O, Valois M, Bykerk V, Bingham CO. PROMIS Symptom Clusters at Diagnosis Predict Poor Treatment Response during first 6 months of Rheumatoid

Arthritis. Presented at the PROMIS International Conference, Cologne, Germany, October 17, 2024.

17. **Bartlett S**, Schieir O, Valois MF, Bessette L, Pope J, Boire G, Hitchon C, Keystone E, Thorne C, Tin D, **Hazlewood G**, **Allard-Chamard H**, Kuriya B, Bykerk V, Bingham C, **and Investigators with the Canadian Early Arthritis Cohort (CATCH)**. Treatment Response over the First 6 Months in Newly Diagnosed RA Patients by Pain, Anxiety, Depression & Fatigue (PADF) Symptom Clusters: Results from the Canadian Early Arthritis Cohort. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):4492-4493.
18. **Bartlett S**, Bingham C, Schieir O, Valois MF, Pope J, Thorne C, Bessette L, Hitchon C, Boire G, Tin D, Keystone E, **Hazlewood G**, Bykerk V. Distinct Symptom Clusters Predict Initial Response to Methotrexate in Adults with New RA: a Longitudinal Analysis of the Canadian Early Arthritis Cohort. 2025. *J Rheumatol*. In Press.
19. **Bartlett SJ**, Bingham CO, Falois MF, Pope J, Allard-Chamard H, Bessette L, Boire G, **Hazlewood G**, Hitchon CA, Kkuriya B, Thorne C, Bykerk V. Anxiety at 3 months is associated with worse disease activity, pros, and predicts progression to advanced therapies by 12 months in early RA: results from the Canadian Early Arthritis Cohort (CATCH). *Ann Rheum Dis*. 2025;84(suppl 1):450.
20. Beckett M, **Yue C**, Ye C, **Hudson M**, **Roberts J**, Pope J, Appleton T, **Hoa S**, Fifi-Mah A, Maltez A, Saltman A, Himmel M, **Colmegna I**, Ladouceur A, Khokhar F, **Arreola L**, **Obrzut A**, **Jamal S**. Immune Checkpoint Inhibitors in Patients with Pre-Existing Rheumatic Disease and the Impact of Immunosuppression: Data from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO). 2025. *J Rheumatol*. In Press.
21. Beckett M, Yue C, **Ye C**, **Hudson M**, **Roberts J**, Pope J, Appleton T, **Hoa S**, Fifi-Mah A, Maltez N, Saltman S, Himmel M, **Colmegna I**, Ladouceur A, Faiza K, Gonzalez Arreola L, Obrzut A, **Jamal S**. Baseline Immunosuppression and Cancer Survival in Patients with Pre-existing Rheumatic Disease treated with Immune Checkpoint Inhibitors: Data from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO). *Ann Rheum Dis*. 2025;84(suppl 1):152.
22. Bendelow J, Warburton J, Macintyre VG, Boonen A, **Lacaille D**, Crepaldi G, Dadoun S, Hagel S, Canas da Silva J, Mihai C, Ramiro S, Sakellariou G, Meisalu S, Wallman JK, Verstappen S. The impact of depression on absenteeism, presenteeism and health-related quality of life in patients with inflammatory arthritis - an international study. *Ann Rheum Dis*. 2025;84(suppl 1):25.
23. Bessette J, Lagacé S, **Michou L**. A Rare Coexistence of SAPHO Syndrome and Hidradenitis Suppurativa: Case Report and Clinical Insights. 2025. *J Rheumatol*. In Press.
24. Boivin J, Sacre K, Bernatsky S, **Clarke AE**, **Barber M**, **Fortin PR**, Hanly J, **Legge A**, Bae SC, Vinet E. Overweight and Obesity Are Key Modifiable Risk Factors for Adverse Outcomes in SLE Pregnancies. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):881-883.
25. Bozan F, Bae S, Rivero Gallegos D, Zanframundo G, Faghihi-Kashani S, Bauer Ventura J, Dourado E, Lim D, Loganathan A, Sambataro G, Yoshida A, Bonella F, Corte TJ, Doyle TJ, Fiorentino D, Gonzalez-Gay MA, **Hudson M**, Kuwana M,

- Notarnicola A, Mammen A, McHugh N, Miller F, Montecucco C, Oddis C, Rojas-Serrano J, Schmidt J, Scire CA, Villar A, Werth V, Aggarwal R, Cavagna L. Baseline Interstitial Lung Disease (ILD) Characteristics and Outcomes in Patients with Anti-synthetase Syndrome Related ILD (ASSD-ILD): Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):646-649.
26. Burns G, **Legge A.** Developing and Evaluating a Laboratory-Based Frailty Index for the Prediction of Long-Term Health Outcomes in Systemic Lupus Erythematosus. 2025. *J Rheumatol.* In Press.
27. Burns G, **Legge A.** Developing and Evaluating a Laboratory-Based Frailty Index for the Prediction of Long-Term Health Outcomes in Systemic Lupus Erythematosus. 2025. *J Rheumatol.* In Press. LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
28. Bykerk V, Schieir O, **Bartlett S**, Bessette L, **Hazlewood G**, Hitchon C, Keystone E, Pope J, Thorne C, Tin D, Proulx L, Kuriya B, **Allard-Chamard H.** Catching on to CATCH (Canadian Early Arthritis Cohort) Rheumatoid Arthritis Research: Translating 15 Years of Knowledge for Clinicians. 2025. *J Rheumatol.* In Press.
29. Cardwell F, Elliott SJ, Gibson PS, Soliman N, Skeith L, **Clarke AE, Barber M.** Living with Antiphospholipid Antibodies: A Photovoice Exploration. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):2521-2524.
30. Ceylan A, Baskan E, Inanc I, Sarac DC, Ozkan A, Karaca NB, Solmaz D, Gucenmez S, Akar S, **Bayraktar D.** Effectiveness of the remote video-based SARAH exercise program in individuals with rheumatoid arthritis: a randomized controlled single-blinded study. *Ann Rheum Dis.* 2025;84(suppl 1):104.
31. Challener G, Sheng-kai Ma K, Kohler M, Yokose C, Yinh J, **McCormick N, Choi HK.** Impact of SGLT2i Initiation on the Need for Urate-Lowering Therapy and Colchicine Among Gout Patients with Type 2 Diabetes: Propensity-Score Matched, Active Comparator, New User Design Study. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):1784-1786.
32. Challener G, Sheng-kai Ma K, **McCormick N**, Yokose C, Tinianow A, **Choi HK.** Risk of Mortality and Major Cardiovascular-Kidney Outcomes in Patients with Tophaceous versus Non-Tophaceous Gout. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):2243-2245.
33. Challener G, Ma KSK, **McCormick N**, Kohler M, Yinh J, Yokose C, **Rai S**, Porterfield F, Jorge A, **Choi HK.** Impact of tirzepatide on musculoskeletal pain and risky analgesic use among non-diabetic individuals with overweight or obese body habitus: a propensity score-matched, active comparator, new user design study. *Ann Rheum Dis.* 2025;84(Suppl 1);240
34. Challener G, Sheng-Kai ma K, Kohler M, Yokose C, Choi HK. Mortality in Patients with Pre-existing Autoimmune Disease on Immune Checkpoint Inhibitor Therapy. *Arthritis Rheumatol.* 2025;76(Suppl 9):5150-52.

35. Champagne C, Dufour A, Vachey C, Morin S N, Agharazii M, Mac-Way F, **Michou L**. Increased Cardiovascular Events in Paget's Disease of Bone, a Study from the Cartagene Cohort. 2025. *J Rheumatol*. In Press.
36. **Chan D**, Kotlo A, Kowlessur M, Xie R, Dhillon D, Clarke J, **Aviña-Zubieta JA**, **Shojania K**, To F, **Huang K**. A Retrospective Descriptive Analysis of a British Columbian Myositis Cohort. 2025. *J Rheumatol*. In Press.
37. Charbonneau J, Ngeuleu A, Panuta B, Vo C, Rich E, Bourré-Tessier J, Villeneuve E, Manganas H, Gauthier A, Morisset J, Landon-Cardinal O, **Hoà S**. Pulmonary Fibrosis with Autoimmune Features and Sjögren's Syndrome. 2025. *J Rheumatol*. In Press.
38. Charbonneau J, **Hoà S**. Cardiovascular Risk Assessment and Management in a Systemic Sclerosis Cohort: a Quality Improvement Initiative. 2025. *J Rheumatol*. In Press.
39. **Cheng V**, **Amiri N**, Cheng V, Ellis U, Cragg JJ, **Harrison M**, **De Vera MA**. Pregnancy Outcomes of Biosimilars and Non-TNF Inhibitor Biologic Disease-Modifying Antirheumatic Drugs: A Scoping Review. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):873-876.
40. Chitineni S, Solomon DH, **Choi HK**, Fernandes A, Billa S, Tan K, Yokose C, Barry M, Paudel ML. Assessing reliability of an electronic gout flare assessment protocol: the trust trial. *Ann Rheum Dis*. 2025;84(Suppl 1):1295
41. **Choi M**, Moghaddam F, Sajadi M, **Clarke AE**, Bernatsky S, Costenbader K, Chen I, Urowitz M, Hanly J, Caroline Gordon<sup>7</sup>, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Wallace D, Isenberg D, Rahman A, Merrill J, **Fortin P**, Gladman D, Bruce I, Petri M, Ginzler E, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcon G, Van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S et al. Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader<sup>©</sup>) for ANA Pattern Identification and Titer Quantification. *Arthritis Rheumatol*. 2025;76(Suppl 9):5487-5490.
42. Clark JJ, Chan D, Kowlessur M, **Dutz J**, **Huang K**. Clinical characteristics and evolution of interstitial lung disease in a retrospective analysis of patients with antisynthetase syndrome, anti-MDA5 syndrome, and scleromyositis. *Ann Rheum Dis*. 2025;(Suppl 1):1702
43. **Clarke AE**, St-Pierre Y, **Barber M**, Bernatsky S, Vinet E, Pineau C, Urowitz M, Gladman D, Peschken C, Hanly J, **Legge A**, **Fortin PR**. The Forgotten Costs of SLE: Estimating Indirect Costs in a National SLE Cohort. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):5436-5438.
44. Cobanoglu RK, Willis R, Paredes-Ruiz D, Tektonidou MG, Pengo V, Sciascia S, Nalli C, Signorelli FV, **Fortin PR**, Efthymiou M, Belmont HM, Petri M, Cervera R, Barber M, Atsumi T, Lopez-Pedrerá C, Knight J, Branch D, Kello N, Ji L, Rodríguez-Almaraz E, Esen BA, Gea JP, Quintana R, Pazzola G, Shi H, Duarte-Garcia A, Meroni P, Roubey R, Bertolaccini ML, Cohen H, Andrade D, Erkan D, and on behalf of APS ACTION. The Incident Risk and Predictors of Systemic Autoimmune Rheumatic Disease (SARD) Development in Persistently Antiphospholipid Antibody Positive Patients

Without SARDs: Prospective Results from the APS ACTION Clinical Database and Repository ("Registry"). 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):1769-1772.

45. Cokol EB, Sarac DC, Karaca NB, Ustun O, Akatay EA, Aysin IA, Ozmen M, Gucenmez S, Akar S, **Bayraktar D**. Objective Assessment of Physical Activity in Adults with Systemic Sclerosis. *Ann Rheum Dis.* 2025;84(Suppl 1);1607.
46. **Contreras D, Barber CEH, Aviña-Zubieta JA**, Quan H, Lee S, King J, **Barnabe C**. Avoidable Hospitalizations by Persons with Rheumatoid Arthritis: A Population-Based Study Using Administrative Data. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):3498-3499.
47. **Contreras D**, Bhanji Z, **Aviña-Zubieta JA, Barber CEH, Barnabe C**. Emergency Department Visits for Ambulatory Care Sensitive Conditions by Persons with Rheumatoid Arthritis: A Population-Based Study. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):3842-3842.
48. **Contreras DG**, Bhanji Z, **Aviña-Zubieta JA, Barber CEH, Barnabe C**. Emergency Department Visits for Ambulatory Care Sensitive Conditions by Persons with Rheumatoid Arthritis: a Population-Based Study. 2025. *J Rheumatol.* In Press.
49. **Contreras D, Barber CEH, Aviña-Zubieta JA**, Quan H, Lee S, King JA, **Barnabe C**. Hospitalizations for Ambulatory Care Sensitive Conditions by Persons with Rheumatoid Arthritis: a Population-Based Study Using Administrative Data. 2025. *J Rheumatol.* In Press.
50. **Cooles FA, Obrzut A, Lu N**, Levy R, **Aviña-Zubieta JA, Lacaille D**. Retrospective single-centre analysis of survival and safety signals in autoimmune rheumatic disease patients undergoing lung transplantation. *Ann Rheum Dis.* 2025;84(Suppl 1);1528.
51. Cotton T, **Leclair V**, Berger C, Troyanov Y, **Hudson M**, Gyger G, and Canadian Inflammatory Myopathy Study (CIMS). Nailfold Videocapillaroscopy Abnormalities in Different Autoimmune Inflammatory Myopathy Subsets. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):2347-2349.
52. Cui S, Arencibia C, Li L, Zhang Q, Wang O, Saillot JL, Peterson R, **Choi HK**, Saag K, Dalbeth N, Terkeltaub R, Miao W. Sap-001, a first –in-class compound targeting a renal urate transporter, shows potent serum urate-lowering effects and favorable safety profile in a US phase 2b study in patients with refractory gout with or without palpable tophi. *Ann Rheum Dis.* 2025;84(Suppl 1);320.
53. **Davidson E**. Sweat It Out: How the Sauna Has Helped Me Cope with Rheumatoid Arthritis. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):5519-5521.
54. **Da Costa D, Andersen N, McGuire E**, Rollet-Labelle E, Hanly JG, Hitchon C, Deville-Stoetzel JB, Bessette L, Audet M-C, Lagacé S, Grondin C, Desaulniers P, **Fortin PR**. Loneliness among individuals living with inflammatory rheumatic diseases during the later stages of the COVID-19 pandemic. 2024 *Lupus Science and Medicine.* In Press.
55. Dobrowolski C, Diaz Martinez JP, Bingham K, Barraclough M, Kretzmann R, Tartaglia MC, Ruttan L, **Choi M**, Appenzeller S, Marzouk S, Bonilla D, Katz P, Beaton D, Green R, Wither J, Whittall Garcia LP, Gladman D, Touma Z. Cognitive Impairment

Prevalence and Most Affected Domains in Patients with SLE by the ACR Comprehensive Neuropsychological Battery. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):3077-3079.

56. Easterbrook A, Pang A, Berger M, Tam ACT, Tseng LO, Law MR, Lynd LD, Mitton C, Zed PJ, Bansback N, **Zhang W** (presenter). Influencing factors for expanding clinical services by pharmacists and policy recommendations: a qualitative study. Society for Medical Decision Making 46th Annual Meeting, October 27, 2024, Boston, USA (poster).
57. **Ester M**, White K, **Dhiman K**, **Zafar S**, Charlton A, **Hazlewood G**, Zimmermann GL, **Hoens A**, Manske SL, **Lacaille D**, Perry MG, **Barber MRW**, Fifi-Mah A, Panich N, **Szpunar M**, Then K, Osinski K, Subdar S, Al-Azem H, Jung M, **Barber CEH**. A Theory of Change for Patient-Initiated Follow-Up Care in Rheumatoid Arthritis. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):2130-2132.
58. **Ester M**, **Dhiman K**, Rebutoc A, Charlton A, White K, **Hazlewood G**, Manske SL, **Lacaille D**, **Hoens AM**, **Szpunar M**, Then KL, Zimmermann GL, Jung M, Carter E, Mosher DP, **Barber C**. Appointments by Choice: an Implementation Pilot Study for Patient-Initiated Follow-Up Care in Rheumatoid Arthritis. 2025. *J Rheumatol.* In Press.
59. **Ester M**, Kulhawy-Wibe S, **Barber C**. Moving More with Inflammatory Arthritis: The Benefits of Physical Activity and Strategies for Supporting Physical Activity Behaviour Change. 2025. *J Rheumatol.* In Press.
60. **Ester M**, **Dhiman K**, **Githumbi R**, **Siple M**, Adhikari Dahal K, **Barber CEH**. Priority setting of physical activity barriers and facilitators among individuals with rheumatoid arthritis: a nominal group technique study. *Ann Rheum Dis.* 2025;(Suppl 1):2008.
61. Eum L, Puddicombe L, **Legge A**. Polypharmacy among people living with systemic lupus erythematosus. LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
62. Fernandez-Codina A, Valois MF, **Bartlett SJ**, Wahed M, Allard-Chamard H, Bessette L, **Hazlewood G**, Hitchon CA, Kuria B, Thorne, Bykerk V, Pope J. Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance of being off steroids and escalation of therapy at 1 year. *Ann Rheum Dis.* 2025;84(Suppl 1):831.
63. **Fortin PR**, Amiabile N, **Colmegna I**, Hare F, Julien AS, Benlarbi M, Dubé M, Léger-Thériault S, Godbout A, Delgado G, Duchesne M, Cloutier R, Perreault J, Gravel A, Fournier L, Alfonso G, Bourré-Tessier J, **Hudson M**, Richard N, Makhzoum JP, Mendel A, Bernatsky S, Dionne M, Libman M, De Serres G, Dieudé M, Flamand L, Kaufmann D, Finzi A, Bazin R. Protein subunit and mRNA Covid-19 vaccines: comparative study on induced-immunogenicity in rituximab-treated patients with systemic lupus erythematosus, rheumatoid arthritis and vasculitis. Presented at LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.

64. **Fortin PR**, Amiable N, **Colmegna I**, Harel F, Julien AS, Benlarbi M, Dubé M, Léger-Thériault S, Godbout A, Delgado G, Duchesne M, Cloutier R, Perreault J, Gravel A, Fournier L, Alfonso G, Bourré-Tessier J, **Hudson M**, Richard N, Makhzoum JP, Mendel A, Bernatsky S, Dionne M, Libman M, De Serres G, Dieudé M, Flamand L, Kaufmann D, Finzi A, Bazin R. Covid-19 booster vaccination, either mRNA or protein subunit vaccines, appears safe in rituximab-treated Presented Lupus 2025 at the 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
65. Fuhrmann AC, **Marshall DA**, Dal Ben R, Currie GR, Yeung RSM, Vastert SJ, Wulffraat N, Swart JF, Benseler S. The impact of caring for juvenile idiopathic arthritis on caregivers' quality of life. Presented at the Professional Society for Health Economics and Outcomes Research (ISPOR) 2025 Conference, Montreal, QC, May 13 – 16, 2025.
66. **Githumbi R**, Katz S, Kania-Richmond A, Giroux K, Wallace Y, **Barnabe C**, **Hazlewood G**, **Jones CA**, Steiman A, Ambasta A, **Lacaille D**, Yacyshyn E, Widdifield J, Gakhal N, Williamson T, **Barber CEH**. Identifying Patient Priorities for Patient-Reported Outcome Measures in Rheumatoid Arthritis: A Modified Delphi Consensus Study. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):2132-2134.
67. **Githumbi R**, Hill V, Lonergan K, Katz S, Kania-Richmond A, Giroux K, Wallace Y, **Jones A**, Steiman A, Ambasta A, **Barnabe C**, **Lacaille D**, Yacyshyn E, **Hazlewood G**, Widdifield J, Williamson T, **Barber CEH**. Implementation of a Data-Driven Learning Health System in Rheumatology: a Novel Application of Dashboard Quality Reporting to Support Optimal Rheumatoid Arthritis Care. 2025. *J Rheumatol.* In Press.
68. **Githumbi R**, Katz S, Kania-Richmond A, Giroux K, Wallace Y, **Jones A**, Steiman A, Ambasta A, **Barnabe C**, **Lacaille D**, Yacyshyn E, **Hazlewood G**, Widdifield J, Williamson T, **Barber CEH**. Prioritizing Patient-Reported Outcome Measures for Routine Collection in Rheumatoid Arthritis: an Integrated Consensus-Building Process with Patients and Health Care Providers. 2025. *J Rheumatol.* In Press.
69. **Githumbi R**, **Barber CEH**, **Bartlett SJ**, Toupin-April K, Twilt M, **Lacaille D**, **Barnabe C**, **Dhiman K**, **Hoens AM**, Grebowicz A, McMillan T, Widdifield J. Canadian Rheumatology Association Guidance for Developing & Endorsing Quality Measures to Support Learning Health Systems. *J Rheumatol.* April 2025, 2024-1065; DOI: <https://doi.org/10.3899/jrheum.2024-1065>
70. Gkrouzman E, **Clarke AE**, Tektonidou M, Pengo V, Sciascia S, Pardos-Gea J, Kello N, Paredes-Ruiz D, Aguirre-Zamorano MA, Belmont HM, **Fortin PR**, Ramires de Jesús G, Atsumi T, Zhang Z, Efthymiou M, Branch D, Pazzola G, Andreoli L, Duarte-Garcia A, Rodriguez-Almaraz E, Petri M, Cervera R, Esen BA, Pons-Estel G, Shi H, Knight J, Willis R, Meroni P, Bertolaccini ML, Cohen H, Roubey R, Andrade D, Erkan D, and on behalf of APS ACTION. Regional and Ethnoracial Differences Among Antiphospholipid Antibody-Positive Patients with No Other Systemic Autoimmune Rheumatic Diseases: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Registry. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):223-226.

71. Gomez-Puerta JA, Ramirez J, Ponce A, Azuaga A, Grau M, Tebe C, Sarmiento-Monroy L, Alascia L, Varela F, Arango Silva C, Carbonell-Abella C, Martinez-Laguna D, Novell M, Sanmarti R, **Aviña-Zubieta JA**, Canete Crespillo DD. Increase in Prevalence and Incidence Rates of Psoriatic Arthritis in Catalonia, Spain: A Population-Based Study. *Ann Rheum Dis.* 2025;84(suppl 1):34.
72. Gómez-Puerta JA, Grau M, Tebe C, Frade-Sosa B, Sarmiento-Monroy J, Carbonell-Abella C, Martínez-Laguna D, Corzo P, Sanmarti R, Aviña-Zubieta JA. Prevalence and incidence of systemic lupus erythematosus in Catalonia Spain. A population-based study. *Ann Rheum Dis.* 2025;84(suppl 1):2199.
73. Gómez-Puerta JA, Frade-Sosa B, Ponce A, Grau M, Tebe C, Sarmiento-Monroy J, Azuaga A, Alascio L, Chacur CA, Farietta Varela S, Ramirez J, Carbonell-Abella C, Martinez-Laguna D, Ruiz Esquide V, **Aviña-Zubieta JA**, Sanmarti R. Is there an Increase in the Prevalence and Incidence rates of Rheumatoid Arthritis in Catalonia, Spain A population-based study (2006–2021). *Ann Rheum Dis.* 2025;(Suppl 1):830.
74. Gómez-Puerta J, Grau M, Tebé C, Frade-Sosa B, Sarmiento Monroy J, Corzo P, Sanmartí R, **Aviña-Zubieta JA**. Prevalence and incidence of systemic lupus erythematosus in Catalonia (Spain) a population-based study. Presented at LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
75. Greenwood B, **Jamal S, Hudson M, Roberts J**, Appleton T, Fifi-Mah A, Himmel M, Pope J, Saltman A, **Arreola L, Choi M**, Khokhar F, Ladouceur A, Ye C. Description of Immune Checkpoint Inhibitor Associated Sicca-Like Syndrome from the Canadian Research Group of Rheumatology in Immuno-Oncology Database: A Case Series. 2025. *J Rheumatol.* In Press.
76. Guertin C, Bernatsky S, **Larché M, Choi M**, Osman M, Pope J, Thorne C, **Hudson M, Hoa S**. Distinct Systemic Sclerosis Phenotypes Related to Race/ethnicity: an Opportunity to Personalize Care? 2025. *J Rheumatol.* In Press.
77. Haberfield MJ, Donaldson A, Crossley KM, Patterson BE, **Whittaker JL**, Culvenor AG, Bruder AM. What factors should be considered for rehabilitation of women following anterior cruciate ligament rupture? A concept are Canadian
78. approach. Presented at Sports Medicine Australia, October 18, Melbourne, Australia.
79. Hanly JG, Robertson JW, **Legge A**, Kamintsky L, Aristi G, Friedman A, Beyea SD, Fisk JD, Omisade A, Calkin A, Bardouille T, Bowen D, Matheson K, Fashmi JA. Resting state functional connectivity in SLE patients and association with cognitive impairment and blood-brain barrier permeability. 2024 *Lupus Science and Medicine.* In Press.
80. Hans V, Voaklander D, **Jones CA**, Yacyshyn E. Comparing the Prevalence of Sarcoidosis in Canadian Rural, Urban, and Farming Populations. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):2032-2033.
81. Harvey G, Ashur I, Bossuyt X, Bluethner M, Bruschi A, Bundell C, Chinoy H, Coeshott C, Donald C, Dunphy J, Fritzler M, Heaps A, **Hudson M**, Kuwana M, Landon-Cardinal

- O, Lu H, McMorrow F, Mayrhofer M, Meyer A, Michiels B, Nespola B, O'Loughlin S, Putova I, Rönnelid J, Sadler R, Sanz-Martinez MT, Sciore P, Selva-O'Callaghan A, Storfors H, Trallero-Araguás E, Troyanov Y, Tyson J, Vencovský J, Yoshida A, Tansley S. An Interlaboratory Variability Study of Detection Methods for Myositis-Specific and Myositis-Associated Autoantibodies in Sera from Patients with Idiopathic Inflammatory Myopathies. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):677-680.
82. **Hazlewood G**, Jung M, Kaminska E, **Bansback N**, Buchbinder R, Whittle S, Richards DP, Proulx L, Rebutoc A, **Barber CEH**. One-Year Outcomes After Decision Aid Led Tapering of Advanced Therapy in Rheumatoid Arthritis. 2025. *J Rheumatol.* In Press.
83. Henderson N, Theakston C, Chowhury S, Mott D, Skedgel C, Freitas R, Ivanicius S, Petersen G, Schofield S, Botto-van Bemden A, Hiligsmann M, Iarrainzar R, **Marshall D**, Tervonen T, Walsh D. Patient and Physician Preferences for Pain Relief Treatment for Moderate-to-Severe Pain Associated with Knee Osteoarthritis: A Qualitative Exploration. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):2511-2512.
84. Herrington J, Luca N, Linsley E, McColl J, Gakhal N, Rozenblyum E, Pardo J, **Hazlewood G**, Sirotych E, Garner S, Batthish M, Bessey J, Liu K, Jarvis P, Broderick L, Spiegel S, Matsos M, Stringer E. Development of National Clinical Practice Guidelines for Transition in Rheumatology. 2025. *J Rheumatol.* In Press.
85. Hitchon C, Bowdish D, Boire G, **Fortin PR**, Flamand L, Chandran V, Dayam RM, Gingras AC, Card C, **Colmegna I**, **Larche M**, Kaplan G, Lukusa L, Lee J, Bernatsky S, and SUCCEED investigative team. Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies After SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):260-262.
86. Hitchon C, Taylor C, Bernstein CN, Peschken C, **Aviña-Zubieta JA**, Bernatsky S, Kaplan G, **Lacaille D**, Widdifield J, Marrie RA. COVID-19 Vaccination and Hospitalization Rates Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-based Study. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):387-389.
87. Hollick R, Ghiglieri C, Anderson RS, Wainwright E, **Lacaille D**, Macfarlane GJ, Morton L, on behalf of the Making it Work™ - Scotland study team. Making it Work™ – UK: Adaptation, development and user-testing of a Canadian programme to support people working with musculoskeletal conditions in the UK. Presented at the British Society for Rheumatology Annual Conference, BSR 2025, April 28-30, 2025, Manchester, UK.
88. **Hoque MR**, **Lacaille D**, **Aviña-Zubieta JA**, **De Vera MA**, Qian Y, **Esdaile J**, **Xie H**. Early Antimalarial Adherence Reduces Future Hospitalization Cost in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: Evidence from a Population-based Study. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):3505-3506.
89. Huot S, **Fortin PR**, Julien AS, Godbout A, Amiable N, Laflamme C, Pouliot M. Visualizing lupus through clinical data-driven Butterflies. 2024 *Lupus Science and Medicine.* In Press.

90. Inanc I, Solmaz D, Sarac DC, Baskan E, Ozkan A, Karaca NB, Akar S, **Bayraktar D**. Effects of Mat Pilates Exercises on Physical Performance and Related Parameters in Women with Psoriatic Arthritis: A Randomized Controlled Single-Blinded Clinical Trial. *Ann Rheum Dis*. 2025;(Suppl 1):305.
91. **Irwin K**, Huo R, **Barber CEH**, **Barnabe C**. Frequencies and Rates of All-Cause Emergency Visits and Hospitalizations in Persons with Inflammatory Arthritis Conditions and Gout: A Systematic Review. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):303-304.
92. **Irwin, K**, Huo R, Ward A, Sudheer C, Li A, **Barber CEH**, **Barnabe C**. Specific Causes for Hospitalization in Persons with Inflammatory Arthritis Conditions and Gout: A Systematic Review. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):2024-2025.
93. **Jade J**, **Huang K**, **Zheng Y**, **Aviña-Zubieta JA**, To F. Cancer Trends in Idiopathic Inflammatory Myopathy: A Population-Based Study. 2025. *J Rheumatol*. In Press.
94. **Jamal S**, Smolen JS, Burmester G, Tanaka Y, Takeuchi T, Curtis JR, Mikuls TR, López-Medina C, Taylor PC, Tilt N, Lauwerys B, Ufuktepe B, Huizinga T. Certolizumab Inhibits Radiographic Progression Even in Rheumatoid Arthritis Patients with High Rheumatoid Factor Levels: a Pooled, Post-Hoc Analysis of Two Phase 3 Trials. *J Rheumatol*. In Press.
95. **Jones A**, **Pham A**, Drummond N, Widdifield J, Koehn S, Jasper L, Klein D, Lindeman C, **Barber CEH**. DMARD Utilization Patterns in Community-Dwelling Rheumatoid Arthritis Patients: Insights from Linked Primary Care and Pharmaceutical Data. *J Rheumatol*. In Press.
96. **Jones A**, **Pham A**, Koehn S, Widdifield J, Drummond N, Jasper L, Klein D, Lindeman C, **Barber CEH**. Bridging the Gap: Prednisone Use Patterns in Primary Care Reveal Challenges in Rheumatoid Arthritis Management and Access to Specialist Care. 2025. *J Rheumatol*. In Press.
97. Jorge A, Zhou B, Zhang Y, **Choi H**. Risk of damage progression with belimumab versus oral immunosuppressant use in patients with systemic lupus erythematosus. 2024 *Lupus Science and Medicine*. In Press.
98. Jorge A, Lee G, Panchot K, Zhou B, **Choi HK**, Sepucha K, Costenbader K. Patient preferences for treatment of systemic lupus erythematosus— a qualitative study. Presented at LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
99. **Joy S**, Martin J, **Colmegna I**. Comparative analysis of the anti-fibrotic effects of resting and cytokine-primed human umbilical cord-derived mesenchymal stromal cells in systemic sclerosis-associated lung and skin fibrosis. **Poster** presented on 08/12/24 at the Keystone Symposium: Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, Whistler BC
100. **Joy S**, Martin J, **Colmegna I**. Investigating Cellular Therapies for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease. **Oral presentation** presented 17/01/25 at the Journée du Maladies Autoimmune et Thérapies Cellulaire (MATHEC), Paris France.

101. **Joy S, Colmegna I**, Martin J. Surfactant Dysfunction and Alveolar Macrophage Impairment Precede Fibrosis in a Mouse Model of Interstitial Lung Disease. Presented at the 17<sup>th</sup> Annual Canadian Respiratory Conference, April 3-5, 2026, Quebec City, QC.
102. Kaddoura R, Almeida-Brasil C, Hanly J, Urowitz M, **Clarke AE**, Ruiz-Irastorza G, Gordon C, Ramsey Goldman R, Petri M, Ginzler E, Wallace DJ, Bae SC, Romero-Diaz J, Dooley MA, Peschken C, Isenberg D, Rahman A, Manzi S, Jacobsen S, Lim SS, Van Vollenhoven R, Nived O, Jönsen A, Kamen DL, Aranow C, Sanchez-Guerrero J, Gladman DD, **Fortin PR**, Alarcón GS, Merrill J, Kalunian K, Ramos-Casals M, Steinsson K, Zoma A, Askanase A, Khamashta MA, Bruce I, Inanc M, Lukusa L, Abrahamowicz M, Bernatsky S. Interval-censored outcomes and flare risk after hydroxychloroquine tapering/cessation: sensitivity analyses of Systemic Lupus International Collaborating Clinics (SLICC) inception cohort data. Presented at LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
103. Kallas R, Nimoni A, Piatichou Donfack NM, Jannat-Khah D, **Barber M**, Kello N, Belmont HM, **Fortin PR**, Branch DW, Duarte-Garcia A, Petri M, Knight J, Willis R, Bertolaccini ML, Cohen H, Niewold T, Erkan D. Type I interferon activity in persistently antiphospholipid antibody-positive patients with or without lupus: results from antiphospholipid syndrome alliance for clinical trials and international networking (aps action) clinical database and repository (“registry”). *Ann Rheum Dis.* 2025;84(Suppl 1):480.
104. **Karacabeyli D, Lacaille D, Lu N, Xie H, Aviña-Zubieta JA**. Incidence of Autoimmune Rheumatic Diseases Following Treatment with Glucagon-Like Peptide-1 Receptor Agonists or Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Study. *Ann Rheum dis.* 2025;84(Suppl 1):32.
105. Keret S, Tang IYK, Kim H, Yoshida A, Dourado E, Conticini E, Landon-Cardinal O, Ardalán K, Bishnoi A, Pais F, Usman SY, Dominguez S, Tulluru G, Kavadiachanda C, Rivero Gallegos D, Bozan F, Lilleker JB, Sreerama Reddy K, Smail R, Khoo T, Lan TY, Leclair V, Rosina S, Jansen M, Yi B, Oddis CV, Vencovsky J, Kuwana M, Rider L, Gandiga PC, Aggarwal R. Gaps in training and expertise in myositis outcome measures: insights from the 2024 MCTC investigators’ survey. *Ann Rheum Dis.* 2025;(Suppl 1):1158.
106. Khan U, **Ho S, Choi M**, Pope J. Is There Relevance of a Positive Rheumatoid Factor in Systemic Sclerosis? A Systematic Review of the Literature. 2025. *J Rheumatol.* In Press.
107. **Kherani R**, Wooster D, Wooster E. Mini-Practice Audit Model (mPAM): Facilitating the CRA RA Guideline Implementation. 2025. *J Rheumatol.* In Press.
108. Kundakci B, **Barber M, Clarke AE**, Johnson S, Bruce I, and On behalf of the revised SLE organ damage index (SDI) collaborators. Can Damage Items Be Graded

According to Severity in a Revised Organ Damage Index for Lupus? 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):4807-4808.

109. Kundakci B, **Barber M, Clarke AE**, Johnson SR, Bruce I, OBO the Revised Systemic Lupus Erythematosus (SLE) Organ Damage Index (SDI) Collaborators. Lupus damage index revision – item generation and reduction phase. *Ann Rheum Dis.* 2025;84(suppl 1):169.
110. Krustev E, Fritzler M, Bernatsky S, St-Pierre Y, Vinet E, Pineau C, Mendel A, Kalache F, Grenier LP, Cotton T, Zahedi O, **Choi M**. Anti-Myxovirus Resistance Protein 1: A Novel Biomarker for Autoimmune Myositis and Interstitial Lung Disease in Systemic Lupus Erythematosus. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):1321-1323.
111. Kuriya B, **Bartlett SJ**, Valois MF, **Allard-Charmard H**, Hitchon CA, Thorne C, **Hazlewood G**, Bessette L, Pope J, Boire G, Bykerk V. Exploring the Potential for Cardiorenal-Metabolic Therapies to Target Comorbidities in Early Rheumatoid Arthritis. *Ann Rheum Dis.* 2025;84(suppl 1):450.
112. **Lacaille D**, Danieli C, **Moolooghy K, Abrahamowicz M**. Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-based Study in Rheumatoid Arthritis. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):5421-23.
113. Li G, Barreth N, Krustev E, Moran-Toro C, St. Pierre Y, Sciore P, **Hudson M**, Fritzler MJ, **Leclair V, Choi MY**, on behalf of the Canadian Inflammatory Myopathy Study (CIMS) group. Addressing Complications of Complement Activation Product Evaluation in Autoimmune Inflammatory Myopathies. 2025. *J Rheumatol.* In Press.
114. **Li LC, Xie H, Lu L, Prlic H, Lacaille D, Aviña-Zubieta JA, Cibere J, Esdaile J, and PRECISION Team**. Sleep Quality Is Associated with Perceived Memory Performance in Females with Osteoarthritis: A Population-based Cross-sectional Study. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):323-325.
115. Li M, Barreth N, Cheema K, Muruve D, St. Pierre Y, **Clarke A**, Sciore P, Fritzler M, **Choi M**. Novel urinary biomarker model for differentiating lupus nephritis from ANCA associated vasculitis. Presented at LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
116. Lim L, Jahaghi N, Golding M, Nishat F, Merrill K, **Lacaille D**, Oguzoglu U, Woodgate R, Stinson J, Peschken C, Touma Z, Protudjer J. Comparing childhood-onset versus adult-onset systemic lupus erythematosus young adults' lived employment experiences. Presented at LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
117. Macintyre VG, Boonen A, **Lacaille D**, Wilkinson S, Lund M, Shoop-Worrall S, Canas da Silva J Crepaldi G, Dadoun S, Haged S, Mihai C, Ramiro S, Sakellariou G, Meisalu S, Wallman JK, Verstappen S. Predictors of presenteeism over time in individuals with inflammatory and non-inflammatory arthritis. *Ann Rheum Dis.* 2025;84(suppl 1):25.

118. Macintyre VG, Boonen A, **Lacaille D**, Wilkinson S, Webers C, **Luquini Pereira AL**, Shea B, Bosworth A, Hofstetter C, Verstappen S. Reliability and validity of four global measures of presenteeism in a sample of adults with inflammatory arthritis. *Ann Rheum Dis*. 2025;84(Suppl 1);643.
119. **Marshall DA**, Dal Ben R, **Currie GR**, Yeung RSM, Vastert S, Kip M, Wulffraat N, Swart J, **Benseler SM**, on behalf of the UCAN CAN-DU and UCAN CURE consortia. How Does Juvenile Idiopathic Arthritis Affect the Work and Usual Activities of Parent Caregivers? The Ucan Can-Du and Cure International Prospective Study. 2025. *J Rheumatol*. In Press.
120. **Marshall DA**, Fuhmann A, Dal Ben R, **Currie GR**, Yeung RSM, Vastert S, Wulffraat N, Swart J, **Benseler SM**, On behalf of the UCAN CAN-DU and UCAN CURE Consortia. What is the Impact of Caregiving on Quality of Life for Parents of Children with Juvenile Idiopathic Arthritis: the Ucan Can-Du and Cure International Prospective Study. 2025. *J Rheumatol*. In Press.
121. **Marshall DA**, Dal Ben R, Currie GR, Yeung RSM, Vastert S, Wulffraat N, Swart J, **Benseler SM**, On behalf of the UCAN CAN-DU and UCAN CURE Consortia. How Does Juvenile Idiopathic Arthritis Affect the Employment and Usual Activities of Adolescents? The Ucan Can-Du and Cure International Prospective Study. 2025. *J Rheumatol*. In Press.
122. **Marshall DA**, Dal Ben R, **Currie GR**, Yeung RSM, Vastert S, Swart J, **Benseler SM**, On behalf of the UCAN CAN-DU and UCAN CURE Consortia. Juvenile Idiopathic Arthritis and Out-Of-Pocket Costs for Medical and Other Health Professional Visits: the Ucan Can-Du and Cure International Prospective Study. 2025. *J Rheumatol*. In Press.
123. **Marshall DA**, Sidhu S, Oddone Paolucci E, Gallant N, Lopatina E, McGrail K, Manhas KP, Wasylak T, Doupe M, Singal D, Stirling B, Zelinsky S, Noseworthy T. Building a National Curriculum and Community for Health Services and Policy Research Training. Presented at the Canadian Association for Health Services and Policy Research (CAHSPR) Annual Meeting, Ottawa, ON, May 26 – 29, 2025.
124. **Marshall DA**, Suryaprakash N, Thorsteinson V, Gallant N, Oddone Paolucci E, Sidhu S, McGail K, Doupe M, Manhas KP, Wasylak T, Singal D, Zelinsky S, Noseworthy T. Evaluating the HSIF National Cohort Training Program using the Kirkpatrick Framework. CAHSPR Annual Meeting, Ottawa, Ontario, Canada May 26 – 29. 2025. Presented at the Canadian Association for Health Services and Policy Research (CAHSPR) Annual Meeting, Ottawa, ON, May 26 – 29, 2025.
125. Marzouk O, **Aviña-Zubieta JA**, Fox M, Shaw W, Ho M, Li Q, Ivory C, **Fortin P**, Bingham K, Keeling S, Reynolds J, Haaland D, Pope J, Lim L, Katz P, Urowitz M, Whittall Garcia LP, Gladman D, Nowrouzi-Kia B, Touma Z. Assessing Subjective Cognitive Impairment in a Cohort of Canadian Systemic Lupus Erythematosus Patients: Construct Validity of PDQ-20. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):3093-3095.

126. **McCormick N**, Joshi A, Terkeltaub R, Merriman T, Naylor M, Yokose C, **Choi HK**. Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):5200-5202.
127. **McCormick N**, Yokose C, **Lu L**, Wexler D, **Aviña-Zubieta JA**, **De Vera MA**, Chigurupati S, Tan K, Chen C, McCoy R, Curhan G, **Choi HK**. The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):4104-06.
128. **McCormick N**, Yokose C, **Lu L**, **Rai S**, Challener G, **Choi HK**. Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout? Population-Based Target Trial Emulation Studies. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):4106-08.
129. **McCormick N**, **Rai S**, Yokose C, Lu L, Terkeltaub R, Nazzal L, Li H, Dodd D, **Choi HK**. Anaerobic antibiotic use and risk of gout flares: target trial emulation for potential role of the microbiome in gout with chronic kidney disease. *Ann Rheum Dis*. 2025;84(Suppl 1);244.
130. Mendel A, Barra L, Bernatsky S, Clifford AH, Dabaghjamanesh M, **Dehghan N**, FifiMah A, Makhzoum JP, Meunier R, Milman N, Soowamber M, Cohen Tervaert J, Yacyshyn E, Khalidi N, Pagnoux C. Comparative Safety and Effectiveness of Biosimilar and Originator Rituximab for Induction or Maintenance in Anca Associated Vasculitis: 6-Month Results of a Longitudinal Cohort Study. 2025. *J Rheumatol*. In Press.
131. Meng C, Valois MF, Caci J, Lee Y, **Allard-Chamard H**, Kuriya B, Bessette L, **Hazlewood G**, Hitchon CA, Thorne C, Pope J, Boire G, **Bartlett SJ**. Think outside the joints: the impact of regional and widespread non-articular pain on symptoms and function in the Canadian Early Arthritis Cohort. *Ann Rheum Dis*. 2025;(Suppl 1):1311.
132. **Michou L** et al. Evolution of gene and protein expressions of SUPT20H and SUPT20H-interacting proteins in monocytes and macrophages upon modulation of autophagy. Presented at the French Rheumatology Society Annual Meeting – Paris, December 2024.
133. Moghaddam F, Tarnopolsky M, **Leclair V**, **Hudson M**, Mitchell R, Buhler K, Hatcher E, Zhang M, Dufour A, de Almeida L, Fritzler M, **Choi M**. Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):624-626.
134. Moghaddam F, Javad Sajadi M, Hou H, **Clarke A**, Bernatsky S, Chen I, Costenbader K, Fritzler MJ, Aminghafari, M, **Choi MY**, on behalf of the SLICC investigators. Rheumatology Diagnostics Utilizing Artificial Intelligence for ANA Pattern Identification and Titre Quantification. 2025. *J Rheumatol*. In Press.

135. Moghaddam F, Ludwig T, Aminghafari M, **Choi MY**, Nicholls F. Analysis of the Implications of Lumbopelvic Alignment on the Alignment of the Cervical Spine. 2025. J Rheumatol. In Press.
136. Moghaddam F, Javad Sajadi M, Hou H, **Clarke A**, Bernatsky S, Hou H, Costenbader K, Fritzler MJ, Aminghafari, M, **Choi MY**, on behalf of the SLICC investigators. Machine Learning Can Identify An Antinuclear Antibody Pattern That May Rule Out Systemic Autoimmune Rheumatic Diseases. 2025. J Rheumatol. In Press.
137. Moghaddam F, Sajadi J, **Clarke A**, Bernatsky S, Costenbader K, Urowitz M, Hanly J, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Isenberg D, Rahman A, Merrill J, **Fortin PR**, Gladman DD, Bruce I, Petri M, Ginzler E, Dooley MA, Ramsey Goldman R, Manzi S, Jönsen A, Alarcón GS, Van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Fritzler M, Aminghafari M, **Choi M**. Machine learning can identify an antinuclear antibody pattern that may rule out systemic autoimmune rheumatic diseases. May 21 2025. 52;(Suppl 1):30. DOI: <https://doi.org/10.3899/jrheum.2025-0390.O032>.
138. Moghaddam F, Sajadi J, **Clarke AE**, Bernatsky S, Costenbader K, Chen I, Urowitz M, Hanly J, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Isenberg D, Rahman A, Merrill J, **Fortin PR**, Gladman DD, Bruce I, Petri M, Ginzler E, Dooley MA, Ramsey Goldman R, Manzi S, Jönsen A, Alarcón GS, Van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Fritzler M, Aminghafari M, **Choi MY**. Rheumatology diagnostics utilizing artificial intelligence for ANA pattern identification and titre quantification. Presented at LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
139. Moghaddam F, Sajadi J, **Clarke A**, Bernatsky S, Costenbader K, Urowitz M, Hanly J, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Isenberg D, Rahman A, Merrill J, **Fortin PR**, Gladman DD, Bruce I, Petri M, Ginzler E, Dooley MA, RamseyGoldman R, Manzi S, Jönsen A, Alarcón GS, Van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, KamenDL, Askanase A, Fritzler M, Aminghafari M, **Choi M**. Machine learning can identify an antinuclear antibody pattern that may rule out systemic autoimmune rheumatic diseases. Presented at LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
140. **Moolooghy K, Xie H, Zheng Y, Aviña-Zubieta JA, Lacaille D**. Comparing the Risk of Severe Infections Associated with Different Classes of Biologic or Targeted Synthetic Agents for Inflammatory Arthritis: A Population-based Study. 2024. Arthritis Rheumatol. 2024;76(Suppl 9):3502-3504.
141. Morand E, Arriens C, Geraldino L, **Clarke AE**, Pomponi S, Hobar C, Wegman T, Koti R, Banerjee S, Van Vollenhoven R. Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline

Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):1367-1369.

142. Murphy M, Coventry M, Taylor J, Latella C, Rio E, Mosler A, **Whittaker JL**. People with hip osteoarthritis have poor muscle activation and altered motor cortex excitability: a case-control study. Presented at Sports Medicine Australia, October 18, Melbourne, Australia.
143. Neary E, Munoz-Grajales C, Wither J, Diaz Martinez P, Barraclough M, Bingham K, Kretzmann R, Tartaglia MC, Ruttan L, **Choi M**, Appenzeller S, Marzouk S, Bonilla D, Katz P, Beaton D, Green R, Whittall Garcia LP, Gladman D, Touma Z. Novel Analytes Associated with Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Serum S100A8/A9, MMP-9 and IL-6. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):3071-3074.
144. Neary E, Munoz-Grajales C, Withers J, Diaz Martinez JP, Barraclough M, Bingham K, Kretzmann R, Tartaglia C, Ruttan L, **Choi M**, Appenzeller S, Marzouk S, Bonilla D, Katz P, Beaton D, Green R, Whittall-Garcia L, Gladman D, Touma Z. Serum S100A8/A9, MMP-9 and IL-6 are associated with impairment in executive function, simple attention and processing speed in patients with systemic lupus erythematosus. Presented at LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
145. **Needham A, Tan J, Cheng V, De Vera MA, Amiri N**. Janus Kinase Inhibitor Exposure During Pregnancy in Immune-Mediated Inflammatory Diseases: a Case Series of 3 Patients. 2025. *J Rheumatol.* In Press.
146. **Needham A, Tan J, Cheng V, De Vera M, Amiri N**. Janus Kinase Inhibitor Exposure During Pregnancy in Immune-Mediated Inflammatory Diseases: A Case Series of 3 Patients. Presented at the 13th International Conference on Reproduction, Pregnancy and Rheumatic Disease (RheumaPreg 2025), May 8 – 10, 2025, Vienna, Austria.
147. Nowrouzi-Kia B, **Aviña-Zubieta JA**, Fox M, Shaw W, Ho M, Li Q, Ivory C, **Fortin P**, Keeling S, Reynolds J, Haaland D, Pope H, Lim L, Katz P, Urowitz M, Whittall Garcia LP, Gladman D, Touma Z. Work-Related Disability and Function in Systemic Lupus Erythematosus (SLE): Outcomes of an Exploratory Study from Different Canadian Centres. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):3063-3064.
148. Nowrouzi-Kia B, Touma Z, **Aviña-Zubieta JA**, Fox M, Shaw W, Ho M, Li Q, Ivory C, **Fortin P**, Keeling S, Reynolds J, Haaland DA, Pope J, Lim LSH, Urowitz M, Whittall Garcia LP, Gladman D. Work-Related Disability and Function in Systemic Lupus Erythematosus (SLE): Outcomes of an Exploratory Study from Different Canadian Centres. 2025. *J Rheumatol.* In Press.
149. Pandya J, Andrade D, **Clarke AE**, Tektonidou M, Pengo V, Radin M, Pardos-Gea J, Kello N, Paredes-Ruiz D, Aguirre-Zamorano MA, Belmont HM, **Fortin PR**, Signorelli FV, Atsumi T, Zhang Z, Efthymiou M, Branch D, Pazzola G, Tincani A, Duarte-Garcia A, Rodriguez-Almaraz E, Petri M, Cervera R, Esen BA, Pons-Estel G, Shi H, Zuo Y, Willis R, Meroni P, Roubey R, Bertolaccini ML, Cohen H, Erkan D, and on behalf of

- APS ACTION. Antiphospholipid Antibody-related Clinical Manifestations Presenting During Childhood versus Adulthood: Descriptive Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry"). 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):2577-2579.
150. Pascart T, Dauphin E, Yokose C, Jauffret C, Choi HK, Budzik JF. The Role of Renal Dual-Energy CT in Exploring the Gouty Kidney: The RENODECT Study. *Arthritis Rheumatol.* 2025;76(Suppl 9):2246-47.
151. Patel A, Zhang L, Zhou B, **Choi H**, Jorge A. Contemporary kidney outcomes among patients with lupus nephritis in the United States. Presented at LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
152. Pongtarakulpanit N, Keret S, Kothari V, Bozana F, Kavadichanda C, Yoshida A, **Leclair V**, Bishnoi A, Ardalan K, Conticini E, Lan TY, Landon-Cardinal O, Tang IYK, Rosina S, Yi B, Lilleker JB, Dourado E, Gandiga PC, Aggarwal R. Defining criteria and predictors of remission in adult idiopathic inflammatory myopathies: a scoping review. *Ann Rheum Dis.* 2025;(Suppl 1):1684.
153. Poole J, Carandang K, Thelander Hill M, Salazar J, Koch A, Dionne T, **Lacaille D**. Piloting an Adaptation of the Making It Work Program for Systemic Sclerosis: Promising Effects on Job Related Self-efficacy and Risk of Work Disability. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):690-691.
154. **Primeau C, Bayraktar D**, Kho M, Tong C, **Li LC**. Challenges and Opportunities in Integrating Sleep Recommendations into Counselling Patients with Arthritis: A Survey of Physical Therapists and Physical Therapy Students. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):5135-37.
155. Proulx L, Bykerk V, Schieir O, **Bartlett S**, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Pope J, Thorne C, Tin D, Kuriya B, **Allard-Chamard H**, Richards DP. Returning Research Results to Patients with Rheumatoid Arthritis: a Patient-Driven Knowledge Translation Strategy from the Canadian Early Arthritis Cohort (Catch). 2025. *J Rheumatol.* In Press.
156. Rafieinia M, Stringer E, Martini R, Proulx L, **Trehan N**, Abrahams N, Sirotich E, Sirois A, Huber M, Duffy C, Décary S, Morgan E, Gaboury I, Birnie KA, Branco P, Kashif I, Brandelli Y, Cappon J, Cavallo S, Connelly M, Cunningham N, Barcellos de Souza J, Ghio D, El Tal T, Gmuca S, Luca N, Mannion M, Tugwell P, Stinson JN, Toupin-April K. **A Scoping Review of Approaches to Treat Juvenile Idiopathic Arthritis Symptoms to Inform the Expanded Version of the JIA Option Map.** 2025. *J Rheumatol.* In Press.
157. **Rai S, Choi HK**, Yokose C, **McCormick N**. Three Novel Metabolomic Signatures of Inflammation for Female Gout Risk: A Prospective Cohort Study over 26 Years. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):1780-81.

158. **Rai S, Choi HK**, Yokose C, **McCormick N**. Distinct Metabolomic Signatures of Insulinemia and Incident Gout Risk: A Prospective Cohort Study Among Women. 2024. *Arthritis Rheumatol*. 76;(Suppl 9):2238-39.
159. **Rai S, McCormick N**, Yokose C, Terkeltaub R, Dodd D, Nazzal L, Li H, Sun Q, **Choi H**. Dietary fiber intake and the risk of gout among women: prospective analysis for the potential role of the microbiome in gout. *Ann Rheum Dis*. 2025;84(Suppl 1):240.
160. **Ramanathan B**, Shen HC, Gerber Z, del Carmen Crespo C, Karamchandani J, O’Ferrall E, Troyanov Y, Landon-Cardinal O, Bourre-Tesier J, **Hudson M, Leclair V**, Labrie M, **Allard-Chamard H**. Immune infiltrate profiling in B cell-enriched autoimmune myopathies. *Ann Rheum Dis*. 2025;84(suppl 1):119.
161. Rausch Osthoff AK, Vlieland V, Ferreira JO, Amarnani R, Battista S, **Bayraktar D**, Boyadzhieva V, Brodin N, Cox A, Davergne T, Tuncay Duruoz M, Esbenson BA, Fongen C, Gunther KP, Henrotin Y, Juhl C, Kennedy N, Kiltz U, Knittle K, Metsios GS, Nurmohamed M, Robero Pazos V, Swinnen TW, Thomsen T, Warburton L, Niedermann K. EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis: 2025 update. *Ann Rheum Dis*. 2025;(Suppl 1):1451.
162. Roberts E, **Bansback N**, Tseng CW, Shiboski S, Li J, Schmajuk G, Yazdany J. Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):5290-5292.
163. Rivero Gallegos D, Bozan F, Bae S, Zanframundo G, Faghihi-Kashani S, Bauer Ventura J, Dourado E, Sambataro G, Yoshida A, Corte TJ, Bonella F, Doyle TJ, Fiorentino D, Gonzalez-Gay MA, **Hudson M**, Kuwana M, Notarnicola A, Mammen A, McHugh N, Miller F, Montecucco C, Oddis C, Rojas-Serrano J, Schmidt S, Scire CA, Selva-O’Callaghan A, Werth V, Aggarwal R, Cavagna L, and CLASS project participating investigators. Association of Anti-Synthetase Antibody Subtypes with Radiographic Progression of Interstitial Lung Disease in Anti-Synthetase Syndrome: An Analysis of the CLASS Project Database. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):4168-4171.
164. **Ryzhaya N, Hassen N, Bartlett S, Barber CEH, Michou L, Bansback N, Hazlewood G, Barnabe C, Lacaille D**. The Impact of Collecting Electronic Patient-Reported Outcomes (Epros) Between Visits on Rheumatological Care: a Scoping Review. 2025. *J Rheumatol*. In Press.
165. Saag K, Kragh N, Athavale A, Desai B, Gulaid A, Oladapo A, Smith B, **Choi HK**. Variations in chronic refractory gout management between rheumatologists and nephrologists. *Ann Rheum Dis*. 2025;(Suppl 1):1224.
166. Sakertkoo LA, Cheng K, de Groot I, de Visser M, Shenoi S, Dimachkie M, Gilkeson G, Werth VP, Day J, Paul J, Chandwar KA, Gono T, Gupta L, Paik J, Valenzuela Vegara A, Muehlensiepen F, Naddaf E, Erste FC, Albayda J, Basharat P, Aleanderson H, Shafranski B, Highland K, Christopher L, **Leclair V** et al. Myositis Community

Proposes a Framework to Guide Clinical Trials and Ensure Patient Safety during Influx of CAR-T based Therapies. *Ann Rheum Dis.* 2025;(Suppl 1):1204.

167. Saleh N, Chang A, Yu A, Seyed-Jalaldin D, **Hoa S**, Levy R, Wilson J, Poirier C, Yee J, Choi J, Landon-Cardinal O, Kim H, **Huang K**. Lung transplant outcomes in patients with myositis- and systemic sclerosis-associated interstitial lung disease compared to idiopathic pulmonary fibrosis: a multicentric retrospective analysis. *Ann Rheum Dis.* 2025;84(Suppl 1);256.
168. Sarmiento-Monroy J, Grau M, Tebe C, Carbonell-Abella C, Martinez-Laguna D, Frade-Sosa B, Peñafiel Sam JA, Corzo P, **Aviña-Zubieta JA**, Gómez-Puerta JA. Epidemiology of Sjögren syndrome in Catalonia Spain. A population-based cohort study. *Ann Rheum Dis.* 2025;84(Suppl 1):984.
169. Schieir O, Valois MF, Boire G, Bessette L, Thorne C, **Bartlett S, Hazlewood G**, Hitchon C, Tin D, **Allard-Chamard H**, Kuriya B, Pope J, Bykerk V, and on behalf of CATCH Investigators. Deciphering Variation in Real-World Early RA Outcomes: A Longitudinal Analysis of the Canadian Early Arthritis Cohort (CATCH) Study. 2024. *Arthritis Rheumatol.* I 2025;76(Suppl 9):2707-2709.
170. Schieir S, Valois MF, Bessette L, Thorne C, Boire G, **Bartlett S, Hazlewood G**, Hitchon C, Tin D, **Allard-Chamard H**, Kuriya B, Pope J, Bykerk V, and on behalf of CATCH Investigators. Time-Trends in Real-World Glucocorticoid Treatment Strategies in Patients with Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort (CATCH) Study. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):4571-4572.
171. Shahtalebi N, Rieger-Torres S, **Tan J, Huang K, Amiri N**. Case Series of Six Patients with Inflammatory Myositis Seen at a Specialized Pregnancy and Rheumatic Diseases Clinic. Presented at the 13th International Conference on Reproduction, Pregnancy and Rheumatic Disease (RheumaPreg 2025), May 8 – 10, 2025, Vienna, Austria.
172. Shahtalebi N, Rieger-Torres S, **Tan J, Needham A, Huang K, Amiri N**. Case Series of Six Patients with Inflammatory Myositis Seen at a Specialized Pregnancy and Rheumatic Diseases Clinic. 2025. *J Rheumatol.* In Press.
173. Shantz E, Williamson T, Elliott S, Sperling C, **Choi M**. Investigating Canadians' information needs related to lupus: a google trends analysis of online search query data. Presented at LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
174. Shen HC, **Hudson M, Ramanathan B**, Troyanov Y, Landon-Cardinal O, O'Ferrall E, Karamchandani J, Ellezam B, **Allard-Chamard H, Leclair V**. Funded by Myositis Canada. Expanding the Clinical Spectrum of Myositis with Prominent B Cell Aggregates (Bcm). 2025. *J Rheumatol.* In Press.
175. Shen HC, **Hudson M**, Proudman SM, Walker JG, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, **Leclair V**, Troyanov Y, Baron M, **Larche M, Choi MY**, Osman M, Pope J, Thorne C, Fritzler M, **Hoa S**. Anti-nor-90 antibodies in an international

cohort of 2140 systemic sclerosis subjects: clinical associations. *Ann Rheum Dis.* 2025;(Suppl 1):1069.

176. Silveira A, Beaupre L, Voaklander D, Niemelainen R, **Jones A**. A shoulder care pathway reduces claim duration among workers with shoulder injuries: A cohort study. Presented at the 2024 SECEC Congress (European Society of Elbow & Shoulder Surgery), September 4 – 6, 2024, Munich, Germany. 2024.
177. **Siple M, Zafar S, Ester M, Hazlewood G, Dhiman K**, Charlton A, Then KL, Dempsey E, Lester R, **Hoens AM, Lacaille D**, Sloss S, **Barnabe C**, Mosher D, **Barber CEH**. Text-Based Messaging to Support Rheumatoid Arthritis Care: An Analysis of Frequency and Content of Text Messages. 2025. *J Rheumatol.* In Press.
178. Staal L, Kip M, **Currie GR**, Swart JS, **Benseler SM**, Yeung RSM, Vastert S, Wulffraat N, Koffijberg H, **Marshall DA**, On behalf of the UCAN CAN-DU and UCAN CURE Consortia. Economic Evaluation of Including Biomarker-Testing in the Biologic Therapy Withdrawal Decision Making Process in Non-Systemic Juvenile Idiopathic Arthritis: the International Ucan Candu and Cure Study. 2025. *J Rheumatol.* In Press.
179. Stone JH, Martinez Valle F, **Carruthers M**, Baker MC, Wu T, Choi J, Mikol V, Mannent L, Hagino O. Efficacy and safety of Rilzabrutinib, an oral Bruton's Tyrosine Kinase Inhibitor in patients with IgG4-related disease: Results from a 52-week, Phase 2, Open Label, proof-of-concept study. *Ann Rheum Dis.* 2025;84(suppl 1):155.
180. Storwick J, Ye C, **Jamal S**, Maltez N, Chan M. Confidence Check: Closing the Educational Gaps in Immune Checkpoint Inhibitors. 2025. *J Rheumatol.* In Press.
181. Storwick J, Ye C, **Jamal S**, Maltez N, Chan M. Immune Checkpoint Inhibitors: a Pediatric Needs Assessment. 2025. *J Rheumatol.* In Press.
182. **Tan J, Aviña-Zubieta JA, Fortin PR**, Gingras AC, **Larche M**, Bowdish D, Berger C, **Colmegna I**, Hitchon C, **Lacaille D**, Richards D, **Lalonde N**, Kirmani A, Lee JLF, Bernatsky S. Anti-Spike Antibodies Protect Against COVID-19 Infection in Immune-Mediated Inflammatory Diseases: Findings from the SUCCEED Study. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):3838-3840.
183. **Tan J, Aviña-Zubieta JA, Fortin PR**, Gingras AC, **Larché MH**, Bowdish D, Berger C, **Colmegna I**, Hitchon C, **Lacaille D**, Richards DP, Lalonde N, Kirmani A, Lee JLF, Bernatsky S. Anti-Spike Antibodies Protect Against Covid-19 Infection in Immune-Mediated Inflammatory Diseases: Findings from the Succeed Study. 2025. *J Rheumatol.* In Press.
184. **Tan J, De Vera M, Amiri N**. Back To the Clinic? Evaluating Pregnancy Management Outcomes in Virtual and In-Person Care. Presented at the 13<sup>th</sup> International Conference on Reproduction, Pregnancy and Rheumatic Disease (RheumaPreg 2025), May 8 – 10, 2025, Vienna, Austria.
185. Tang IYK, Keret S, Kim H, Yoshida A, Dourado E, Conticini E, Landon-Cardinal O, Ardalan K, Bishnoi A, Pais F, Usman SY, Doniguez S, Tulluru G, Kavadichanda C, Rivero Gallegos D, Bozan F, Lilleker JB, Sreerama Reddy K, Smail R, Khoo T, Lan TY, **Leclair V**, Jansen M, Yi B, Rosina S, Oddis CV, Vencovskyy J, Kuwana m, Rider

- L, Gandiga PC, Aggarwal R. Global patterns and challenges in patient enrolment in idiopathic inflammatory myopathy (iim) clinical trials – results from the 2024 MCTC investigators' survey. *Ann Rheum Dis.* 2025;(Suppl 1):1679.
186. Thaler J, Parides M, Andrade D, Paredes-Ruiz D, Tektonidou MG, Pengo V, Sciascia S, Nalli C, Ramires de Jesús G, **Fortin PR**, Efthymiou M, Belmont HM, Petri M, Cervera R, Skeith L, Atsumi T, Lopez-Pedreira C, Zuo C, Branch D, Willis R Kello N, Zhang Z, Rodriguez-Almaraz E, Artim Esen B, Pardos-Gea J Pons-Estel G, Pazzola G, Shi H, Duarte-Garcia A, Barbhaiya M, Yelnik C, Meroni P, Roubey R, Bertolaccini ML, Cohen H, Rand J, Erkan D, and on behalf of APS ACTION. Clinical and Biologic Predictors of Thrombosis in Persistently Antiphospholipid Antibody Positive Patients: Prospective Analysis of the International APS ACTION Clinical Database and Repository ("Registry"). 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):1765-1769.
187. **Thomas MM**, Sayre EC, **Harrison M**, **De Vera MA**. Impact of social determinants of health on outcomes among adults with arthritis: A latent class analysis of nationally representative data from the Canadian Longitudinal Study of Aging. *Ann Rheum Dis.* 2025;(Suppl 1):1433.
188. Toupin-April K, Gaboury I, Popescu S, Stinson JN, M, Duffy C, Huber A, Proulx L, **Trehan N**, Abrahams N, Sirotich E, Sirois A, Stringer E, Kashif I, Rafieinia M, Martini R, Abrahams N, Décary S, Morgan E, Birnie KA, Branco P, Kashif I, Dachevski A, Morgan E, Decary S, Cavallo S, Boyd A, Tugwell P, Martini R. How Are Determinants of Health Inequities Related to Decision-Making in Juvenile Idiopathic Arthritis Care? A Narrative Synthesis. 2025. *J Rheumatol.* In Press.
189. **Trehan N**. Bridging the Gap from Pediatric to Adult Rheumatology Care. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):5528-29.
190. **Trehan N**, Proulx L, Duffy C, Huber A, Abrahams N, Sirois A, Sirotich E, Stringer E, Morgan E, Cohen J, Gaboury I, Li L, Houston A, Cavallo S, Gibbon M, Brinkman W, Connelly M, Weiss J, Gmuca S, Paterson G, Décary S, Tugwell P, Stinson JN, Toupin-April K. Usability and Acceptability of the French Version of the "JIA Option Map". ("Carte d'Options en AJI"): A Web-Based Patient Decision Aid for Young People with Juvenile Idiopathic Arthritis". 2025. *J Rheumatol.* In Press.
191. Tremblay C, Carrier N, **Allard-Chamard H**, Marrugo J, Roux S, Boire G, Masetto A. Clinical impact of signs of calcium pyrophosphate deposition disease (cPPD) on radiographs of hands and wrists in a real-world cohort of patients with early rheumatoid arthritis. *Ann Rheum Dis.* 2025;84(Suppl 1);619.
192. Vandeveld A, Meroni P, Cohen H, Andrade D, Amengual O, Atsumi T, Tincani A, Belmont HM, Borghi M, Branch D, Cervera R, Ramires de Jesús G, **Fortin P**, Gris JC, Grossi C, Knight J, Moore GW, Musiał J, Petri M, Rodriguez-Almaraz E, Paredes-Ruiz D, Roubey R, Tebo A, Tektonidou M, Wahl D, Zuily S, Willis R, Pengo V, Bertolaccini ML, Erkan D, Devreese K. Efforts to Harmonize ELISA and Non-ELISA Anticardiolipin and Anti- $\beta$ 2-glycoprotein-I Levels Based on ISTH SSC LA/aPL and APS ACTION International Multicenter Cohorts. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):214-217.

193. Vinet E, **Clarke AE, Barber M, Fortin PR**, Hanly J, **Legge A**, Bae SC, Sacre K, Bernatsky S. Overweight and obesity are key modifiable risk factors for adverse outcomes in SLE pregnancies. Presented at LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
194. Westby M, Koehn C, **Barber CEH**, Lalande JF, **Kerr S**, Guirguis M. Assessing Quality of Post-TJR Rehabilitation: Care Gaps and Patient Perspectives. 2025. *J Rheumatol*. In Press.
195. Willis R, Tebo A, Skeith L, Kello N, Belmont HM, **Fortin PR**, Ramires de Jesús G, Branch D, Petri M, Knight J, Cobanoglu RK, Bertolaccini ML, Cohen H, Roubey R, Erkan D, Andrade D, and on behalf of APS ACTION. Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):207-209.
196. Willis R, Murthy V, Roye-Green K, Thees A, **Choi M**, Dier K, Fritzler M, Fink S, Nandakumar V, Snyder M, Tebo A, and the Association of Medical Laboratory Immunologists. Binding Characteristics of Patient Clusters Among Anticardiolipin and Anti- $\beta$ 2-Glycoprotein I ELISA and Non-ELISA Assays: A Survey by the Association of Medical Laboratory Immunologists. 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):210-212.
197. Wong K, Maximilien L Zhang Q, Banina M, Prabhune R, Biard L, **Ho S**, Wang H, Gilkeson G, Farge D, **Colmegna I, Hudson M**. Clinical Features and Disease Phenotypes as Study Entry Criteria for Scleroderma Encompass Patients with Significant Biological Heterogeneity. 2025. *J Rheumatol*. In Press.
198. **Worthington H, Wang E, Bayraktar D, Therrien S, Primeau C, Whittaker J, Hoens A, Aviña-Zubieta JA, Xie H, Li LC**. Barriers and Facilitators of Access to Physical Therapy: A Scoping Review. 2024. *Arthritis Rheumatol*. 2024;76(Suppl 9):2162-65.
199. **Yan XH, Losciale JM**, Charlton JM, Mitchell CJ, Hunt MA, **Whittaker JL**. Explosive neuromuscular performance of the quadriceps muscles following anterior cruciate ligament reconstruction: implications for osteoarthritis prevention. *Osteoarthritis & Cartilage*. 2025;33(4):S195-196.
200. Yelnik C, Chaturvedi S, Labreuche J, Pan XY, Belmont HM, Kello N, **Fortin PR**, Branch D, Zuo Y, Willis R, Brodsky R, Salmon J, Bertolaccini ML, Cohen H, Petri M, Erkan D, and on behalf of APS ACTION. Rare Germline Variants in Complement Regulatory Genes in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). 2024. *Arthritis Rheumatol*. 2025;76(Suppl 9):221-222.
201. Yokose C, Pascart T, Randhawa M, Kennedy P, Schwabl C, Chigurupati S, Jiang B, **Lu L**, Held J, Widmann G, Simeone FJ, Ghoshhajra B, Sheikh A, Shojania K, Feuchtner G, Klauser A, Nicolaou S, Budzik JF, Becce F, **Choi HK**. Coronary Dual-Energy Computed Tomography for the Detection of Monosodium Urate Crystal

- Deposition in the Arteries of Individuals with and Without Gout (CORODECT): A Multi-Center Prospective Imaging Study. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):2239-41.
202. Yokose C, **Lu L, Rai S, McCormick N, Choi HK.** The Contemporary Prevalence of Comorbid Gout and Chronic Kidney Disease, Two Common Conditions with High Morbidity, in the US General Population. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):2242-43.
203. Yokose C, Chigurupati S, Jiang B, Tan K, **McCormick N, Choi HK.** Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):4110-11.
204. Yokose C, Jiang B, **McCormick N, Rai S, Choi HK.** The Association Between Gout and Gallstone Disease: US General Population Analysis. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):266-267.
205. Yokose C, Pascart T, Randhawa M, Kennedy P, Schwabl C, Chigurupati S, Jiang B, **Lu L, Held J, Widmann G, Simeone FJ, Ghoshajra B, Sheikh A, Shojania K, Feuchtner G, Klauser A, Nicolaou S, Budzik JF, Becce F, Choi HK.** Coronary Dual-Energy Computed Tomography for the Detection of Monosodium Urate Crystal Deposition in the Arteries of Individuals with and Without Gout (CORODECT): A Multi-Center Prospective Imaging Study. *Arthritis Rheumatol.* 2025;76(Suppl 9):2239-40.
206. Yoshida A, Bauer Ventura J, Dourado E, Zanframundo G, Faghihi Kashani S, Loganathan A, Rivero Gallegos D, Bozan F, Sambatar G, Bae S, Trallero-Araguás E, Mammen A, Scire C, Montecuccio C, Oddis C, Fiorentino D, Bonella F, Miller F, Notarnicola A, Schmidt J, Rojas-Serrano J, **Hudson M,** Kuwana M, Gonzalez-Gay MA, McHugh N, Corte TJ, Doyle TJ, Werth V, Aggarwal R, Cavagna L, and the CLASS project investigators. Different Clinical Phenotypes of Patients with Anti-synthetase Syndrome: Unsupervised Cluster Analysis in the CLASS Database. 2024. *Arthritis Rheumatol.* 2025;76(Suppl 9):4210-4214.
207. Yu CM, **Kim H,** Levy R, Wilson J, Yee J, **Huang K.** Lung Transplantation Outcomes in Patients with Interstitial Pneumonia with Autoimmune Features. *Ann Rheum Dis.* 2025;(Suppl 1):877.
208. **Yue C, Arreola L, Needham A,** De Sa Ellwanger H, **Li L, Chan J, Chan D, Tan J, Lu N, Aviña-Zubieta JA.** Psoriasis/psoriatic Arthritis Patients Do Not Have an Increased Risk of Venous Thromboembolism: a General Population-Based Study. 2025. *J Rheumatol.* In Press.
209. ZanframundoG, Faghihi Kashani S, Yoshida A, Dourado E, Bauer Ventura I, Rivero Gallegos D, Loganathan A, Sambataro G, Bozan F, Bae S, Lim D, Cheli M, Yamano Y, Bonella F, Corte T, Doyle TJ, Fiorentino D, Gonzalez-Gay M, **Hudson M,** Kuwana M, Lundberg I, Mammen A, McHugh N, Miller F, Montecuccio C, Oddis C, Rojas-Serrano J, Schmidt J, Alberto Scirè C, Selva-O'Callaghan A, Werth V, Rozza D, Morosin M, Bozzini S, Cavagna L, Aggarwal R and the CLASS project investigators. The Classification Criteria for Anti-Synthetase Syndrome (Class) Project. *Arthritis Rheumatol.* 2025;76(Suppl 9):5475-5478.

210. Zhao N, Smargiassi A, Chen H, **Choi MY**, Fritzler M, Touma Z, Awadalla P, **Aviña-Zubieta JA**, Bernatsky S. Fine particulate matter air pollution and anti-nuclear antibody positivity: the Ontario Health Study. *Ann Rheum Dis.* 2025;(Suppl 1):396.
211. Zhao N, Smargiassi A, Chen H, **Choi M**, Fritzler M, Touma Z, Awadalla P, **Aviña-Zubieta JA**, Bernatsky S. Fine particulate matter air pollution and anti-nuclear antibody positivity: the Ontario Health Study. Presented at LUPUS 2025 – 16th international on Systemic Lupus Erythematosus (SLE), May 21-24, 2025, Toronto, Canada.
212. **Zhao K**, Jing B, **Aviña-Zubieta JA**, **Xie H**. A Longitudinal Analysis of Outcomes of Systemic Lupus Erythematosus Patients Commencing Antimalarial Medication Using a Multistate Model Approach. *Ann Rheum Dis.* 2025;84(suppl 1):956.